Revvity (RVTY) 10-K 25 Feb 20 2019 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 29, 2019	Feb. 21, 2020	Jun. 28, 2019	Dec. 30, 2018
Entity Listings [Line Items]
Document Annual Report	true
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Public Float			$ 10,536,461,974
Sale of Stock, Price Per Share			$ 96.34
Common stock, par value	$ 1			$ 1
Document Type	10-K
Document Period End Date	Dec. 29, 2019
Document Transition Report	false
Entity File Number	001-5075
Entity Registrant Name	PERKINELMER INC
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2052042
Entity Address, Address Line One	940 Winter Street,
Entity Address, City or Town	Waltham,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	663-6900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		111,303,859
Entity Central Index Key	0000031791
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Current Fiscal Year End Date	--12-29
PKI [Member]
Entity Listings [Line Items]
Trading Symbol	PKI
Trading Symbol	PKI
PKI 21A [Member]
Entity Listings [Line Items]
Trading Symbol	PKI 21A
Trading Symbol	PKI 21A
PKI 21B [Member]
Entity Listings [Line Items]
Trading Symbol	PKI 21B
Trading Symbol	PKI 21B
Common stock, $1 par value per share [Member]
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $1 Par Value
Title of 12(b) Security	Common Stock, $1 Par Value
1.875% Notes due 2026 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2026
Title of 12(b) Security	1.875% Notes due 2026
0.60% Notes due 2021 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	0.600% Notes due 2021
Title of 12(b) Security	0.600% Notes due 2021
NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Listings [Line Items]
Security Exchange Name	NYSE
Security Exchange Name	NYSE

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 29, 2019	Feb. 21, 2020	Jun. 28, 2019
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 29, 2019
Document Transition Report	false
Entity File Number	001-5075
Entity Registrant Name	PERKINELMER INC
Entity Central Index Key	0000031791
Current Fiscal Year End Date	--12-29
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2052042
Entity Address, Address Line One	940 Winter Street,
Entity Address, City or Town	Waltham,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	663-6900
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 10,536,461,974
Entity Common Stock, Shares Outstanding		111,303,859
Documents Incorporated by Reference	Portions of PerkinElmer, Inc.’s Definitive Proxy Statement for its Annual Meeting of Shareholders to be held on April 28, 2020 are incorporated by reference into Part III of this Form 10-K.
Common stock, $1 par value per share [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $1 Par Value
1.875% Notes due 2026 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.875% Notes due 2026
0.60% Notes due 2021 [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.600% Notes due 2021
NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Security Exchange Name	NYSE
PKI [Member]
Entity Information [Line Items]
Trading Symbol	PKI
PKI 21A [Member]
Entity Information [Line Items]
Trading Symbol	PKI 21A
PKI 21B [Member]
Entity Information [Line Items]
Trading Symbol	PKI 21B

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended									12 Months Ended
	Dec. 29, 2019		Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Revenue
Revenue from Contract with Customer, Excluding Assessed Tax										$ 2,883,673	$ 2,777,996	$ 2,256,982
Selling, general and administrative expenses										815,318	811,913	626,018
Research and development expenses										189,336	193,998	139,464
Restructuring and other costs, net	$ 1,560		$ 14,068	$ 6,161	$ 7,639	$ (1,942)	$ 6,508	$ 0	$ 6,578	29,428	11,144	12,657
Operating income from continuing operations	138,248	[1]	78,660	91,735	53,330	115,683	80,202	88,064	39,935	361,973	323,884	295,615
Interest and other expense, net										124,831	66,201	(1,103)
Income from continuing operations before income taxes	65,296	[1]	63,254	71,827	36,765	79,429	78,041	71,708	28,505	237,142	257,683	296,718
Provision for income taxes										9,389	20,208	139,828
Income from continuing operations	64,549	[1]	58,610	69,141	35,453	71,322	75,445	64,673	26,035	227,753	237,475	156,890
Income from discontinued operations before income taxes										0	0	650
(Loss) gain on disposition of discontinued operations before income taxes										0	(859)	179,615
(Benefit from) provision for income taxes on discontinued operations and dispositions										(195)	(1,311)	44,522
Income from discontinued operations and dispositions	(48)		(52)	(54)	(41)	(30)	1,103	(610)	(11)	(195)	452	135,743
Net income	$ 64,501	[1]	$ 58,558	$ 69,087	$ 35,412	$ 71,292	$ 76,548	$ 64,063	$ 26,024	$ 227,558	$ 237,927	$ 292,633
Basic earnings per share:
Income from continuing operations	$ 0.58	[1]	$ 0.53	$ 0.62	$ 0.32	$ 0.64	$ 0.68	$ 0.59	$ 0.24	$ 2.06	$ 2.15	$ 1.43
Income from discontinued operations and dispositions	0		0	0	0	0	0.01	(0.01)	0	0	0	1.24
Net income	0.58	[1]	0.53	0.62	0.32	0.64	0.69	0.58	0.24	2.06	2.15	2.67
Diluted earnings per share:
Income from continuing operations	0.58	[1]	0.53	0.62	0.32	0.64	0.68	0.58	0.23	2.04	2.13	1.42
Income from discontinued operations and dispositions	0		0	0	0	0	0.01	(0.01)	0	0	0	1.22
Net income	$ 0.58	[1]	$ 0.52	$ 0.62	$ 0.32	$ 0.64	$ 0.69	$ 0.57	$ 0.23	$ 2.04	$ 2.13	$ 2.64
Product [Member]
Revenue
Revenue from Contract with Customer, Excluding Assessed Tax										$ 2,017,042	$ 1,935,493	$ 1,477,414
Cost of Goods and Services Sold										956,398	908,228	707,962
Service [Member]
Revenue
Revenue from Contract with Customer, Excluding Assessed Tax										866,631	842,503	779,568
Cost of Goods and Services Sold										$ 531,220	$ 528,829	$ 475,266
[1]	The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustments Reclassification From AOCI to Earnings Due to ASU 2018-02	$ 0	$ 6,489	$ 0
Net income	227,558	237,927	292,633
Other comprehensive income (loss)
Foreign currency translation adjustments, net of tax	(23,978)	(123,388)	54,341
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustments Reclassification From AOCI to Earnings Due to ASU 2018-02	0	6,489	0
Unrecognized prior service credit (cost), net of tax	807	(77)	(77)
Unrealized gains (losses) on securities, net of tax	6	(9)	79
Other comprehensive (loss) income	(23,165)	(129,963)	54,343
Comprehensive income	$ 204,393	$ 107,964	$ 346,976

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 29, 2019	Dec. 30, 2018
Current assets:
Cash and cash equivalents	$ 191,877	$ 163,111
Accounts receivable, net	725,184	632,669
Inventories	356,937	338,347
Other current assets	100,381	100,507
Total current assets	1,374,379	1,234,634
Property, plant and equipment, net	318,223	318,590
Operating Lease, Right-of-Use Asset	167,276	0
Intangible assets, net	1,283,286	1,199,667
Goodwill	3,111,227	2,952,608
Other assets, net	284,173	270,023
Total assets	6,538,564	5,975,522
Current liabilities:
Current portion of long-term debt	9,974	14,856
Accounts payable	235,855	220,949
Accrued restructuring and contract termination costs	11,559	4,834
Accrued expenses and other current liabilities	503,332	528,827
Current liabilities of discontinued operations	2,112	2,165
Total current liabilities	762,832	771,631
Long-term debt	2,064,041	1,876,624
Long-term liabilities	751,468	742,312
Operating Lease, Liability, Noncurrent	146,399	0
Total liabilities	3,724,740	3,390,567
Commitments and contingencies (see Notes 14 and 17)
Stockholders' equity:
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 111,140,000 and 110,597,000 shares at December 29, 2019 and December 30, 2018, respectively	111,140	110,597
Capital in excess of par value	90,357	48,772
Retained earnings	2,811,973	2,602,067
Accumulated other comprehensive loss	(199,646)	(176,481)
Total stockholders' equity	2,813,824	2,584,955
Total liabilities and stockholders' equity	$ 6,538,564	$ 5,975,522

Consolidated Balance Sheet Pare

Consolidated Balance Sheet Parenthetical - $ / shares	Dec. 29, 2019	Dec. 30, 2018
Balance Sheet Parenthetical [Abstract]
Preferred stock, par value	$ 1	$ 1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 1	$ 1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	110,597,000	110,361,000
Common stock, outstanding	110,597,000	110,361,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock Amount [Member]	Capital In Excess of Par Value [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Jan. 01, 2017	$ 2,153,570	$ 109,617	$ 26,130	$ 2,118,684	$ (100,861)
Net income	292,633	0	0	292,633	0
Other comprehensive income (loss)	54,343				54,343
Dividends	(30,800)			(30,800)
Exercise of employee stock options and related income tax benefits	18,004	578	17,426
Issuance of common stock for employee benefit plans	2,467	37	2,430
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	4,367	79	4,288
Issuance of common stock for long-term incentive program	12,353	208	12,145
Stock compensation	4,985	0	4,985	0	0
Ending Balance at Dec. 31, 2017	2,503,188	110,361	58,828	2,380,517	(46,518)
Net income	237,927	0	0	237,927	0
Other comprehensive income (loss)	(129,963)
Dividends	(31,013)			(31,013)	0
Exercise of employee stock options and related income tax benefits	24,833	709	24,124
Issuance of common stock for employee benefit plans	1,485	21	1,464
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	57,393	717	56,676
Issuance of common stock for long-term incentive program	15,873	223	15,650
Stock compensation	5,382	0	5,382	0	0
Ending Balance at Dec. 30, 2018	2,584,955	110,597	48,772	2,602,067	(176,481)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	(123,474)				(123,474)
Net income	227,558			227,558
Other comprehensive income (loss)	(23,165)
Dividends	(30,941)			(30,941)
Exercise of employee stock options and related income tax benefits	19,732	415	19,317
Issuance of common stock for employee benefit plans	2,776	33	2,743
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	6,313	67	6,246
Issuance of common stock for long-term incentive program	19,307	162	19,145
Stock compensation	6,626	0	6,626	0	0
Ending Balance at Dec. 29, 2019	2,813,824	$ 111,140	$ 90,357	$ 2,811,973	(199,646)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	$ (23,165)				$ (23,165)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Restricted Cash	$ 17	$ 3,204	$ 236
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	191,894	166,315	202,370
Operating activities:
Net income	227,558	237,927	292,633
Loss (gain) from discontinued operations and dispositions, net of income taxes	195	(452)	(135,743)
Income from continuing operations	227,753	237,475	156,890
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and other costs, net	29,428	11,144	12,657
Depreciation and amortization	214,025	180,588	105,000
Stock-based compensation	31,514	28,767	25,421
Pension and other post-retirement expense (benefits)	26,107	11,915	(10,439)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	3,881	14,639	2,162
Deferred taxes	(61,353)	(51,103)	28,854
Deferred Income Tax Expense (Benefit), Continuing Operations, Discontinuing Operations	(61,353)	(51,103)	28,854
Contingencies and Non-Cash Tax Matters	(424)	(671)	182
Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts	3,846	3,341	2,592
Loss (gain) on disposition of businesses and assets, net	2,469	(12,844)	309
Amortization of acquired inventory revaluation	21,590	19,272	6,188
Gain on Sale of Investments	0	(557)	0
Change in fair value of financial securities	(3,249)	0	0
Gain (Loss) on Extinguishment of Debt	32,541	0	0
Changes in assets and liabilities which (used) provided cash, excluding effects from companies purchased and divested:
Accounts receivable, net	(100,630)	(94,512)	(36,633)
Inventories, net	(9,607)	(30,183)	(17,923)
Accounts payable	7,351	8,900	34,331
Accrued expenses and other	(61,773)	(14,933)	(17,436)
Net cash provided by operating activities of continuing operations	363,469	311,238	292,155
Net cash used in operating activities of discontinued operations	0	(200)	(3,702)
Net cash provided by operating activities	363,469	311,038	288,453
Investing activities:
Capital expenditures	(76,331)	(93,253)	(39,089)
Proceeds from Derivative Instrument, Investing Activities	0	0	36,541
Payments to Acquire Investments	(6,387)	(7,019)	(10,783)
Payments to Acquire Intangible Assets	(5,000)	0	0
Proceeds from Divestiture of Businesses	550	38,027	1,100
Proceeds from surrender of life insurance policies	0	72	45
Activity related to acquisitions, net of cash and cash equivalents acquired	(400,405)	(97,686)	(1,527,183)
Net cash used in investing activities of continuing operations	(487,573)	(159,859)	(1,539,369)
Net cash provided by investing activities of discontinued operations	0	0	272,779
Net cash used in investing activities	(487,573)	(159,859)	(1,266,590)
Financing activities:
Payments on revolving credit facility	(1,692,489)	(1,264,000)	(235,965)
Proceeds from revolving credit facility	1,599,416	857,000	1,060,952
Payments of Senior Debt	(530,276)	0	0
Proceeds from sale of senior debt	847,195	369,340	0
Payments of debt financing costs	(9,879)	(2,634)	0
Net payments on other credit facilities	(14,975)	(28,383)	(2,831)
Settlement of cash flow hedges	(1,280)	(34,132)	(13,824)
Payments for acquisition-related contingent consideration	(29,942)	(12,800)	(8,940)
Excess tax benefit from exercise of common stock options	0	0
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	19,732	24,833	18,004
Purchases of common stock	(6,313)	(57,445)	(3,834)
Dividends paid	(31,059)	(31,009)	(30,793)
Net cash provided by (used in) financing activities of continuing operations	150,130	(179,230)	782,769
Net cash used in financing activities of discontinued operations	0	0	(533)
Net cash provided by (used in) financing activities	150,130	(179,230)	782,236
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(447)	(8,004)	21,703
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	25,579	(36,055)	(174,198)
Cash and cash equivalents at beginning of year	163,111	202,134
Cash and cash equivalents at end of year	191,877	163,111	202,134
Supplemental disclosures of cash flow information
Interest Paid, Excluding Capitalized Interest, Operating Activities	82,693	56,451	35,780
Income taxes	$ 77,059	$ 59,844	$ 77,607

Business Combinations and Asset

Business Combinations and Asset Purchases	12 Months Ended
	Dec. 29, 2019
Business Combinations [Abstract]
Business Combinations and Asset Purchases	Business Combinations Acquisitions in fiscal year 2019 During the fiscal year 2019, the Company completed the acquisition of five businesses for aggregate consideration of $433.1 million in cash. The acquired businesses include Cisbio Bioassays SAS (“Cisbio”), a company based in Codolet, France, which was acquired for a total consideration of $219.9 million in cash, Shandong Meizheng Bio-Tech Co., Ltd. ("Meizheng Group"), a company headquartered in Beijing, China, for a total consideration of $166.5 million in cash, and three other businesses which were acquired for a total consideration of $46.6 million in cash. The Company has a potential obligation to pay the former shareholders of certain of these acquired businesses additional contingent consideration of up to $31.8 million . The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery & Analytical Solutions segments, as applicable, from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.0 years . The total purchase price for the acquisitions in fiscal year 2019 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Cisbio Meizheng Other (In thousands) Fair value of business combination: Cash payments $ 219,795 $ 145,000 $ 45,042 Other liability — 6,446 638 Contingent consideration — 12,100 634 Working capital and other adjustments 138 2,961 302 Less: cash acquired (12,542 ) (2,108 ) (1,334 ) Total $ 207,391 $ 164,399 $ 45,282 Identifiable assets acquired and liabilities assumed: Current assets $ 43,554 $ 15,160 $ 4,042 Property, plant and equipment 4,835 6,278 727 Other assets 100 32 481 Identifiable intangible assets: Core technology 90,000 36,500 27,667 Trade names 5,000 4,900 1,310 Customer relationships 39,000 53,000 6,700 Goodwill 72,341 81,457 17,006 Deferred taxes (34,886 ) (21,231 ) (6,658 ) Debt assumed — (706 ) (2,698 ) Liabilities assumed (12,553 ) (10,991 ) (3,295 ) Total $ 207,391 $ 164,399 $ 45,282 Acquisitions in fiscal year 2018 During fiscal year 2018, the Company completed the acquisition of four businesses for aggregate consideration of $105.8 million . The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations for these acquisitions within the results of the Company's Diagnostics and Discovery & Analytical Solutions segments from the acquisition dates. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.2 years . The total purchase price for the acquisitions in fiscal year 2018 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: (In thousands) Fair value of business combination: Cash payments $ 95,950 Other liability 3,354 Contingent consideration 6,200 Working capital and other adjustments 261 Less: cash acquired (1,132 ) Total $ 104,633 Identifiable assets acquired and liabilities assumed: Current assets $ 4,905 Property, plant and equipment 1,166 Other assets 776 Identifiable intangible assets: Core technology 31,956 Trade names 1,070 GC Libraries 2,065 Customer relationships 10,200 Goodwill 65,886 Deferred taxes (9,049 ) Debt assumed (461 ) Liabilities assumed (3,881 ) Total $ 104,633 Acquisitions in fiscal year 2017 Acquisition of EUROIMMUN Medizinische Labordiagnostika AG. During fiscal year 2017, the Company completed the acquisition of 99.98% of the outstanding stock of EUROIMMUN Medizinische Labordiagnostika AG (“EUROIMMUN”) for aggregate consideration of €1.2 billion (equivalent to $1.4 billion at December 19, 2017, the time of closing). The purchase price was funded by borrowings from the Company's senior unsecured revolving credit facility and senior unsecured term loan credit facility of $710.0 million and $200.0 million , respectively, and available cash on hand of $503.1 million . The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired. As a result of the acquisition, the Company recorded goodwill of $591.3 million , which is not tax deductible, and intangible assets of $907.4 million . The Company has reported the operations for this acquisition within the results of the Company's Diagnostics segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of this acquisition had a weighted average amortization period of 16.1 years . Other acquisitions in 2017. During fiscal year 2017, the Company also completed the acquisition of two other businesses for aggregate consideration of $142.0 million . The acquired businesses were Tulip Diagnostics Private Limited (“Tulip”), which was acquired for total consideration of $127.3 million in cash and one other business acquired for total consideration of $14.7 million in cash. At the acquisition date, the Company had a potential obligation to pay the former shareholders of Tulip up to INR 1.6 billion in additional consideration over a two year period, equivalent to $25.2 million , and is accounted for as compensation expense in the Company's financial statements over a two year period and is excluded from the purchase price allocation shown below. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. The Company has reported the operations of Tulip within the results of the Company's Diagnostics segment and the other acquired business within the results of the Company's Discovery & Analytical Solutions segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, trade names and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.8 years . The total purchase price for the acquisitions in fiscal year 2017 have been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: EUROIMMUN Other (In thousands) Fair value of business combination: Cash payments $ 1,413,113 $ 140,861 Other liability — 1,273 Working capital and other adjustments — (93 ) Less: cash acquired (25,018 ) (2,439 ) Total $ 1,388,095 $ 139,602 Identifiable assets acquired and liabilities assumed: Current assets $ 121,174 $ 16,268 Property, plant and equipment 109,859 11,356 Other assets 71,621 1,691 Identifiable intangible assets: Core technology 160,000 12,400 Trade names 36,000 3,000 Customer relationships 710,000 43,700 In-process research and development ("IPR&D") 1,400 — Goodwill 591,304 75,250 Deferred taxes (251,886 ) (15,735 ) Liabilities assumed (100,020 ) (8,328 ) Debt assumed (61,357 ) — Total $ 1,388,095 $ 139,602 EUROIMMUN's revenue and net loss for the period from the acquisition date to December 31, 2017 were $13.5 million and $1.0 million , respectively. The following unaudited pro forma information presents the combined financial results for the Company and EUROIMMUN as if the acquisition of EUROIMMUN had been completed at the beginning of fiscal year 2016: December 31, (In thousands, except per share data) Pro Forma Statement of Operations Information (Unaudited): Revenue $ 2,562,580 Income from continuing operations 143,459 Basic earnings per share: Income from continuing operations $ 1.31 Diluted earnings per share: Income from continuing operations $ 1.29 The unaudited pro forma information for fiscal year 2017 has been calculated after applying the Company's accounting policies and the impact of acquisition date fair value adjustments. The fiscal year 2017 unaudited pro forma income from continuing operations was adjusted to exclude approximately $9.8 million of acquisition-related transaction costs. These pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments, such as fair value adjustment to inventory, increased interest expense on debt obtained to finance the transaction, and increased amortization for the fair value of acquired intangible assets. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities. The Company does not consider the acquisitions completed during fiscal years 2019, 2018 and 2017 , with the exception of the EUROIMMUN acquisition, to be material to its consolidated results of operations; therefore, the Company is only presenting pro forma financial information of operations for the EUROIMMUN acquisition. The aggregate revenue and the results of operations for the acquisitions completed during fiscal year 2019 for the period from their acquisition dates to December 29, 2019 were no t material. The aggregate revenue and the results of operations for the acquisitions completed during fiscal year 2018 for the period from their acquisition dates to December 30, 2018 were no t material. The aggregate revenue for the acquisitions, with the exception of EUROIMMUN, completed during fiscal year 2017 for the period from their acquisition dates to December 31, 2017 was $38.5 million and the results of operations were no t material. The Company has also determined that the presentation of the results of operations for each of those acquisitions, from the date of acquisition, is impracticable due to the integration of the operations upon acquisition. As of December 29, 2019 , the allocations of purchase prices for acquisitions completed in fiscal years 2018 and 2017 were final. The preliminary allocations of the purchase prices for acquisitions completed in fiscal year 2019 were based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. These adjustments will be made in the periods in which the amounts are determined and the cumulative effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition dates. All changes that do not qualify as adjustments made during the measurement periods are also included in current period earnings. During fiscal year 2019 , the Company obtained information relevant to determining the fair values of certain tangible and intangible assets acquired, and liabilities assumed, related to recent acquisitions and adjusted its purchase price allocations. Based on this information, the Company recognized an increase in goodwill of $6.1 million , an increase in deferred tax liabilities of $5.1 million , a decrease in current assets of $1.6 million , a decrease in liabilities assumed of $0.4 million and a decrease in other assets of $0.1 million . Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. As of December 29, 2019 , the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $57.1 million . As of December 29, 2019 , the Company has recorded contingent consideration obligations of $35.5 million , of which $20.8 million was recorded in accrued expenses and other current liabilities, and $14.7 million was recorded in long-term liabilities. As of December 30, 2018 , the Company has recorded contingent consideration obligations of $69.7 million , of which $67.0 million was recorded in accrued expenses and other current liabilities, and $2.7 million was recorded in long-term liabilities. The expected maximum earnout period for acquisitions with open contingency periods does not exceed 3.0 years from December 29, 2019 , and the remaining weighted average expected earnout period at December 29, 2019 was 1.2 years . If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional contingent consideration which would be recognized as a component of operating expenses from continuing operations. In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of deferred revenue assumed with its acquisitions. The estimated fair value of deferred revenue is determined by the legal performance obligation at the date of acquisition, and is generally based on the nature of the activities to be performed and the related costs to be incurred after the acquisition date. The fair value of an assumed liability related to deferred revenue is estimated based on the current market cost of fulfilling the obligation, plus a normal profit margin thereon. The estimated costs to fulfill the deferred revenue are based on the historical direct costs related to providing the services. The Company does not include any costs associated with selling effort, research and development, or the related margins on these costs. In most acquisitions, profit associated with selling effort is excluded because the acquired businesses would have concluded the selling effort on the support contracts prior to the acquisition date. The estimated research and development costs are not included in the fair value determination, as these costs are not deemed to represent a legal obligation at the time of acquisition. The sum of the costs and operating income approximates, in theory, the amount that the Company would be required to pay a third-party to assume the obligation. Total acquisition and divestiture-related costs for fiscal years 2019 and 2018 were $6.6 million and $15.8 million , respectively. These amounts include $0.5 million of compensation expense related to the Tulip acquisition and $2.6 million of net foreign exchange loss related mainly to the Company's acquisition of Cisbio for fiscal year 2019, and $6.9 million of compensation expense and $0.7 million of net foreign exchange gain related to the foreign currency denominated stay bonus associated with the Tulip acquisition for fiscal year 2018. Acquisition-related interest expenses were minimal in fiscal year 2019 and $0.7 million in fiscal year 2018 . These acquisition and divestiture-related costs were expensed as incurred and recorded in selling, general and administrative expenses and interest and other (income) expense, net in the Company's consolidated statements of operations.

Nature of Operations and Accoun

Nature of Operations and Accounting Policies	12 Months Ended
	Dec. 29, 2019
Accounting Policies [Abstract]
Nature of Operations and Accounting Policies	Nature of Operations and Accounting Policies Nature of Operations: PerkinElmer, Inc. is a leading provider of products, services and solutions to the diagnostics, life sciences and applied markets. Through its advanced technologies and differentiated solutions, critical issues are addressed that help to improve lives and the world around us. The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation. The Company has two operating segments: Discovery & Analytical Solutions and Diagnostics. The Company's Discovery & Analytical Solutions segment focuses on service and innovating for customers spanning the life sciences and applied markets. The Company's Diagnostics segment is targeted towards meeting the needs of clinically-oriented customers, especially within the growing areas of reproductive health, emerging market diagnostics and applied genomics. The Company's fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 29, 2019 (" fiscal year 2019 "), December 30, 2018 (" fiscal year 2018 ") and December 31, 2017 (" fiscal year 2017 ") included 52 weeks. The fiscal year ending January 3, 2021 ("fiscal year 2020") will include 53 weeks. Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Revenue Recognition: The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The Company recognizes revenue in an amount that reflects the consideration the Company expects to receive in exchange for the promised products or services when a performance obligation is satisfied by transferring control of those products or services to customers. Taxes that are collected by the Company from a customer and assessed by a governmental authority, that are both imposed on and concurrent with a specific revenue-producing transaction, are excluded from revenue. Warranty Costs: The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period. Shipping and Handling Costs: The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue. Inventories : Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements. Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. When the Company determines during the period that previously undistributed earnings of certain international subsidiaries no longer meet the requirements of indefinite reinvestment, the Company recognizes the income tax expense in that period. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 7 below for additional details. The Company uses an individual unit of account approach for releasing the income tax effects of unrealized gains and losses from Accumulated Other Comprehensive Income ("AOCI"). Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 8 years. Certain tooling costs are capitalized and amortized over a 3 -year life, while repairs and maintenance costs are expensed. Asset Retirement Obligations : The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as interest expense. The amounts recorded in the consolidated financial statements are not material to any year presented. Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of the calendar month-end that is closest to the Company's fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds. Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive (loss) income, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net. Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. Measurement period adjustments are made in the period in which the amounts are determined and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed. Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of a trade name that is not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset . In addition, the Company evaluates the remaining useful life of its non-amortizing intangible asset at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful life of non-amortizing intangible asset is no longer indefinite, the asset will be tested for impairment. The intangible asset will then be amortized prospectively over its estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 13 below for additional details. Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 19 below. Marketable Securities and Investments: Investments in debt securities that are classified as available for sale are recorded at their fair values with unrealized gains and losses included in accumulated other comprehensive (loss) income until realized. Investments in equity securities are recorded at their fair values with unrealized holding gains and losses included in earnings. Investments in equity securities without a readily available fair value are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, with changes included in earnings. Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments. Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted. Research and Development: Research and development costs are expensed as incurred. The fair value of acquired IPR&D costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned. Restructuring and Other Costs: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and its productivity initiatives. In connection with these initiatives, the Company has recorded restructuring and other charges, as more fully described in Note 5 below, which include employee severance, other exit costs as well as costs of terminating certain lease agreements or contracts and other costs associated with relocating facilities. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Prior to adoption of Accounting Standards Codification ("ASC") 842, Leases , costs related to lease terminations were recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceased use. Comprehensive Income: Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income. Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive (loss) income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements. The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 eliminates certain exceptions and adds guidance to reduce complexity in accounting for income taxes. Specifically, this guidance: (1) removes the intraperiod tax allocation exception to the incremental approach; (2) removes the ownership changes in investments exception in determining when a deferred tax liability is recognized after an investor in a foreign entity transitions to or from the equity method of accounting and applies this provision on a modified retrospective basis through a cumulative-effect adjustment to retained earnings at the beginning of the period of adoption; and (3) removes the exception to using the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. ASU 2019-12 also simplifies accounting principles by making other changes, including requiring an entity to: (1) evaluate whether a step-up in tax basis of goodwill relates to a business combination or a separate transaction; (2) make a policy election to not allocate consolidated income taxes when a member of a consolidated tax return is not subject to income tax and to apply this provision retrospectively to all periods presented; and (3) recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and apply this provision either retrospectively for all periods presented or on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The provisions of this guidance (except as specifically mentioned above) are to be applied prospectively upon their effective date. ASU 2019-12 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those years. Early adoption is permitted but requires simultaneous adoption of all provisions of this guidance. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In April 2019, the FASB issued Accounting Standards Update No. 2019-04, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ("ASU 2019-04"). ASU 2019-04 clarifies certain aspects of previously issued accounting standards related to: (1) ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements ("ASU 2016-13"), in areas of accrued interest receivable, transfers of loans and debt securities between classifications, recoveries and prepayments, (2) ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12"), in areas of partial-term fair value hedges, fair value hedge basis adjustments, certain disclosures and transition requirements and (3) ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"), in areas of remeasurement of equity securities under ASC 820, Fair Value Measurement , when using the measurement alternative and remeasurement of equity securities at historical exchange rates. The amendments related to ASU 2016-13 are required to be adopted in conjunction with that accounting standards update, as further described below. Since the Company has already adopted ASU 2017-12 and ASU 2016-01, the related amendments in ASU 2019-04 are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted in any interim period. The amendments to ASU 2017-12 can either be adopted retrospectively as of the date of adoption of ASU 2017-12 or they can be adopted prospectively. The amendments to ASU 2016-01 are required to be applied using a modified-retrospective adoption approach with a cumulative-effect adjustment to retained earnings as of the date of adoption of ASU 2016-01, except for those related to equity securities without readily determinable fair values that are measured using the measurement alternative, which are required to be applied prospectively. The standard was effective for the Company beginning on December 30, 2019, the first day of the Company's fiscal year 2020. The Company will apply the provisions of this guidance prospectively. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract ("ASU 2018-15"). ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance on capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). The provisions of this guidance are to be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The standard was effective for the Company beginning on December 30, 2019, the first day of the Company's fiscal year 2020. The Company will apply the provisions of this guidance prospectively. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans ("ASU 2018-14"). ASU 2018-14 adds, removes, and clarifies disclosure requirements related to defined benefit pension and other postretirement plans. ASU 2018-14 adds requirements for an entity to disclose the weighted-average interest crediting rates used in the entity’s cash balance pension plans and other similar plans; and an explanation of the reasons for significant gains and losses related to changes in the benefit obligation for the period . Further, ASU 2018-14 removes guidance that currently requires the following disclosures: the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year; the amount and timing of plan assets expected to be returned to the employer; information about (1) benefits covered by related-party insurance and annuity contracts and (2) significant transactions between the plan and related parties; and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. ASU 2018-14 also clarifies the guidance in Compensation-Retirement Benefits (Topic 715-20-50-3) on defined benefit plans to require disclosure of (1) the projected benefit obligation ("PBO") and fair value of plan assets for pension plans with PBOs in excess of plan assets (the same disclosure with reference to the accumulated postretirement benefit obligation rather than the PBO is required for other postretirement benefit plans) and (2) the accumulated benefit obligation ("ABO") and fair value of plan assets for pension plans with ABOs in excess of plan assets. The provisions of this guidance are to be applied retrospectively to all periods presented upon their effective date. ASU 2018-14 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those years with early adoption permitted. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). ASU 2018-13 adds, removes, and modifies certain disclosures related to fair value measurements. ASU 2018-13 adds requirements for an entity to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Further, ASU 2018-13 removes the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. ASU 2018-13 also modifies existing disclosure requirements related to measurement uncertainty. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are to be applied retrospectively to all periods presented upon their effective date. The standard was effective for the Company beginning on December 30, 2019, the first day of the Company's fiscal year 2020. The adoption is not expected to have a material impact on the Company's disclosures related to fair value measurements. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments . ASU 2016-13 changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The standard requires entities to use the expected loss impairment model and will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance sheet credit exposures. Entities are required to estimate the lifetime “expected credit loss” for each applicable financial asset and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The standard also amends the impairment model for available-for-sale (“AFS”) debt securities and requires entities to determine whether all or a portion of the unrealized loss on an AFS debt security is a credit loss. An entity will recognize an allowance for credit losses on an AFS debt security as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment. The provisions of this guidance are to be applied using a modified-retrospective approach. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Subsequent to the issuance of ASU 2016-13, in November 2018, the FASB issued Accounting Standards Update No. 2018-19, Codification Improvements to Topic 326, Financial Instruments -

Revenue (Notes)

Revenue (Notes) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Revenue [Abstract]
Revenue from Contract with Customer [Text Block]	Revenue Nature of goods and services The following is a description of principal activities, by reportable segments, from which the Company generates its revenue. For more detailed information about the reportable segments, see Note 24. i. Discovery & Analytical Solutions The Discovery & Analytical Solutions ("DAS") segment of the Company principally generates revenue from sales of (a) instruments, consumables and services in the applied markets and (b) instruments, reagents, informatics, detection and imaging technologies, extended warranties, training and services in the life sciences market. Products and services may be sold separately or in bundled packages. The typical length of a contract for service is 12 to 36 months. For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis. The Company sells products and services predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including distributors. Payment terms granted to distributors are the same as those granted to end-customers and payments are not dependent upon the distributor's receipt of payment from their end-user customers. In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. The primary purpose of its invoicing terms is to provide customers with simplified and predictable ways of purchasing products and services, rather than to receive financing from the customers or to provide customers with financing. Examples include invoicing at the beginning of a subscription term with revenue recognized ratably over the contract period, and multi-year software licenses or software subscriptions that are invoiced annually with revenue recognized upfront. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year. Products and services Nature, timing of satisfaction of performance obligations, and significant payment terms Instruments For instruments that include installation, and if the installation meets the criteria to be considered a separate performance obligation, product revenue is generally recognized upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers, and installation revenue is recognized when the installation is complete. Certain of the Company's products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days. Consumables and reagents The Company recognizes revenue from the sale of consumables and reagents upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 days. Software licenses and subscriptions Customers may purchase perpetual or term licenses, or subscribe to licenses, which provide customers with the same functionality and differ mainly in the duration over which the customer benefits from the software. The Company sells its software subscriptions or software licenses with maintenance services and, in some cases, with consulting services. The Company recognizes revenue for the software upfront at the point in time when the software is made available to the customer. For maintenance and consulting services, revenue is recognized ratably over the period in which the services are provided. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 60 days. Subscription contracts are typically billed annually on the anniversary date of the contract. Software subscriptions and maintenance service contracts are non-cancelable. Cloud services Cloud services, which allow customers to use hosted software over the contract period without taking possession of the software, are provided on either a subscription or consumption basis. Revenue related to cloud services provided on a subscription basis is recognized ratably over the contract period. Revenue related to cloud services provided on a consumption basis, such as the amount of storage used in a period, is recognized based on the customer utilization of such resources. Payment terms are generally net 30 days from signing of contract and contracts are non-cancelable. Extended warranty The Company recognizes revenue for extended warranties on a straight-line basis over the extended warranty period in service revenue. In the majority of countries in which the Company operates, the customary warranty period is one year and the extended warranty covers periods beyond year one. Customers typically pay for extended warranties on an annual basis over the term of the warranty. In general, customers can cancel the extended warranty at any time with 30 days notice without significant penalty. Laboratory services and training The Company's service offerings include service contracts, field service, including related time and materials, and training. The Company recognizes revenue as the services are performed. Revenue for the service contracts is recognized over the contract period or at a point in time when the service is billable based on time and materials. The Company recognizes revenue as training is provided in service revenue. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 60 days. In general, customers can cancel the service contracts at any time with 30 to 90 days notice without significant penalty. ii. Diagnostics The Diagnostics segment of the Company principally generates revenue from sales of instruments, solutions, consumables, reagents, extended warranties and services in the diagnostics market. Products and services may be sold separately or in bundled packages. For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis. The Company sells products and services predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including distributors. Payment terms granted to distributors are the same as those granted to end-customers and payments are not dependent upon the distributor's receipt of payment from their end-user customers. In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. The primary purpose of its invoicing terms is to provide customers with simplified and predictable ways of purchasing products and services, rather than to receive financing from the customers or to provide customers with financing. Examples include invoicing at the beginning of a storage period with revenue recognized ratably over the contract period. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year. Products and services Nature, timing of satisfaction of performance obligations, and significant payment terms Instruments For instruments that include installation, and if the installation meets the criteria to be considered a separate performance obligation, product revenue is generally recognized upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers, and installation revenue is recognized when the installation is complete. Certain of the Company's products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days. Consumables and reagents The Company recognizes revenue from the sale of consumables and reagents upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 days. Solutions When the Company sells the instrument and reagents that work only on those instruments to a customer or distributor, the Company considers the instrument and reagents as separate performance obligations. The Company recognizes revenue when an instrument is sold to the customer upon delivery or when title has transferred to the customer, which is generally the point in time where control of the products has been transferred to customers. Revenue from the sale of reagents is also recognized at the time of delivery or when title has transferred to the customer. Payment terms for instrument and reagent sales are usually net 30 days from invoice date. When the Company places the instrument at the customer's site and sells the reagents to a customer, the instrument and reagents are accounted for together as one performance obligation. The Company does not charge a fee for the use of the instrument and retains ownership of the placed instrument. The Company has a right to remove the instrument and replace it with another instrument at the customer's site at any time throughout the contract term. The Company recognizes revenue upon delivery of reagents, which is the point in time where the Company has performed its obligation to provide a screening solution to the customer. Payment terms are usually net 30 days from invoice date. Payment terms for certain contracts are based on equal installments over the duration of the contract. Extended warranty The Company recognizes revenue for extended warranties on a straight-line basis over the extended warranty period in service revenue. In the majority of countries in which the Company operates, the customary warranty period is one year and the extended warranty covers periods beyond year one. Customers typically pay for extended warranties on an annual basis over the term of the warranty. In general, customers can cancel the extended warranty at any time with 30 days notice without significant penalty. Services The Company's service offerings include cord blood processing and storage, and training. The Company recognizes revenue for the cord blood processing and training as the services are performed in service revenue. Revenue for the storage contracts are recognized over the contract period. Storage is typically for a period of 1, 20, or 25 years or lifetime. Lifetime storage is recognized over a certain period that is based on the life expectancy estimate from Social Security data. For cord blood processing, customers pay the processing fee in full at the point of sale. The processing fee is non-refundable unless the cord blood is non-viable for storage. For storage, customers are required to pay the storage fees in full upfront. Storage fees are refundable to the customer on a pro-rated basis if the contract is canceled. Disaggregation of revenue In the following tables, revenue is disaggregated by primary geographical market, end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments revenue. Reportable Segments For the fiscal year ended December 29, 2019 December 30, 2018 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 717,205 $ 401,591 $ 1,118,796 $ 680,117 $ 385,005 $ 1,065,122 Europe 495,768 291,610 787,378 494,707 283,385 778,092 Asia 533,188 444,311 977,499 518,387 416,395 934,782 $ 1,746,161 $ 1,137,512 $ 2,883,673 $ 1,693,211 $ 1,084,785 $ 2,777,996 Primary end-markets Diagnostics $ — $ 1,137,512 $ 1,137,512 $ — $ 1,084,785 $ 1,084,785 Life sciences 977,200 — 977,200 934,690 — 934,690 Applied markets 768,961 — 768,961 758,521 — 758,521 $ 1,746,161 $ 1,137,512 $ 2,883,673 $ 1,693,211 $ 1,084,785 $ 2,777,996 Timing of revenue recognition Products and services transferred at a point in time $ 1,276,499 $ 1,053,974 $ 2,330,473 $ 1,210,745 $ 1,002,213 $ 2,212,958 Services transferred over time 469,662 83,538 553,200 482,466 82,572 565,038 $ 1,746,161 $ 1,137,512 $ 2,883,673 $ 1,693,211 $ 1,084,785 $ 2,777,996 Contract Balances Contract assets: The unbilled receivables (contract assets) primarily relate to the Company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheets. The balances of contract assets as of December 29, 2019 and December 30, 2018 were $37.0 million and $31.9 million , respectively. The amount of unbilled receivables recognized at the beginning of fiscal year 2019 that were transferred to trade receivables during the fiscal year ended December 29, 2019 was $17.3 million . The increase in unbilled receivables during the fiscal year ended December 29, 2019 as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period, amounted to $22.4 million . The amount of unbilled receivables recognized at the beginning of fiscal year 2018 that were transferred to trade receivables during the fiscal year ended December 30, 2018 was $21.9 million . The increase in unbilled receivables during the fiscal year ended December 30, 2018 as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period, amounted to $31.1 million . Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related installation for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in "Accounts payable" or long-term in "Long-term liabilities" in the consolidated balance sheets based on the timing of when the Company expects to recognize revenue. The balances of contract liabilities as of December 29, 2019 and December 30, 2018 were $29.9 million and $30.8 million , respectively. The increase in contract liabilities during the fiscal year ended December 29, 2019 due to cash received, excluding amounts recognized as revenue during the period, was $20.4 million . The amount of revenue recognized during the fiscal year ended December 29, 2019 that was included in the contract liability balance at the beginning of the period was $21.2 million . The increase in contract liabilities during the fiscal year ended December 30, 2018 due to cash received, excluding amounts recognized as revenue during the period, was $23.6 million . The amount of revenue recognized during the fiscal year ended December 30, 2018 that was included in the contract liability balance at the beginning of the period was $21.8 million . Contract costs: The Company recognizes the incremental costs of obtaining a contract with a customer as an asset if it expects the benefit of those costs to be longer than one year. The Company determined that certain sales incentive programs meet the requirements to be capitalized. Total capitalized costs to obtain a contract were immaterial during the period and are included in other current and long-term assets on the consolidated balance sheet. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the Company's internal sales force compensation program, as the Company determined that annual compensation is commensurate with annual sales activities. Transaction price allocated to the remaining performance obligations The Company applies the practical expedient in ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized beyond one year in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders and noncancelable software subscriptions and cloud service contracts.
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 2,883,673	$ 2,777,996	$ 2,256,982
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	2,330,473	2,212,958
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	553,200	565,038
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,118,796	1,065,122
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	787,378	778,092
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	977,499	934,782
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,137,512	1,084,785
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	977,200	934,690
Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	768,961	758,521
Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,746,161	1,693,211	1,578,459
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,276,499	1,210,745
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	469,662	482,466
Discovery & Analytical Solutions [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	717,205	680,117
Discovery & Analytical Solutions [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	495,768	494,707
Discovery & Analytical Solutions [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	533,188	518,387
Discovery & Analytical Solutions [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Discovery & Analytical Solutions [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	977,200	934,690
Discovery & Analytical Solutions [Member] | Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	768,961	758,521
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,137,512	1,084,785	$ 678,523
Diagnostics [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,053,974	1,002,213
Diagnostics [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	83,538	82,572
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	401,591	385,005
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	291,610	283,385
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	444,311	416,395
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,137,512	1,084,785
Diagnostics [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Diagnostics [Member] | Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 29, 2019
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Disposition of Businesses and Assets As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. When the discontinued operations represented a strategic shift that will have a major effect on the Company's operations and financial statements, the Company has accounted for these businesses as discontinued operations and accordingly, has presented the results of operations and related cash flows as discontinued operations. Any business deemed to be a discontinued operation prior to the adoption of Accounting Standards Update 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of An Entity, continues to be reported as a discontinued operation, and the results of operations and related cash flows are presented as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within assets and liabilities from discontinued operations in the accompanying consolidated balance sheets as of December 29, 2019 and December 30, 2018 . The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years ended: December 29, December 30, December 31, (In thousands) (Loss) gain on disposition of the Medical Imaging business $ — $ (793 ) $ 179,615 Loss on disposition of Fluid Sciences business — (66 ) — (Loss) gain on disposition of discontinued operations before income taxes $ — $ (859 ) $ 179,615 On May 1, 2017 (the "Closing Date"), the Company completed the sale of its Medical Imaging business to Varex Imaging Corporation ("Varex") pursuant to the terms of the Master Purchase and Sale Agreement, dated December 21, 2016 (the “Agreement”), by and between the Company and Varian Medical Systems, Inc. ("Varian") and the subsequent Assignment and Assumption Agreement, dated January 27, 2017, between Varian and Varex, pursuant to which Varian assigned its rights under the Agreement to Varex. On the Closing Date, the Company received consideration of approximately $277.4 million for the sale of the Medical Imaging business. During fiscal year 2017, the Company paid Varex $4.2 million to settle a post-closing working capital adjustment. During fiscal year 2017, the Company recorded a pre-tax gain of $179.6 million and income tax expense of $43.1 million related to the sale of the Medical Imaging business in discontinued operations and dispositions. The corresponding tax liability was recorded within the other tax liabilities in the consolidated balance sheet, and the Company expects to utilize tax attributes to minimize the tax liability. Following the closing, the Company provided certain customary transitional services during a period of up to 12 months . Commercial transactions between the parties following the closing of the transaction were not significant. During fiscal year 2018, the Company completed the sale of substantially all of the assets and liabilities related to its multispectral imaging business for aggregate consideration of $37.3 million , recognizing a pre-tax gain of $13.0 million . The pre-tax gain is included in interest and other expense, net in the consolidated statement of operations. The multispectral imaging business was a component of the Company's DAS segment. The divestiture of the multispectral imaging business has not been classified as a discontinued operation in this Form 10-K because the disposition does not represent a strategic shift that will have a major effect on the Company's operations and financial statements. During fiscal year 2017, the Company sold Suzhou PerkinElmer Medical Laboratory Co., Ltd. ("Suzhou") for aggregate consideration of $2.3 million , recognizing a pre-tax loss of $1.1 million . The pre-tax loss is included in interest and other expense, net in the consolidated statement of operations. Suzhou was a component of the Company's Diagnostics segment. The divestiture of Suzhou has not been classified as a discontinued operation in this Form 10-K because the disposition does not represent a strategic shift that will have a major effect on the Company's operations and financial statements. The summary pre-tax operating results of the discontinued operations were as follows during the three fiscal years ended: December 29, December 30, December 31, (In thousands) Revenue $ — $ — $ 44,343 Cost of revenue — — 32,933 Selling, general and administrative expenses — — 5,869 Research and development expenses — — 4,891 Restructuring and other costs, net — — — Income from discontinued operations before income taxes $ — $ — $ 650 The Company recorded a provision for (benefit from) income taxes of $0.2 million , $(1.3) million and $44.5 million on discontinued operations and dispositions in fiscal years 2019, 2018 and 2017 , respectively.

Restructuring and Contract Term

Restructuring and Contract Termination Charges, Net	12 Months Ended
	Dec. 29, 2019
Restructuring and Related Activities [Abstract]
Restructuring and Contract Termination Charges, Net	Restructuring and Other Costs, Net The Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of the Company's operations with its growth strategy, the integration of its business units and its productivity initiatives. The activities associated with these plans have been reported as restructuring and other costs, net, as applicable, and are included as a component of income from continuing operations. The current portion of restructuring and other costs is recorded in short-term accrued restructuring and other costs and accrued expense and other current liabilities. The long-term portion of restructuring and other costs is recorded in long-term liabilities and operating lease liabilities. The Company implemented a restructuring plan in each quarter of fiscal year 2019 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q1 2019 Plan", "Q2 2019 Plan", "Q3 2019 Plan" and "Q4 2019 Plan", respectively). The Company implemented a restructuring plan in each of the first, third and fourth quarters of fiscal year 2018 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q1 2018 Plan", "Q3 2018 Plan" and "Q4 2018 Plan", respectively). The Company implemented a restructuring plan in each of the fourth and third quarters of fiscal year 2017 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q4 2017 Plan and "Q3 2017 Plan", respectively). The Company implemented a restructuring plan in the first quarter of fiscal year 2017 consisting of workforce reductions and the closure of excess facility space principally intended to focus resources on higher growth end markets (the "Q1 2017 Plan"). All other previous restructuring plans were workforce reductions or the closure of excess facility space principally intended to integrate the Company's businesses in order to realign operations, reduce costs, achieve operational efficiencies and shift resources into geographic regions and end markets that are more consistent with the Company's growth strategy (the "Previous Plans"). The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions implemented during fiscal years 2019, 2018 and 2017 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Diagnostics Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Severance Excess Facility (In thousands, except headcount data) Q4 2019 Plan 22 $ 2,404 $ 177 $ — $ — $ 2,581 Q3 FY2020 — Q3 2019 Plan 259 2,641 11,156 — — 13,797 Q2 FY2020 — Q2 2019 Plan 44 1,129 4,461 — — 5,590 Q1 FY2020 — Q1 2019 Plan 105 1,459 6,001 — — 7,460 Q4 FY2019 — Q4 2018 Plan 1 — 348 — — 348 Q1 FY2019 — Q3 2018 Plan 61 618 1,146 — — 1,764 Q4 FY2019 — Q1 2018 Plan 47 902 5,096 — — 5,998 Q4 FY2019 — Q4 2017 Plan 29 255 1,680 — — 1,935 Q1 FY2019 — Q3 2017 Plan 27 1,021 1,321 — — 2,342 Q4 FY2018 — Q1 2017 Plan 90 1,631 5,000 33 33 6,697 Q2 FY2018 Q2 FY2018 The Company expects to make payments under the Previous Plans for remaining residual lease obligations, with terms varying in length, through fiscal year 2022 . The Company has terminated various contractual commitments in connection with certain disposal activities and has recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company. The Company recorded additional pre-tax charges of $0.2 million , $5.0 million and $3.6 million in the Discovery & Analytical Solutions segment during fiscal years 2019, 2018 and 2017 , respectively, and $0.2 million and $0.5 million during fiscal year 2019 and 2017, respectively, in the Diagnostics segment as a result of these contract terminations. The Company recorded pre-tax charges of $0.8 million associated with relocating facilities during fiscal year 2019. The Company expects to make payments on these relocation activities through fiscal year 2021. At December 29, 2019 , the Company had $13.9 million recorded for accrued restructuring and other costs, of which $11.6 million was recorded in short-term accrued restructuring and other costs, $0.4 million was recorded in accrued expenses and other current liabilities, $0.8 million was recorded in long-term liabilities, and $1.1 million was recorded in operating lease liabilities. At December 30, 2018 , the Company had $6.2 million recorded for accrued restructuring and other costs, of which $4.8 million was recorded in short-term accrued restructuring and other costs and $1.4 million was recorded in long-term liabilities. The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as other accrual balances and related activity, during fiscal years 2019, 2018 and 2017 in continuing operations: Balance at January 1, 2017 2017 Charges and Changes in Estimates, Net 2017 Amounts Paid Balance at December 31, 2017 2018 Charges and Changes in Estimates, Net 2018 Amounts Paid Balance at December 30, 2018 2019 Charges and Changes in Estimates, Net 2019 Amounts Paid Balance at December 29, 2019 Severance: Q4 2019 Plan $ — $ — $ — $ — $ — $ — $ — $ 2,581 $ (1,692 ) $ 889 Q3 2019 Plan — — — — — — — 13,797 (7,486 ) 6,311 Q2 2019 Plan — — — — — — — 5,590 (3,701 ) 1,889 Q1 2019 Plan — — — — — — — 7,483 (5,354 ) 2,129 Q4 2018 Plan — — — — 348 — 348 3 (351 ) — Q3 2018 Plan (1) — — — — 2,054 (639 ) 1,415 (77 ) (1,314 ) 24 Q1 2018 Plan (2) — — — — 5,998 (4,389 ) 1,609 (1,069 ) (282 ) 258 Q4 2017 Plan — 1,935 (16 ) 1,919 (381 ) (1,538 ) — — — — Q3 2017 Plan — 2,342 (270 ) 2,072 (1,204 ) (868 ) — — — — Q1 2017 Plan (3) — 6,631 (4,133 ) 2,498 (983 ) (1,232 ) 283 (276 ) (7 ) — Facility: Q1 2017 Plan — 66 (33 ) 33 — (33 ) — — — — Previous Plans (4) 10,424 (1,568 ) (4,457 ) 4,399 570 (2,581 ) 2,388 117 (1,140 ) 1,365 Restructuring 10,424 9,406 (8,909 ) 10,921 6,402 (11,280 ) 6,043 28,149 (21,327 ) 12,865 Contract Termination 117 3,251 (320 ) 3,048 4,742 (7,653 ) 137 452 (401 ) 188 Other Costs — — — — — — — 827 — 827 Total Restructuring and Other Liabilities $ 10,541 $ 12,657 $ (9,229 ) $ 13,969 $ 11,144 $ (18,933 ) $ 6,180 $ 29,428 $ (21,728 ) $ 13,880 ____________________________ (1) During fiscal year 2019 , the Company recognized pre-tax restructuring reversals of $0.4 million in the Diagnostics segment related to lower than expected costs associated with workforce reductions and an additional expense of $0.3 million in the Discovery & Analytical Solutions segment for the Q3 2018 Plan. (2) During fiscal year 2019 , the Company recognized pre-tax restructuring reversals of $1.1 million in the Discovery & Analytical Solutions segment related to lower than expected costs associated with workforce reductions for the Q1 2018 Plan. (3) During fiscal year 2019 , the Company recognized pre-tax restructuring reversals of $0.3 million in the Discovery & Analytical Solutions segment related to lower than expected costs associated with workforce reductions for the Q1 2017 Plan. (4) During fiscal year 2019 , the Company recognized pre-tax restructuring expense of $0.1 million in the Discovery & Analytical Solutions segment related to higher than expected costs associated with workforce reductions for the Previous Plans.

Interest and Other Expense (Inc

Interest and Other Expense (Income), Net	12 Months Ended
	Dec. 29, 2019
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and Other Expense, Net Interest and other expense, net, consisted of the following for the fiscal years ended: December 29, December 30, January 1, Interest income $ (1,495 ) $ (1,141 ) $ (2,571 ) Interest expense 63,627 66,976 43,940 Loss (gain) on disposition of businesses and assets, net (see Note 4) 2,469 (12,844 ) 309 Debt extinguishment costs (see Note 14) 32,541 — — Other expense (income), net 27,689 13,210 (42,781 ) Total interest and other expense, net $ 124,831 $ 66,201 $ (1,103 ) Foreign currency transaction losses (gains) were $6.5 million , $(9.4) million and $(29.2) million in fiscal years 2019, 2018 and 2017 , respectively. Net (gains) losses from forward currency hedge contracts were $(3.5) million , $11.7 million and $(4.5) million in fiscal years 2019, 2018 and 2017 , respectively. The other components of net periodic pension cost (credit) were $25.3 million , $11.5 million and $(9.2) million in fiscal years 2019, 2018 and 2017

Income Taxes

Income Taxes	12 Months Ended
	Dec. 29, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position. The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: December 29, December 30, December 31, (In thousands) Unrecognized tax benefits, beginning of year $ 33,009 $ 30,308 $ 29,607 Gross increases—tax positions in prior periods 4,433 6,931 749 Gross decreases—tax positions in prior periods (2,183 ) (1,622 ) (828 ) Gross increases—current-period tax positions 152 — 2,346 Settlements (45 ) (2,253 ) (324 ) Lapse of statute of limitations — (181 ) (1,371 ) Foreign currency translation adjustments 181 (174 ) 129 Unrecognized tax benefits, end of year $ 35,547 $ 33,009 $ 30,308 The Company classifies interest and penalties as a component of income tax expense. At December 29, 2019 and December 30, 2018 , the Company had accrued interest and penalties of $4.1 million and $2.5 million , respectively. During fiscal years 2019, 2018 and 2017 , the Company recognized a net expense (benefit) of $1.6 million , $0.4 million and $(0.3) million , respectively, for interest and penalties in its total tax provision which includes settlements and statutes of limitations that had lapsed. At December 29, 2019 , the Company had gross tax effected unrecognized tax benefits of $35.5 million , of which $33.8 million , if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations. The Company believes that it is reasonably possible that approximately $2.4 million of its uncertain tax positions at December 29, 2019 , including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2010 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as Finland, Germany, Italy, Netherlands, Singapore, China and the United States. The tax years under examination vary by jurisdiction. During fiscal year 2019 , the Company recorded net discrete income tax benefit of $23.4 million , of which $12.3 million was a result of a valuation allowance reversal, $4.9 million related to the recognition of excess tax benefits on stock compensation, $6.7 million related to provision to return adjustments, and $3.7 million was a result of tax elections made during fiscal year 2019 . The preceding discrete benefits were partially offset by $2.7 million expense related to the one-time transition tax under the Tax Cut and Jobs Act (the "Tax Act") and additional discrete expense of $1.4 million related to other tax matters. During fiscal years 2018 and 2017 , the Company recorded net discrete income tax benefits of $8.1 million and income tax expense of $98.6 million , respectively. The $8.1 million tax benefit in fiscal year 2018 was primarily due to a discrete benefit of $7.2 million related to the recognition of excess tax benefits on stock compensation, along with an additional discrete benefit of $2.0 million as a result of the Tax Act, partially offset by $1.1 million expense related to other tax matters. The $98.6 million of tax expense in fiscal year 2017 was primarily related to $106.5 million expense as a result of the Tax Act, partially offset by discrete benefits of $5.1 million related to the recognition of excess tax benefits on stock compensation and $2.8 million related to other tax matters. The components of income from continuing operations before income taxes were as follows for the fiscal years ended: December 29, December 30, December 31, (In thousands) U.S. $ 29,252 $ 32,627 $ 3,743 Non-U.S. 207,890 225,056 292,975 Total $ 237,142 $ 257,683 $ 296,718 On a U.S. income tax basis, the Company has reported significant taxable income over the three-year period ended December 29, 2019 . The Company has utilized tax attributes to minimize cash taxes paid on that taxable income. The components of the provision for income taxes on continuing operations were as follows: Current Expense Deferred Expense (Benefit) Total (In thousands) Fiscal year ended December 29, 2019 Federal $ 3,735 $ (267 ) $ 3,468 State 4,425 (1,574 ) 2,851 Non-U.S. 62,582 (59,512 ) 3,070 Total $ 70,742 $ (61,353 ) $ 9,389 Fiscal year ended December 30, 2018 Federal $ 7,938 $ (5,250 ) $ 2,688 State 2,345 2,572 4,917 Non-U.S. 61,028 (48,425 ) 12,603 Total $ 71,311 $ (51,103 ) $ 20,208 Fiscal year ended December 31, 2017 Federal $ 62,003 $ 35,435 $ 97,438 State 3,332 (792 ) 2,540 Non-U.S. 45,639 (5,789 ) 39,850 Total $ 110,974 $ 28,854 $ 139,828 The total provision for (benefit from) income taxes included in the consolidated financial statements is as follows for the fiscal years ended: December 29, December 30, December 31, (In thousands) Continuing operations $ 9,389 $ 20,208 $ 139,828 Discontinued operations 195 (1,311 ) 44,522 Total $ 9,584 $ 18,897 $ 184,350 A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended: December 29, December 30, December 31, (In thousands) Tax at statutory rate $ 49,799 $ 54,114 $ 103,851 Non-U.S. rate differential, net (32,124 ) (27,281 ) (65,836 ) U.S. taxation of multinational operations 4,251 7,047 5,408 State income taxes, net 1,941 2,028 1,810 Prior year tax matters (5,103 ) 1,124 (2,888 ) Effect of stock compensation (2,053 ) (6,331 ) (5,067 ) General business tax credits (4,325 ) (3,738 ) (8,249 ) Change in valuation allowance (1,117 ) (759 ) 1,951 Tax elections (3,700 ) — — Impact of U.S. Tax Act 2,718 (2,025 ) 106,538 Others, net (898 ) (3,971 ) 2,310 Total $ 9,389 $ 20,208 $ 139,828 The variation in the Company's effective tax rate for each year is primarily a result of the recognition of earnings in foreign jurisdictions, predominantly Singapore, Finland and The Netherlands, which are taxed at rates lower than the U.S. federal statutory rate, resulting in a benefit from income taxes of $16.7 million in fiscal year 2019 , $18.7 million in fiscal year 2018 and $55.9 million in fiscal year 2017 . These amounts include $10.4 million in fiscal year 2019 , $10.3 million in fiscal year 2018 and $10.1 million in fiscal year 2017 of benefits derived from tax holidays in China and Singapore. The effect of these benefits derived from tax holidays on basic and diluted earnings per share for fiscal year 2019 was $0.09 and $0.09 , respectively, for fiscal year 2018 was $0.09 and $0.09 , respectively, and for fiscal year 2017 was $0.09 and $0.09 , respectively. The tax holiday in China is renewed every three years. The Company expects to renew the tax holiday of one of its subsidiaries in China that expired in fiscal year 2019 . The tax holiday in one of the Company's subsidiaries in Singapore is scheduled to expire in fiscal year 2023 . The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of December 29, 2019 and December 30, 2018 were as follows: December 29, December 30, (In thousands) Deferred tax assets: Inventory $ 4,662 $ — Reserves and accruals 46,817 39,487 Accrued compensation 18,953 21,709 Net operating loss and credit carryforwards 116,751 144,421 Accrued pension 35,890 31,146 Restructuring reserve 2,983 1,780 Deferred revenue 30,412 31,045 Operating lease liabilities 46,477 — Total deferred tax assets 302,945 269,588 Deferred tax liabilities: Inventory — (278 ) Postretirement health benefits (4,106 ) (3,406 ) Depreciation and amortization (330,768 ) (309,958 ) Operating lease right-of-use assets (42,774 ) — All other, net (1,780 ) (1,879 ) Total deferred tax liabilities (379,428 ) (315,521 ) Valuation allowance (88,449 ) (102,087 ) Net deferred tax liabilities $ (164,932 ) $ (148,020 ) The components of net deferred tax liabilities as of December 29, 2019 and December 30, 2018 were recognized in the consolidated balance sheets as follows: December 29, December 30, (In thousands) Other assets, net $ 60,004 $ 79,312 Long-term liabilities (224,936 ) (227,332 ) Total $ (164,932 ) $ (148,020 ) At December 29, 2019 , for income tax return purposes, the Company had U.S. federal net operating loss carryforwards of $33.6 million , state net operating loss carryforwards of $213.8 million , foreign net operating loss carryforwards of $408.7 million , state tax credit carryforwards of $6.7 million , general business tax credit carryforwards of $5.7 million , and foreign tax credit carryforwards of $0.1 million . These are subject to expiration in years ranging from 2020 to 2038 , and without expiration for certain foreign net operating loss carryforwards and certain state credit carryforwards. Valuation allowances take into consideration limitations imposed upon the use of the tax attributes and reduce the value of such items to the likely net realizable amount. The Company regularly evaluates positive and negative evidence available to determine if valuation allowances are required or if existing valuation allowances are no longer required. Valuation allowances have been provided on state net operating loss and state tax credit carryforwards and on certain foreign tax attributes that the Company has determined are not more likely than not to be realized. The decrease in the valuation allowance of $13.6 million in fiscal year 2019 is primarily due to the reversal of $12.3 million of valuation allowance related to the utilization of net operating loss carryforwards by some of the Company's non-U.S. subsidiaries. The components of net deferred tax (liabilities) assets as of December 29, 2019 and December 30, 2018 were as follows: December 29, December 30, (In thousands) U.S. $ 43,683 $ 52,469 Non-U.S. (208,615 ) (200,489 ) Total $ (164,932 ) $ (148,020 ) Historically, deferred income tax expense has not been provided on the cumulative undistributed earnings of the Company's international subsidiaries. In fiscal year 2018, the Company determined that previously undistributed earnings of certain international subsidiaries of $1.4 billion no longer met the requirements of indefinite reinvestment. The Company recognized $2.9 million of income tax expense in fiscal year 2018 associated with the change in its assertion. In addition, during fiscal years 2019 and 2018 , the Company refined its calculations of the one-time transition tax and recorded a tax expense (benefit) of $2.7 million and $(4.6) million , respectively. The Company’s intent is to continue to reinvest the remaining undistributed earnings of its international subsidiaries indefinitely. While federal income tax expense has been recognized as a result of the Tax Act, the Company has not provided any additional deferred taxes with respect to items such as foreign withholding taxes, state income tax or foreign exchange gain or loss. In addition, no additional income taxes have been provided for any remaining undistributed foreign earnings not subject to the transition tax, or any additional outside basis difference inherent in these entities, as these amounts continue to be indefinitely reinvested in foreign operations. As of December 29, 2019 , the amount of foreign earnings that the Company has the intent and ability to keep invested outside the U.S. indefinitely and for which no additional incremental tax cost has been provided, other than the $86.0 million from the one-time transition tax on deemed repatriation, was approximately $449.2 million

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 29, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: December 29, December 30, December 31, (In thousands) Number of common shares—basic 110,827 110,561 109,857 Effect of dilutive securities: Stock options 541 761 708 Restricted stock awards 133 212 294 Number of common shares—diluted 111,501 111,534 110,859 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 364 349 287 Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Accounts Receivable, Net

Accounts Receivable, Net	12 Months Ended
	Dec. 29, 2019
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable, net as of December 29, 2019 and December 30, 2018 consisted of the following: December 29, December 30, (In thousands) Accounts receivable, net, current $ 725,184 $ 632,669 Long-term accounts receivable, net, included in Other assets 19,677 — Total accounts receivable, net $ 744,861 $ 632,669 Accounts receivable were net of reserves for doubtful accounts of $35.2 million and $30.6 million as of December 29, 2019 and December 30, 2018 , respectively.

Inventories, Net

Inventories, Net	12 Months Ended
	Dec. 29, 2019
Inventory Disclosure [Abstract]
Inventories, Net	Inventories Inventories as of December 29, 2019 and December 30, 2018 consisted of the following: December 29, December 30, (In thousands) Raw materials $ 130,673 $ 119,115 Work in progress 26,409 18,110 Finished goods 199,855 201,122 Total inventories $ 356,937 $ 338,347

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 29, 2019
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment as of December 29, 2019 and December 30, 2018 , consisted of the following: December 29, December 30, (In thousands) At cost: Land $ 5,272 $ 5,482 Building and leasehold improvements 250,639 272,277 Machinery and equipment 445,669 402,424 Total property, plant and equipment 701,580 680,183 Accumulated depreciation (383,357 ) (361,593 ) Total property, plant and equipment, net $ 318,223 $ 318,590 Depreciation expense on property, plant and equipment for the fiscal years ended December 29, 2019 , December 30, 2018 and December 31, 2017 was $49.7 million , $44.7 million and $31.3 million , respectively.

Marketable Securities and Inves

Marketable Securities and Investments	12 Months Ended
	Dec. 29, 2019
Marketable Securities [Abstract]
Marketable Securities and Investments	Marketable Securities and Investments Investments as of December 29, 2019 and December 30, 2018 consisted of the following: December 29, December 30, (In thousands) Marketable securities $ 2,906 $ 2,447 Equity investments 29,228 16,783 $ 32,134 $ 19,230 Marketable securities. Marketable securities include equity and fixed-income securities held to meet obligations associated with the Company’s supplemental executive retirement plan and other deferred compensation plans. The Company has, accordingly, classified these securities as long-term. The net unrealized holding gain and loss on marketable securities, net of deferred income taxes, reported as a component of other comprehensive income (loss) in the statements of stockholders’ equity, were not material in fiscal years 2019 and 2018 . The proceeds from the sales of securities and the related gains and losses are not material for any period presented. Marketable securities classified as available for sale as of December 29, 2019 and December 30, 2018 consisted of the following: Market Value Gross Unrealized Holding Cost Gains (Losses) (In thousands) December 29, 2019 Equity securities $ 752 $ 1,109 $ — $ (357 ) Fixed-income securities 7 7 — — Other 2,147 2,210 — (63 ) $ 2,906 $ 3,326 $ — $ (420 ) December 30, 2018 Equity securities $ 671 $ 1,037 $ — $ (366 ) Fixed-income securities 22 22 — — Other 1,754 1,817 — (63 ) $ 2,447 $ 2,876 $ — $ (429 ) Equity investments. The Company has equity interests in privately-held entities over which the Company neither has significant influence nor control. These equity investments are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, with changes included in earnings. The Company also recognizes income for any dividends declared from distribution of investee’s earnings. The Company regularly reviews its investments for impairment, including when the carrying value of an investment exceeds its market value. If the Company determines that an investment has sustained an other-than-temporary decline in its value, the investment is written down to its fair value by a charge to earnings that is included in Interest and other expense, net in the consolidated statements of operations. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the security in relation to its cost basis, (ii) the financial condition of the investee, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery in the market value of the investment. For investments without a readily available fair value, the Company evaluates the available information (e.g., budgets, business plans, financial statements, etc.) in addition to quoted market prices, if any, in determining whether an other-than-temporary decline in value exists. Factors indicative of an other-than-temporary decline include recurring operating losses, credit defaults and subsequent rounds of financing at an amount below the cost basis of the Company’s investment.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	12 Months Ended
	Dec. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. The Company performed its annual impairment testing for its reporting units as of January 1, 2019 , its annual impairment testing date for fiscal year 2019 . Non-amortizing intangibles are also subject to an annual impairment test. The Company consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible asset. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset. In addition, the Company evaluates the remaining useful life of our non-amortizing intangible asset at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful life of our non-amortizing intangible asset is no longer indefinite, the asset will be tested for impairment. This intangible asset will then be amortized prospectively over its estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. The changes in the carrying amount of goodwill for fiscal years 2019 and 2018 are as follows: Discovery & Analytical Solutions Diagnostics Consolidated Balance at December 31, 2017 $ 1,344,235 $ 1,657,963 $ 3,002,198 Foreign currency translation (32,189 ) (35,289 ) (67,478 ) Acquisitions, earnouts and other 22,946 (5,058 ) 17,888 Balance at December 30, 2018 1,334,992 1,617,616 2,952,608 Foreign currency translation (8,559 ) (9,725 ) (18,284 ) Acquisitions, earnouts and other 172,387 4,516 176,903 Balance at December 29, 2019 $ 1,498,820 $ 1,612,407 $ 3,111,227 Identifiable intangible asset balances at December 29, 2019 by category and by business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,122 $ 2,709 $ 30,831 Less: Accumulated amortization (27,142 ) (281 ) (27,423 ) Net patents 980 2,428 3,408 Trade names and trademarks 39,859 48,138 87,997 Less: Accumulated amortization (23,632 ) (16,663 ) (40,295 ) Net trade names and trademarks 16,227 31,475 47,702 Licenses 50,393 8,103 58,496 Less: Accumulated amortization (47,607 ) (2,126 ) (49,733 ) Net licenses 2,786 5,977 8,763 Core technology 390,116 298,973 689,089 Less: Accumulated amortization (205,263 ) (115,663 ) (320,926 ) Net core technology 184,853 183,310 368,163 Customer relationships 313,898 847,628 1,161,526 Less: Accumulated amortization (156,967 ) (221,221 ) (378,188 ) Net customer relationships 156,931 626,407 783,338 IPR&D — 1,328 1,328 Net amortizable intangible assets 361,777 850,925 1,212,702 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 432,361 $ 850,925 $ 1,283,286 Identifiable intangible asset balances at December 30, 2018 by category and business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,030 $ 14,616 $ 42,646 Less: Accumulated amortization (25,978 ) (11,775 ) (37,753 ) Net patents 2,052 2,841 4,893 Trade names and trademarks 29,811 48,335 78,146 Less: Accumulated amortization (21,728 ) (12,073 ) (33,801 ) Net trade names and trademarks 8,083 36,262 44,345 Licenses 50,178 3,127 53,305 Less: Accumulated amortization (44,376 ) (1,174 ) (45,550 ) Net licenses 5,802 1,953 7,755 Core technology 240,734 300,177 540,911 Less: Accumulated amortization (189,033 ) (76,711 ) (265,744 ) Net core technology 51,701 223,466 275,167 Customer relationships 222,892 866,635 1,089,527 Less: Accumulated amortization (128,142 ) (165,822 ) (293,964 ) Net customer relationships 94,750 700,813 795,563 IPR&D — 1,360 1,360 Net amortizable intangible assets 162,388 966,695 1,129,083 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 232,972 $ 966,695 $ 1,199,667 Total amortization expense related to definite-lived intangible assets was $164.3 million in fiscal year 2019 , $135.9 million in fiscal year 2018 and $73.7 million in fiscal year 2017 . Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $188.8 million in fiscal year 2020 , $173.0 million in fiscal year 2021 , $156.6 million in fiscal year 2022 , $132.6 million in fiscal year 2023 , and $111.3 million in fiscal year 2024 .

Debt

Debt	12 Months Ended
	Dec. 29, 2019
Debt Disclosure [Abstract]
Debt	Debt Senior Unsecured Revolving Credit Facility. On September 17, 2019, the Company terminated its previous senior unsecured revolving credit facility and entered into a new senior unsecured revolving credit facility with a five-year term and a borrowing capacity of $1.0 billion . The new senior unsecured revolving credit facility provides for revolving loans that may be either US Dollar Base Rate loans or Eurocurrency Rate loans, as those terms are defined in the new credit agreement. As of December 29, 2019 , undrawn letters of credit in the aggregate amount of $11.4 million were treated as issued and outstanding when calculating the borrowing availability under the new senior unsecured revolving credit facility. As of December 29, 2019 , the Company had $663.2 million available for additional borrowing under the facility. The Company plans to use the new senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates on the Eurocurrency Rate loans are based on the Eurocurrency Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The interest rates on the US Dollar Base Rate loans are based on the US Dollar Base Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The base rate is the higher of (i) the Federal Funds Rate (as defined in the new credit agreement) plus 50 basis points, (ii) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its "prime rate," or (iii) the Eurocurrency Rate plus 1.00%. The Eurocurrency margin as of December 29, 2019 was 102.0 basis points. The weighted average Eurocurrency interest rate as of December 29, 2019 was 1.67%, resulting in a weighted average effective Eurocurrency Rate, including the margin, of 2.68%, which was the interest applicable to the borrowings outstanding as of December 29, 2019 . As of December 29, 2019 , the new senior unsecured revolving credit facility had outstanding borrowings of $325.4 million , and $3.4 million of unamortized debt issuance costs. As of December 30, 2018 , the previous senior unsecured revolving credit facility had $418.0 million of outstanding borrowings, and $2.4 million of unamortized debt issuance costs. The credit agreement for the new facility contains affirmative, negative and financial covenants and events of default. The financial covenants include a debt-to-capital ratio that remains applicable for so long as the Company's debt is rated as investment grade. In the event that the Company's debt is not rated as investment grade, the debt-to-capital ratio covenant is replaced with a maximum consolidated leverage ratio covenant and a minimum consolidated interest coverage ratio covenant. 5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “November 2021 Notes”) in a registered public offering and received $493.6 million of net proceeds from the issuance. The November 2021 Notes were issued at 99.4% of the principal amount, which resulted in a discount of $3.1 million . On October 13, 2019, the Company redeemed all of its outstanding November 2021 Notes. The redemption of the November 2021 Notes resulted in a pre-tax, non-operating charge of $32.3 million . The non-operating charge consists of a make-whole premium payment of $31.3 million , partially offset by $1.0 million of proceeds received from a reverse treasury rate lock settlement, to call the November 2021 Notes and $2.0 million associated with the write-off of the existing deferred costs and original issue discount. As of December 30, 2018 , the November 2021 Notes had an aggregate carrying value of $497.4 million , net of $1.1 million of unamortized original issue discount and $1.6 million of unamortized debt issuance costs. 1.875% Senior Unsecured Notes due 2026. On July 19, 2016, the Company issued €500.0 million aggregate principal amount of senior unsecured notes due in 2026 (the “2026 Notes”) in a registered public offering and received approximately €492.3 million of net proceeds from the issuance. The 2026 Notes were issued at 99.118% of the principal amount, which resulted in a discount of €4.4 million . The 2026 Notes mature in July 2026 and bear interest at an annual rate of 1.875% . Interest on the 2026 Notes is payable annually on July 19th each year. The proceeds from the 2026 Notes were used to pay in full the outstanding balance of the Company's previous senior unsecured revolving credit facility. As of December 29, 2019 , the 2026 Notes had an aggregate carrying value of $552.2 million , net of $3.5 million of unamortized original issue discount and $3.3 million of unamortized debt issuance costs. As of December 30, 2018 , the 2026 Notes had an aggregate carrying value of $564.5 million , net of $4.0 million of unamortized original issue discount and $3.8 million of unamortized debt issuance costs. Prior to April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2026 Notes to be redeemed, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2026 Notes being redeemed, discounted on an annual basis, at the applicable Comparable Government Bond Rate (as defined in the indenture governing the 2026 Notes) plus 35 basis points; plus, in each case, accrued and unpaid interest. In addition, at any time on or after April 19, 2026 (three months prior to their maturity date), the Company may redeem the 2026 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2026 Notes due to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2026 Notes) and a contemporaneous downgrade of the 2026 Notes below investment grade, the Company will, in certain circumstances, make an offer to purchase the 2026 Notes at a price equal to 101% of their principal amount plus any accrued and unpaid interest. 0.6% Senior Unsecured Notes due in 2021. On April 11, 2018, the Company issued €300.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “April 2021 Notes”) in a registered public offering and received approximately €298.7 million of net proceeds from the issuance. The April 2021 Notes were issued at 99.95% of the principal amount, which resulted in a discount of €0.2 million . As of December 29, 2019 , the April 2021 Notes had an aggregate carrying value of $334.2 million , net of $0.1 million of unamortized original issue discount and $1.1 million of unamortized debt issuance costs. As of December 30, 2018 , the April 2021 Notes had an aggregate carrying value of $341.3 million , net of $0.1 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs. The April 2021 Notes mature in April 2021 and bear interest at an annual rate of 0.6% . Interest on the April 2021 Notes is payable annually on April 9th each year. Prior to the maturity date of the April 2021 Notes, the Company may redeem them in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the April 2021 Notes to be redeemed, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the April 2021 Notes being redeemed, discounted on an annual basis, at the applicable Comparable Government Bond Rate (as defined in the indenture governing the April 2021 Notes) plus 15 basis points; plus, in each case, accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the April 2021 Notes) and a contemporaneous downgrade of the April 2021 Notes below investment grade, the Company will, in certain circumstances, make an offer to purchase the April 2021 Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest. 3.3% Senior Unsecured Notes due in 2029. On September 12, 2019, the Company issued $850.0 million aggregate principal amount of senior unsecured notes due in 2029 (the "2029 Notes”) in a registered public offering and received $847.2 million of net proceeds from the issuance. The 2029 Notes were issued at 99.67% of the principal amount, which resulted in a discount of $2.8 million . As of December 29, 2019 , the 2029 Notes had an aggregate carrying value of $839.9 million , net of $2.7 million of unamortized original issue discount and $7.4 million of unamortized debt issuance costs. The 2029 Notes mature in September 2029 and bear interest at an annual rate of 3.3% . Interest on the 2029 Notes is payable semi-annually on March 15th and September 15th each year. Proceeds from the 2029 Notes were used to repay all outstanding borrowings under the Company’s previous senior unsecured revolving credit facility with the remaining proceeds used in the redemption of the November 2021 Notes. Prior to June 15, 2029 (three months prior to their maturity date), the Company may redeem the 2029 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2029 Notes to be redeemed, and (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2029 Notes being redeemed (not including any portion of such payments of interest accrued but unpaid as of the date of redemption) assuming that such 2029 Notes matured on June 15, 2029, discounted at the date of redemption on a semi-annual basis (assuming a 360-day year of twelve 30-day months), at the Treasury Rate (as defined in the indenture governing the 2029 Notes) plus 25 basis points, plus accrued and unpaid interest. At any time on or after June 15, 2029 (three months prior to their maturity date), the Company may redeem the 2029 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2029 Notes) and a contemporaneous downgrade of the 2029 Notes below investment grade, each holder of 2029 Notes will have the right to require the Company to repurchase such holder's 2029 Notes for 101% of their principal amount, plus accrued and unpaid interest. Other Debt Facilities. The Company's other debt facilities include Euro-denominated bank loans with an aggregate carrying value of $23.8 million (or €21.3 million ) and $32.1 million (or €28.0 million ) as of December 29, 2019 and December 30, 2018 , respectively. These bank loans are primarily utilized for financing fixed assets and are required to be repaid in monthly or quarterly installments with maturity dates extending to 2028. Of these bank loans, loans in the aggregate amount of $23.7 million bear fixed interest rates between 1.1% and 4.3% and a loan in the amount of $0.1 million bears a variable interest rate based on the Euribor rate plus a margin of 1.5% . An aggregate amount of $6.3 million of the bank loans are secured by mortgages on real property and the remaining $17.5 million are unsecured. Certain credit agreements for the unsecured bank loans include financial covenants which are based on an equity ratio or an equity ratio and minimum interest coverage ratio. In addition, the Company had secured bank loans in the amount of $1.9 million as of December 29, 2019 , and unsecured revolving credit facilities and a secured bank loan in the amount of $5.8 million and $0.3 million , respectively, as of December 30, 2018 . The unsecured revolving debt facilities had fixed interest at a rate of 2.3% . The secured bank loans of $1.9 million bear fixed annual interest rates between 1.95% and 21.5% and are required to be repaid in monthly installments until 2027. Financing Lease Obligations. In fiscal year 2012, the Company entered into agreements with the lessors of certain buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, and as a result the Company was considered the owner of the buildings during the construction period. At the end of the construction period, the Company was not reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property, plant and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At December 30, 2018 , the Company had $34.5 million recorded for these financing lease obligations, of which $1.5 million was recorded as short-term debt and $33.0 million was recorded as long-term debt. Prior to adoption of ASC 842, Leases ("ASC 842"), the buildings were depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other. Upon adoption of ASC 842 in fiscal year 2019, the Company derecognized the impact of this build-to-suit arrangement. The following table summarizes the maturities of the Company’s indebtedness as of December 29, 2019 : Sr. Unsecured Revolving Credit Facility Maturing 2024 April 2021 Notes 2026 Notes 2029 Notes Other Debt Facilities Total (In thousands) 2020 $ — $ — $ — $ — $ 9,974 $ 9,974 2021 — 335,370 — — 7,910 343,280 2022 — — — — 3,759 3,759 2023 — — — — 2,278 2,278 2024 325,377 — — — 1,287 326,664 2025 and thereafter — — 558,950 850,000 536 1,409,486 Total before unamortized discount and debt issuance costs 325,377 335,370 558,950 850,000 25,744 2,095,441 Unamortized discount and debt issuance costs (3,356 ) (1,194 ) (6,756 ) (10,120 ) — (21,426 ) Total $ 322,021 $ 334,176 $ 552,194 $ 839,880 $ 25,744 $ 2,074,015

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 29, 2019
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities as of December 29, 2019 and December 30, 2018 consisted of the following: December 29, December 30, (In thousands) Payroll and incentives $ 77,892 $ 86,549 Employee benefits 42,405 44,060 Deferred revenue 164,261 155,064 Federal, non-U.S. and state income taxes 29,876 30,687 Other accrued operating expenses 188,898 212,467 Total accrued expenses and other current liabilities $ 503,332 $ 528,827

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 30, 2018
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit Plans Savings Plan: The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Savings plan expense was $13.6 million in fiscal year 2019 , $13.2 million in fiscal year 2018 , and $12.5 million in fiscal year 2017 . Pension Plans: The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan was closed to new hires effective January 31, 2001, and benefits for those employed by the Company’s former Life Sciences business were frozen as of that date. Plan benefits were frozen as of March 2003 for those employed by the Company’s former Analytical Instruments business and corporate employees. Plan benefits were frozen as of January 31, 2011 for all remaining employees that were still actively accruing in the plan. The plans provide benefits that are based on an employee’s years of service and compensation near retirement. Net periodic pension cost (credit) for U.S. and non-U.S. plans included the following components for fiscal years ended: December 29, December 30, December 31, (In thousands) Service and administrative costs $ 6,598 $ 6,853 $ 4,951 Interest cost 16,546 16,146 16,707 Expected return on plan assets (24,561 ) (28,939 ) (26,401 ) Actuarial loss (gain) 27,134 17,146 (7,085 ) Curtailment gain (1,547 ) — — Amortization of prior service (credit) cost (152 ) 375 (195 ) Net periodic pension cost (credit) $ 24,018 $ 11,581 $ (12,023 ) The Company recognizes actuarial gains and losses, unless an interim remeasurement is required, in the fourth quarter of the year in which the gains and losses occur, in accordance with the Company's accounting method for defined benefit pension plans and other postretirement benefits as described in Note 1, Nature of Operations and Accounting Policies . Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company's control, including changes in interest rates, the performance of the financial markets and mortality assumptions. Actuarial gains and losses, including other components of periodic pension cost, are recognized in the line item "Interest and other expense, net" in the consolidated statements of operations. The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 29, 2019 and December 30, 2018 . December 29, 2019 December 30, 2018 Non-U.S. U.S. Non-U.S. U.S. (In thousands) Actuarial present value of benefit obligations: Accumulated benefit obligations $ 338,722 $ 304,710 $ 304,065 $ 283,310 Change in benefit obligations: Projected benefit obligations at beginning of year $ 311,168 $ 283,310 $ 343,410 $ 308,713 Service and administrative costs 4,248 2,350 4,528 2,325 Interest cost 5,448 11,098 5,484 10,662 Benefits paid and plan expenses (12,778 ) (21,162 ) (13,081 ) (19,709 ) Participants’ contributions 162 — 176 — Business acquisitions — — 537 — Plan amendments — — 533 — Plan curtailments (1,420 ) — — — Actuarial loss (gain) 34,602 29,114 (13,141 ) (18,681 ) Effect of exchange rate changes 25 — (17,278 ) — Projected benefit obligations at end of year $ 341,455 $ 304,710 $ 311,168 $ 283,310 Change in plan assets: Fair value of plan assets at beginning of year $ 159,163 $ 234,342 $ 179,736 $ 253,427 Actual return on plan assets 19,873 41,270 (5,653 ) (14,376 ) Benefits paid and plan expenses (12,778 ) (21,162 ) (13,081 ) (19,709 ) Employer’s contributions 8,200 — 8,480 15,000 Participants’ contributions 162 — 176 — Effect of exchange rate changes 5,240 — (10,495 ) — Fair value of plan assets at end of year $ 179,860 $ 254,450 $ 159,163 $ 234,342 Net liabilities recognized in the consolidated balance sheets $ (161,595 ) $ (50,260 ) $ (152,005 ) $ (48,968 ) Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 36,699 $ — $ 31,419 $ — Current liabilities (6,764 ) — (6,752 ) — Long-term liabilities (191,530 ) (50,260 ) (176,672 ) (48,968 ) Net liabilities recognized in the consolidated balance sheets $ (161,595 ) $ (50,260 ) $ (152,005 ) $ (48,968 ) Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — $ (278 ) $ — Actuarial assumptions as of the year-end measurement date: Discount rate 1.34 % 3.01 % 2.07 % 4.05 % Rate of compensation increase 3.36 % None 3.48 % None Actuarial assumptions used to determine net periodic pension cost during the year were as follows: December 29, 2019 December 30, 2018 December 31, 2017 Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Discount rate 2.07 % 4.05 % 1.99 % 3.56 % 2.06 % 4.06 % Rate of compensation increase 3.48 % None 3.50 % None 3.64 % None Expected rate of return on assets 5.30 % 7.25 % 5.90 % 7.25 % 6.00 % 7.25 % The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: December 29, December 30, (In thousands) Pension Plans with Projected Benefit Obligations in Excess of Plan Assets Projected benefit obligations $ 198,294 $ 183,424 Fair value of plan assets — — Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets Accumulated benefit obligations $ 195,657 $ 180,560 Fair value of plan assets — — Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 29, 2019 and December 30, 2018 , and target asset allocations for fiscal year 2020 are as follows: Target Allocation Percentage of Plan Assets at January 3, 2021 December 29, 2019 December 30, 2018 Asset Category Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Equity securities 0-5% 40-60% — % 41 % 48 % 39 % Debt securities 85-90% 40-60% 87 % 59 % 51 % 61 % Other 10-15% 0-10% 13 % — % 1 % — % Total 100 % 100 % 100 % 100 % 100 % 100 % The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans which are designed to maximize the total rate of return (income and appreciation) after inflation within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments. The Company’s expected rate of return on assets assumptions are derived from management’s estimates, as well as other information compiled by management, including studies that utilize customary procedures and techniques. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study gives appropriate consideration to recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate. The Company's discount rate assumptions are derived from a range of factors, including a yield curve for certain plans, composed of the rates of return on high-quality fixed-income corporate bonds available at the measurement date and the related expected duration for the obligations, and a bond matching approach for certain plans. During fiscal year 2017, for the plans in the United States, the Society of Actuaries issued an updated projection scale, MP-2017, as of December 31, 2017. The adoption of MP-2017 resulted in a $2.6 million decrease to the projected benefit obligation at December 31, 2017. During fiscal year 2018, the Society of Actuaries issued an updated projection scale, MP-2018, which incorporated an additional year (2016) of U.S. population data and reduced the life expectancy used to determine the projected benefit obligation. The Company adopted MP-2018 as of December 30, 2018. The adoption of MP-2018 resulted in a $1.0 million decrease to the projected benefit obligation at December 30, 2018. During fiscal year 2019, the Society of Actuaries issued an updated projection scale, MP-2019, which incorporated an additional year (2017) of U.S. population data and reduced the life expectancy used to determine the projected benefit obligation. The Company adopted MP-2019 as of December 29, 2019. The adoption of MP-2019 resulted in a $4.4 million decrease to the projected benefit obligation at December 29, 2019. The changes to the projected benefit obligations due to the adoption of the mortality base table and projection scale are included within "Actuarial loss (gain)" in the Change in Benefit Obligations for fiscal years 2019 and 2018 above. The target allocations for plan assets are listed in the above table. Equity securities primarily include investments in large-cap and mid-cap companies located in the United States and abroad, and equity index funds. Debt securities include corporate bonds of companies from diversified industries, high-yield bonds, and U.S. government securities. Other types of investments include investments in non-U.S. government index linked bonds, multi-strategy hedge funds and venture capital funds that follow several different strategies. The fair values of the Company’s pension plan assets as of December 29, 2019 and December 30, 2018 by asset category, classified in the three levels of inputs described in Note 22 to the consolidated financial statements are as follows: Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 6,177 $ 6,177 $ — $ — Equity securities: U.S. large-cap 57,797 57,797 — — International large-cap value 26,914 26,914 — — U.S. small mid-cap 2,700 2,700 — — Emerging markets growth 12,853 12,853 — — Domestic real estate funds 2,010 2,010 — — Foreign real estate funds 22,688 — — 22,688 Fixed income securities: Non-U.S. treasury securities 93,473 — 93,473 — Corporate and U.S. debt instruments 139,300 47,104 92,196 — Corporate bonds 29,846 — 29,846 — High yield bond funds 5,734 5,734 — — Other types of investments: Multi-strategy hedge funds 1,721 — — 1,721 Non-U.S. government index linked bonds 33,097 — 33,097 — Total assets measured at fair value $ 434,310 $ 161,289 $ 248,612 $ 24,409 Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 6,326 $ 6,326 $ — $ — Equity Securities: U.S. large-cap 35,072 35,072 — — International large-cap value 24,175 24,175 — — U.S. small-cap 1,928 1,928 — — Emerging markets growth 11,993 11,993 — — Equity index funds 54,342 — 54,342 — Domestic real estate funds 1,353 1,353 — — Foreign real estate funds 22,196 — — 22,196 Commodity funds 886 886 — — Fixed income securities: Non-U.S. Treasury Securities 23,352 — 23,352 — Corporate and U.S. debt instruments 131,211 48,133 83,078 — Corporate bonds 24,848 — 24,848 — High yield bond funds 5,186 5,186 — — Other types of investments: Multi-strategy hedge funds 16,934 — — 16,934 Non-U.S. government index linked bonds 33,703 — 33,703 — Total assets measured at fair value $ 393,505 $ 135,052 $ 219,323 $ 39,130 Valuation Techniques: Valuation techniques utilized need to maximize the use of observable inputs and minimize the use of unobservable inputs. There have been no changes in the methodologies utilized at December 29, 2019 compared to December 30, 2018 . The following is a description of the valuation techniques utilized to measure the fair value of the assets shown in the table above. Equity Securities: Shares of registered investment companies that are publicly traded are categorized as Level 1 assets; they are valued at quoted market prices that represent the net asset value of the fund. These instruments have active markets. Equity index funds are mutual funds that are not publicly traded and are comprised primarily of underlying equity securities that are publicly traded on exchanges. Price quotes for the assets held by these funds are readily observable and available. Equity index funds are categorized as Level 2 assets. Fixed Income Securities: Fixed income mutual funds that are publicly traded are valued at quoted market prices that represent the net asset value of securities held by the fund and are categorized as Level 1 assets. Fixed income index funds that are not publicly traded are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments and are categorized as Level 2 assets. Individual fixed income bonds are categorized as Level 2 assets except where sufficient quoted prices exist in active markets, in which case such securities are categorized as Level 1 assets. These securities are valued using third-party pricing services. These services may use, for example, model-based pricing methods that utilize observable market data as inputs. Broker dealer bids or quotes of securities with similar characteristics may also be used. Other Types of Investments: Non-U.S. government index link bond funds are not publicly traded and are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments. Underlying investments consist of bonds in which payment of income on the principal is related to a specific price index and are categorized as Level 2 assets. Hedge funds, private equity funds, foreign real estate funds and venture capital funds are valued at fair value by using the net asset values provided by the investment managers and are updated, if necessary, using analytical procedures, appraisals, public market data and/or inquiry of the investment managers. The net asset values are determined based upon the fair values of the underlying investments in the funds. These other investments invest primarily in readily available marketable securities and allocate gains, losses, and expense to the investor based on the ownership percentage as described in the fund agreements. They are categorized as Level 3 assets. The Company's policy is to recognize significant transfers between levels at the actual date of the event. A reconciliation of the beginning and ending Level 3 assets for fiscal years 2019, 2018 and 2017 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Foreign Real Estate Funds Multi-strategy Hedge Funds Total (In thousands) Balance at January 1, 2017 $ — $ 23,790 $ 23,790 Sales — (8,189 ) (8,189 ) Realized gains — 1,542 1,542 Unrealized losses — (354 ) (354 ) Balance at December 31, 2017 — 16,789 16,789 Purchases 22,196 — 22,196 Unrealized gains — 145 145 Balance at December 30, 2018 22,196 16,934 39,130 Sales — (15,586 ) (15,586 ) Realized gains — 4,175 4,175 Unrealized gains (losses) 492 (3,802 ) (3,310 ) Balance at December 29, 2019 $ 22,688 $ 1,721 $ 24,409 With respect to plans outside of the United States, the Company expects to contribute $6.6 million in the aggregate during fiscal year 2020. During fiscal years 2019, 2018 and 2017 , the Company contributed $8.2 million , $8.5 million and $8.4 million in the aggregate, respectively, to pension plans outside of the United States. During fiscal year 2018, the Company contributed $15.0 million to its defined benefit pension plan in the United States for the plan year 2017. The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Non-U.S. U.S. (In thousands) 2020 $ 11,540 $ 19,200 2021 12,006 19,346 2022 12,083 19,449 2023 12,362 19,561 2024 13,119 19,539 2025-2029 66,950 94,159 The Company also sponsors a supplemental executive retirement plan to provide senior management with benefits in excess of normal pension benefits. Effective July 31, 2000, this plan was closed to new entrants. At December 29, 2019 and December 30, 2018 , the projected benefit obligations were $25.7 million and $22.1 million , respectively. Assets with a fair value of $2.1 million and $1.8 million , segregated in a trust (which is included in marketable securities and investments on the consolidated balance sheets), were available to meet this obligation as of December 29, 2019 and December 30, 2018 , respectively. Pension expenses and income for this plan netted to expense of $4.8 million in fiscal year 2019 , income of $0.3 million in fiscal year 2018 and expense of $3.2 million in fiscal year 2017 . Postretirement Medical Plans: The Company provides healthcare benefits for eligible retired U.S. employees under a comprehensive major medical plan or under health maintenance organizations where available. Eligible U.S. employees qualify for retiree health benefits if they retire directly from the Company and have at least ten years of service. Generally, the major medical plan pays stated percentages of covered expenses after a deductible is met and takes into consideration payments by other group coverage and by Medicare. The plan requires retiree contributions under most circumstances and has provisions for cost-sharing charges. Effective January 1, 2000, this plan was closed to new hires. For employees retiring after 1991, the Company has capped its medical premium contribution based on employees’ years of service. The Company funds the amount allowable under a 401(h) provision in the Company’s defined benefit pension plan. Assets of the plan are primarily equity and debt securities and are available only to pay retiree health benefits. Net periodic postretirement medical benefit (credit) cost included the following components for the fiscal years ended: December 29, December 30, December 31, (In thousands) Service cost $ 87 $ 106 $ 92 Interest cost 116 120 125 Expected return on plan assets (1,175 ) (1,254 ) (1,114 ) Actuarial (gain) loss (1,776 ) 1,621 (741 ) Net periodic postretirement medical benefit (credit) cost $ (2,748 ) $ 593 $ (1,638 ) The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of December 29, 2019 and December 30, 2018 . December 29, December 30, (In thousands) Actuarial present value of benefit obligations: Retirees $ 583 $ 688 Active employees eligible to retire 362 408 Other active employees 1,966 2,317 Accumulated benefit obligations at beginning of year 2,911 3,413 Service cost 87 106 Interest cost 116 120 Benefits paid (122 ) (117 ) Actuarial loss (gain) 108 (611 ) Change in accumulated benefit obligations during the year 189 (502 ) Retirees 611 583 Active employees eligible to retire 420 362 Other active employees 2,069 1,966 Accumulated benefit obligations at end of year $ 3,100 $ 2,911 Change in plan assets: Fair value of plan assets at beginning of year $ 16,279 $ 17,374 Actual return on plan assets 2,937 (993 ) Benefits reimbursements paid — (102 ) Fair value of plan assets at end of year $ 19,216 $ 16,279 Net assets recognized in the consolidated balance sheets $ 16,116 $ 13,368 Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 16,116 $ 13,368 Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 3.09 % 4.09 % Actuarial assumptions used to determine net cost during the year are as follows: December 29, December 30, December 31, Discount rate 4.09 % 3.60 % 4.11 % Expected rate of return on assets 7.25 % 7.25 % 7.25 % The Company maintains a master trust for plan assets related to the U.S. defined benefit plans and the U.S. postretirement medical plan. Accordingly, investment policies, target asset allocations and actual asset allocations are the same as those disclosed for the U.S. defined benefit plans. The fair values of the Company’s plan assets at December 29, 2019 and December 30, 2018 by asset category, classified in the three levels of inputs described in Note 22, are as follows: Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 408 $ 408 $ — $ — Equity securities: U.S. large-cap 4,365 4,365 — — International large-cap value 2,033 2,033 — — U.S. small mid-cap 204 204 — — Emerging markets growth 971 971 — — Domestic real estate funds 152 152 — — Fixed income securities: Corporate debt instruments 10,520 3,557 6,963 — High yield bond funds 433 433 — — Other types of investments: Multi-strategy hedge funds 130 — — 130 Total assets measured at fair value $ 19,216 $ 12,123 $ 6,963 $ 130 Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 390 $ 390 $ — $ — Equity securities: U.S. large-cap 2,436 2,436 — — International large-cap value 1,679 1,679 — — U.S. small mid-cap 134 134 — — Emerging markets growth 833 833 — — Domestic real estate funds 94 94 — — Commodity funds 62 62 — — Fixed income securities: Corporate debt instruments 9,115 3,344 5,771 — High yield bond funds 360 360 — — Other types of investments: Multi-strategy hedge funds 1,176 — — 1,176 Total assets measured at fair value $ 16,279 $ 9,332 $ 5,771 $ 1,176 Valuation Techniques: Valuation techniques are the same as those disclosed for the U.S. defined benefit plans above. A reconciliation of the beginning and ending Level 3 assets for fiscal years 2019, 2018 and 2017 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Multi-strategy Hedge Funds (In thousands) Balance at January 1, 2017 $ 1,508 Sales (562 ) Realized gains 229 Unrealized losses (24 ) Balance at December 31, 2017 1,151 Unrealized gains 25 Balance at December 30, 2018 1,176 Sales (1,074 ) Realized gains 315 Unrealized losses (287 ) Balance at December 29, 2019 $ 130 The Company does no t expect to make any contributions to the postretirement medical plan during fiscal year 2020 . The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Postretirement Medical Plan (In thousands) 2020 $ 130 2021 146 2022 165 2023 177 2024 187 2025-2029 995 Deferred Compensation Plans: During fiscal year 1998, the Company implemented a nonqualified deferred compensation plan that provides benefits payable to officers and certain key employees or their designated beneficiaries at specified future dates, or upon retirement or death. The plan was amended to eliminate deferral elections, with the exception of Company 401(k) excess contributions for eligible participants, for plan years beginning January 1, 2011. Benefit payments under the plan are funded by contributions from participants, and for certain participants, contributions by the Company. The obligations related to the deferred compensation plan totaled $1.1 million at each of December 29, 2019 and December 30, 2018 .

Contingencies

Contingencies	12 Months Ended
	Dec. 29, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company's responsibility is established and when the cost can be reasonably estimated. The Company has accrued $7.7 million and $7.9 million as of December 29, 2019 and December 30, 2018 , respectively, in accrued expenses and other current liabilities, which represents its management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at December 29, 2019 should not have a material adverse effect on the Company’s consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Warranty Reserves

Warranty Reserves	12 Months Ended
	Dec. 29, 2019
Product Warranties Disclosures [Abstract]
Warranty Reserves	Warranty Reserves The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the consolidated balance sheets. A summary of warranty reserve activity for the fiscal years ended December 29, 2019 , December 30, 2018 and December 31, 2017 is as follows: (In thousands) Balance at January 1, 2017 $ 9,012 Provision charged to income 13,700 Payments (14,245 ) Adjustments to previously provided warranties, net (815 ) Foreign currency translation and acquisitions 1,398 Balance at December 31, 2017 9,050 Provision charged to income 13,545 Payments (13,775 ) Adjustments to previously provided warranties, net (157 ) Foreign currency translation and acquisitions (270 ) Balance at December 30, 2018 8,393 Provision charged to income 12,199 Payments (14,613 ) Adjustments to previously provided warranties, net 2,889 Foreign currency translation and acquisitions (56 ) Balance at December 29, 2019 $ 8,812

Stock Plans

Stock Plans	12 Months Ended
	Dec. 29, 2019
Share-based Payment Arrangement [Abstract]
Stock Plans	Stock Plans Stock-Based Compensation: The Company’s 2019 Incentive Plan (the “2019 Plan”) authorizes the issuance of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and cash awards as part of the Company’s compensation programs. The 2019 Plan was approved by the Company’s Board on January 24, 2019 and by the Company’s shareholders on April 23, 2019. The 2019 Plan replaced the Company’s 2009 Incentive Plan (the “2009 Plan”), under which the Company’s common stock was made available for stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards as part of the Company’s compensation programs. Upon shareholder approval of the 2019 Plan, 6.25 million shares of the Company’s common stock, as well as shares of the Company’s common stock previously granted under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price subject to a contractual repurchase right, became available for grant under the 2019 Plan. Awards granted under the 2009 Plan prior to its expiration remain outstanding. As part of the Company’s compensation programs, the Company also offers shares of its common stock under its Employee Stock Purchase Plan. The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2019, 2018 and 2017 : December 29, December 30, December 31, (In thousands) Cost of product and service revenue $ 1,620 $ 1,466 $ 1,254 Research and development expenses 1,061 1,359 1,389 Selling, general and administrative expenses 28,833 25,942 22,778 Total stock-based compensation expense $ 31,514 $ 28,767 $ 25,421 The total income tax benefit recognized in the consolidated statements of operations for stock-based compensation was $11.6 million in fiscal year 2019 , $13.6 million in fiscal year 2018 and $14.5 million in fiscal year 2017 . Stock-based compensation costs capitalized as part of inventory were $0.3 million as of each of December 29, 2019 and December 30, 2018 . Stock compensation expense from acceleration of vesting of certain stock awards to the Company's former Chief Executive Officer was $7.7 million for fiscal year 2019 . Stock Options: The Company has granted options to purchase common shares at prices equal to the market price of the common shares on the date the option is granted. Conditions of vesting are determined at the time of grant. Options are generally exercisable in equal annual installments over a period of three years , and will generally expire seven years after the date of grant. Options replaced in association with business combination transactions are generally issued with the same terms of the respective plans under which they were originally issued. The fair value of each option grant is estimated using the Black-Scholes option pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on the historical and implied volatility of the Company’s stock. The average expected life was based on the contractual term of the option and historic exercise experience. The risk-free interest rate is based on United States Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: December 29, December 30, December 31, Risk-free interest rate 2.5 % 3.0 % 2.0 % Expected dividend yield 0.3 % 0.4 % 0.4 % Expected lives 5 years 5 years 5 years Expected stock volatility 22.8 % 20.7 % 22.4 % The following table summarizes stock option activity for the fiscal year ended December 29, 2019 : Number of Shares Weighted- Average Exercise Price (Shares in thousands) Outstanding at beginning of year 1,765 $ 52.91 Granted 304 93.66 Exercised (415 ) 47.60 Canceled (3 ) 75.52 Forfeited (116 ) 78.71 Outstanding at end of year 1,535 $ 60.42 Exercisable at end of year 954 $ 48.65 The aggregate intrinsic value for stock options outstanding at December 29, 2019 was $56.2 million with a weighted-average remaining contractual term of 3.8 years. The aggregate intrinsic value for stock options exercisable at December 29, 2019 was $46.2 million with a weighted-average remaining contractual term of 2.9 years. At December 29, 2019 , there were 1.5 million stock options that were vested, and expected to vest in the future, with an aggregate intrinsic value of $56.2 million and a weighted-average remaining contractual term of 3.8 years. The weighted-average per-share grant-date fair value of options granted during fiscal years 2019, 2018 and 2017 was $22.63 , $17.56 , and $11.83 , respectively. The total intrinsic value of options exercised during fiscal years 2019, 2018 and 2017 was $19.1 million , $35.0 million , and $17.6 million , respectively. Cash received from option exercises for fiscal years 2019, 2018 and 2017 was $19.7 million , $24.8 million , and $18.0 million , respectively. The total compensation expense recognized related to the Company’s outstanding options was $6.7 million in fiscal year 2019 , $5.4 million in fiscal year 2018 and $4.7 million in fiscal year 2017 . There was $6.3 million of total unrecognized compensation cost related to nonvested stock options granted as of December 29, 2019 . This cost is expected to be recognized over a weighted-average period of 1.8 years. Restricted Stock Awards: The Company has awarded shares of restricted stock and restricted stock units to certain employees and non-employee directors at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued employment. The fair value of the award at the time of the grant is expensed on a straight line basis primarily in selling, general and administrative expenses over the vesting period, which is generally 3 years. These awards were granted under the Company’s 2009 Plan. Recipients of the restricted stock have the right to vote such shares and receive dividends. The following table summarizes restricted stock award activity for the fiscal year ended December 29, 2019 : Number of Shares Weighted- Average Grant- Date Fair Value (Shares in thousands) Nonvested at beginning of year 465 $ 61.72 Granted 163 94.80 Vested (218 ) 55.20 Forfeited (65 ) 76.72 Nonvested at end of year 345 $ 78.69 The fair value of restricted stock awards vested during fiscal years 2019, 2018 and 2017 was $12.0 million , $10.4 million , and $10.6 million , respectively. The total compensation expense recognized related to the restricted stock awards was $12.7 million in fiscal year 2019 , $11.7 million in fiscal year 2018 and $10.3 million in fiscal year 2017 . As of December 29, 2019 , there was $14.8 million of total unrecognized compensation cost, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.4 years. Performance Restricted Stock Units: As part of the Company's executive compensation program, the Company granted 76,218 and 39,133 performance restricted stock units during fiscal years 2019 and 2018 , respectively, that will vest based on performance of the Company. The weighted-average per-share grant date fair value of performance restricted stock units granted during fiscal years 2019 and 2018 was $92.95 and $80.31 , respectively. During fiscal year 2019 , 18,777 performance restricted stock units were forfeited. The total compensation expense recognized related to the performance restricted stock units was $5.9 million in fiscal year 2019 and $3.2 million in fiscal year 2018 . As of December 29, 2019 , there were 145,114 performance restricted stock units outstanding. Performance Units: The Company’s performance unit program provides a cash award based on the achievement of specific performance criteria. A target number of units are granted at the beginning of a three-year performance period. The number of units earned at the end of the performance period is determined by multiplying the number of units granted by a performance factor ranging from 0% to 200% . Awards are determined by multiplying the number of units earned by the stock price at the end of the performance period, and are paid in cash and accounted for as a liability based award. The compensation expense associated with these units is recognized over the period that the performance targets are expected to be achieved. No performance units were granted during the fiscal year 2019 . The Company granted 37,281 performance units and 49,845 performance units during fiscal years 2018 and 2017 , respectively. The weighted-average per-share grant-date fair value of performance units granted during fiscal years 2018 and 2017 was $73.23 and $52.69 , respectively. During fiscal years 2019, 2018 and 2017 , 10,116 performance units, zero performance units and 15,139 performance units were forfeited, respectively. The total compensation expense related to performance units was $5.6 million , $7.7 million , and $8.7 million for fiscal years 2019, 2018 and 2017 , respectively. As of December 29, 2019 , there were 71,213 performance units outstanding subject to forfeiture, with a corresponding liability of $10.4 million recorded in accrued expenses and long-term liabilities. Stock Awards: The Company’s stock award program provides an annual equity award to non-employee directors. For fiscal years 2019, 2018 and 2017 , the award equaled the number of shares of the Company’s common stock which has an aggregate fair market value of $100,000 on the date of the award. The stock award is prorated for non-employee directors who serve for only a portion of the year. The compensation expense associated with these stock awards is recognized when the stock award is granted. In fiscal years 2019, 2018 and 2017 , the Company awarded 7,301 shares, 11,088 shares, and 12,006 shares, respectively, to non-employee directors. The weighted-average per-share grant-date fair value of stock awards granted during fiscal years 2019, 2018 and 2017 was $95.84 , $72.17 , and $63.14 , respectively. The total compensation expense recognized related to these stock awards was $0.7 million in fiscal year 2019 and $0.8 million in each of fiscal years 2018 and 2017 . Employee Stock Purchase Plan: In April 1999, the Company’s shareholders approved the 1998 Employee Stock Purchase Plan. In April 2005, the Compensation and Benefits Committee of the Board voted to amend the Employee Stock Purchase Plan, effective July 1, 2005, whereby participating employees have the right to purchase common stock at a price equal to 95% of the closing price on the last day of each six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee’s voluntary contribution, which may not exceed 10% of the employee’s base compensation. During fiscal year 2019 , the Company issued 33,843 shares of common stock under the Company’s Employee Stock Purchase Plan at a weighted-average price of $82.25 per share. During fiscal year 2018 , the Company issued 21,321 shares under this plan at a weighted-average price of $69.57 per share. During fiscal year 2017 , the Company issued 36,769 shares under this plan at a weighted-average price of $67.09 per share. At December 29, 2019 there remains available for sale to employees an aggregate of 0.8 million shares of the Company’s common stock out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 29, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Comprehensive Income: The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Currency Translation Adjustment, net of tax Unrecognized Prior Service Costs, net of tax Unrealized (Losses) Gains on Securities, net of tax Accumulated Other Comprehensive Income (Loss) (In thousands) Balance, January 1, 2017 $ (100,923 ) $ 399 $ (337 ) $ (100,861 ) Current year change 54,341 (77 ) 79 54,343 Balance, December 31, 2017 (46,582 ) 322 (258 ) (46,518 ) Current year change (123,388 ) (77 ) (9 ) (123,474 ) Reclassification to retained earnings upon adoption of ASU 2018-02 (6,489 ) — — (6,489 ) Balance, December 30, 2018 (176,459 ) 245 (267 ) (176,481 ) Current year change (23,978 ) 807 6 (23,165 ) Balance, December 29, 2019 $ (200,437 ) $ 1,052 $ (261 ) $ (199,646 ) During fiscal years 2019, 2018 and 2017 , pre-tax credit (cost) of $0.8 million , $(0.1) million , and $(0.1) million , respectively, was reclassified from accumulated other comprehensive income into selling, general and administrative expenses as a component of net periodic pension cost. Stock Repurchases: On July 23, 2018, the Board of Directors (the "Board") authorized the Company to repurchase shares of common stock for an aggregate amount up to $250.0 million under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on July 23, 2020 unless terminated earlier by the Board and may be suspended or discontinued at any time. During fiscal year 2019 , the Company had no stock repurchases under the Repurchase Program. As of December 29, 2019 , $197.8 million remained available for aggregate repurchases of shares under the Repurchase Program. In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During the fiscal year 2019 , the Company repurchased 68,536 shares of common stock for this purpose at an aggregate cost of $6.3 million . During fiscal year 2018 , the Company repurchased 66,506 shares of common stock for this purpose at an aggregate cost of $5.2 million . During fiscal year 2017 , the Company repurchased 78,644 shares of common stock for this purpose at an aggregate cost of $4.4 million . The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. Dividends: The Board declared a regular quarterly cash dividend of $0.07 per share in each quarter of fiscal years 2019 and 2018 . At December 29, 2019 , the Company had accrued $7.8 million for a dividend declared on October 24, 2019 for the fourth quarter of fiscal year 2019 that was paid in February 2020 . On January 23, 2020 , the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year 2020 that will be payable in May 2020 . In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Derivatives And Hedging Activit

Derivatives And Hedging Activities	12 Months Ended
	Dec. 29, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Derivatives and Hedging Activities The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 70% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business. In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months , have no cash requirements until maturity, and are recorded at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s consolidated statements of cash flows. Principal hedged currencies include the Chinese Yuan, Euro, British Pound, Swedish Krona, and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $277.6 million at December 29, 2019 , $223.3 million at December 30, 2018 , and $212.1 million at December 31, 2017 , and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of fiscal years 2019, 2018 and 2017 . In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions and stock repurchase program, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s consolidated statements of cash flows. The outstanding forward exchange contracts designated as economic hedges, which were intended to hedge movements in foreign exchange rates prior to the settlement of certain intercompany loan agreements, included combined Euro notional amounts of €105.8 million and combined U.S. Dollar notional amounts of $5.6 million as of December 29, 2019 , combined Euro notional amounts of €37.3 million and combined U.S. Dollar notional amounts of $5.7 million as of December 30, 2018 , and combined Euro notional amounts of €57.2 million and combined U.S. Dollar notional amounts of $1.3 billion as of December 31, 2017 . The net gains and losses on these derivatives, combined with the gains and losses on the remeasurement of the hedged intercompany loans were not material for each of the fiscal years 2019 and 2018 . The Company paid $1.3 million and $34.1 million during the fiscal years 2019 and 2018 , respectively, from the settlement of these hedges. During fiscal year 2018, the Company designated a portion of the 2026 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of December 29, 2019 , the total notional amount of the 2026 Notes that was designated to hedge investments in foreign subsidiaries was €203.3 million . The unrealized foreign exchange gains recorded in AOCI related to the net investment hedge were $4.9 million and $9.3 million during the fiscal years 2019 and 2018 , respectively. During fiscal year 2018, the Company designated the April 2021 Notes to hedge its investments in certain foreign subsidiaries. Unrealized translation adjustments from the April 2021 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of December 29, 2019 , the total notional amount of the April 2021 Notes that was designated to hedge investments in foreign subsidiaries was €299.9 million . The unrealized foreign exchange gains recorded in AOCI related to the net investment hedge were $8.0 million and $27.5 million during the fiscal years 2019 and 2018 , respectively. During fiscal year 2019, the Company entered into a cross-currency swap designated as a net investment hedge to hedge the Euro currency exposure of the Company’s net investment in certain foreign subsidiaries. This agreement is a contract to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. Changes in the fair value of this swap are recorded in equity as a component of AOCI in the same manner as foreign currency translation adjustments. In assessing the effectiveness of this hedge, the Company uses a method based on changes in spot rates to measure the impact of the foreign currency exchange rate fluctuations on both its foreign subsidiary net investment and the related swap. Under this method, changes in the fair value of the hedging instrument other than those due to changes in the spot rate are initially recorded in AOCI as a translation adjustment, and then are amortized into other (income) expense, net in the condensed consolidated statement of operations using a systematic and rational method over the instrument’s term. Changes in the fair value associated with the effective portion (i.e. those changes due to the spot rate) are recorded in AOCI as a translation adjustment and are released and recognized in earnings only upon the sale or liquidation of the hedged net investment. The cross-currency swap has an initial notional value of €197.4 million or $220.0 million and matures on November 15, 2021. Interest on the cross-currency swap is payable semi-annually, in Euro, on May 15th and November 15th of each year based on the Euro notional value and a fixed rate of 2.47% . The Company receives interest in U.S. dollars on May 15th and November 15th of each year based on the U.S. dollar equivalent of the Euro notional value and a fixed rate of 5.00% . On December 29, 2019 , the fair value of the cross-currency swap was $0.3 million , which was recorded in AOCI. In connection with the early redemption of the November 2021 Notes, on September 11, 2019, the Company entered into a reverse treasury rate lock agreement with a financial intermediary with a notional amount of $500.0 million . The Company entered into the reverse treasury rate lock agreement in order to hedge the variability in the redemption payment on the entire principal amount of the November 2021 Notes. The reverse treasury rate lock substantively fixed the present value of the forecasted debt make-whole payment, which was priced on October 10, 2019, to mitigate risk associated with the changes in the 2-year U.S. treasury yield. The Company received $1.0 million upon settlement of the reverse treasury rate lock agreement. The Company does no t expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive (loss) income into interest and other expense, net within the next twelve months.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 29, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of December 29, 2019 . The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during fiscal years 2019 and 2018 . The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 29, 2019 and December 30, 2018 classified in one of the three classifications described above: Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,906 $ 2,906 $ — $ — Foreign exchange derivative assets 451 — 451 — Foreign exchange derivative liabilities (1,538 ) — (1,538 ) — Contingent consideration (35,481 ) — — (35,481 ) Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,447 $ 2,447 $ — $ — Foreign exchange derivative assets 750 — 750 — Foreign exchange derivative liabilities, net (594 ) — (594 ) — Contingent consideration (69,661 ) — — (69,661 ) Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date. Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's consolidated balance sheet on a net basis and are recorded in other assets. As of both December 29, 2019 and December 30, 2018 , none of the master netting arrangements involved collateral. Level 3 Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities. Contingent consideration: Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model. During fiscal year 2015, the Company acquired all the shares of Vanadis. Under the terms of the acquisition, the initial purchase consideration was $32.0 million , net of cash and the Company will be obligated to make potential future milestone payments, based on completion of a proof of concept, regulatory approvals and product sales, of up to $93.0 million ranging from 2016 to 2019. The key assumptions used to determine the fair value of the contingent consideration included projected milestone dates of 2016 to 2019 , discount rates ranging from 3.1% to 11.3% , conditional probabilities of success of each individual milestone ranging from 85% to 95% and cumulative probabilities of success for each individual milestone ranging from 53% to 90% . The fair value of the contingent consideration as of the acquisition date was estimated at $56.9 million . During fiscal year 2019 , the Company updated the fair value of the contingent consideration and recorded a liability of $19.0 million as of December 29, 2019 . The key assumptions used to determine the fair value of the contingent consideration as of December 29, 2019 included projected milestone dates within fiscal year 2020 , discount rates ranging from 3.5% to 4.4% , conditional and cumulative probabilities of success of each individual milestone ranging from 95% to 98% . A significant delay in the product development (including projected regulatory milestone) achievement date in isolation could result in a significantly lower fair value measurement; a significant acceleration in the product development (including projected regulatory milestone) achievement date in isolation would not have a material impact on the fair value measurement; a significant change in the discount rate in isolation would not have a material impact on the fair value measurement; and a significant change in the probabilities of success in isolation could result in a significant change in fair value measurement. During the fiscal years 2019 and 2018 , the Company recorded a contingent consideration obligation relating to other acquisitions with an estimated fair value of $12.7 million and $6.5 million , respectively. During the fiscal year 2019 , the Company paid $50.9 million of contingent consideration, of which $29.9 million was included in financing activities and $20.9 million was included in operating activities in the consolidated statements of cash flows. During the fiscal year 2018 , the Company paid $16.5 million of contingent consideration, of which $12.8 million was included in financing activities and $3.7 million was included in operating activities in the consolidated statements of cash flows. The fair values of contingent consideration are calculated on a quarterly basis based on a collaborative effort of the Company’s regulatory, research and development, operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving proof of concept, regulatory approvals and revenue targets as compared to initial projections, the impact of market competition and market landscape shifts from non-invasive prenatal testing products, with the impact of such adjustments being recorded in the consolidated statements of operations. As of December 29, 2019 , the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $57.1 million . The expected maximum earnout period for acquisitions with open contingency period does not exceed 3.0 years from December 29, 2019 , and the remaining weighted average expected earnout period at December 29, 2019 was 1.2 years . A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: (In thousands) Balance at January 1, 2017 $ (63,201 ) Amounts paid and foreign currency translation 35 Change in fair value (included within selling, general and administrative expenses) (2,162 ) Balance at December 31, 2017 (65,328 ) Additions (6,200 ) Amounts paid and foreign currency translation 16,506 Change in fair value (included within selling, general and administrative expenses) (14,639 ) Balance at December 30, 2018 (69,661 ) Additions (12,734 ) Amounts paid and foreign currency translation 50,795 Change in fair value (included within selling, general and administrative expenses) (3,881 ) Balance at December 29, 2019 $ (35,481 ) The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. As of December 29, 2019 , the Company’s new senior unsecured revolving credit facility, which provides for $1.0 billion of revolving loans, had a carrying value of $322.0 million , net of $3.4 million of unamortized debt issuance costs. As of December 30, 2018 , the Company's previous senior unsecured revolving credit facility had a carrying value of $415.6 million , net of $2.4 million of unamortized debt issuance costs. The interest rate on the Company’s new senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during fiscal year 2019 . Consequently, the carrying value approximates fair value and were classified as Level 2. The Company's 2026 Notes, with a face value of €500.0 million , had an aggregate carrying value of $552.2 million , net of $3.5 million of unamortized original issue discount and $3.3 million of unamortized debt issuance costs as of December 29, 2019 . The 2026 Notes had an aggregate carrying value of $564.5 million , net of $4.0 million of unamortized original issue discount and $3.8 million of unamortized debt issuance costs as of December 30, 2018 . The 2026 Notes had a fair value of €518.5 million and €496.1 million as of December 29, 2019 and December 30, 2018 , respectively. The fair value of the 2026 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's April 2021 Notes, with a face value of €300.0 million , had an aggregate carrying value of $334.2 million , net of $0.1 million of unamortized original issue discount and $1.1 million of unamortized debt issuance costs as of December 29, 2019 . The April 2021 Notes had an aggregate carrying value of $341.3 million , net of $0.1 million of unamortized original issue discount and $2.0 million of unamortized debt issuance costs as of December 30, 2018 . The April 2021 Notes had a fair value of €301.9 million and €300.5 million as of December 29, 2019 and December 30, 2018 . The fair value of the April 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's 2029 Notes, with a face value of $850.0 million , had an aggregate carrying value of $839.9 million , net of $2.7 million of unamortized original issue discount and $7.4 million of unamortized debt issuance costs as of December 29, 2019 . The 2029 Notes had a fair value of $872.3 million as of December 29, 2019 . The fair value of the 2029 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company’s other debt facilities had an aggregate carrying value of $25.7 million and $38.2 million as of December 29, 2019 and December 30, 2018 , respectively. As of December 29, 2019 , these consisted of bank loans in the aggregate amount of $25.6 million bearing fixed interest rates between 1.1% and 21.5% and a bank loan in the amount of $0.1 million bearing a variable interest rate based on the Euribor rate plus a margin of 1.5% . The Company had no change in credit standing during fiscal year 2019 . Consequently, the carrying value approximates fair value. As of December 29, 2019 , the April 2021 Notes, 2026 Notes, 2029 Notes and other debt facilities were classified as Level 2. As of December 29, 2019 , there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Leases (Notes)

Leases (Notes)	12 Months Ended
	Dec. 29, 2019
Disclosure Text Block [Abstract]
Leases [Text Block]	Leases Changes in significant accounting policies Except for the changes below, the Company consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. The Company adopted ASC 842 with a date of initial application of December 31, 2018 ("transition date"). As a result, the Company has changed its accounting policy for leases as detailed below. The Company applied ASC 842 using the modified retrospective method and applied the new leases standard at transition date, with a cumulative effect adjustment recognized in the opening balance of retained earnings in fiscal year 2019. Therefore, the comparative information has not been adjusted and continues to be reported under ASC 840. As a lessee, the Company recognized operating leases in the consolidated balance sheet under ASC 842. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized at the transition date based on the present value of the remaining lease payments over the lease term. As most of the Company's leases as of the transition date did not provide an implicit rate, the Company used its incremental borrowing rate based on the information available at transition date in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities. The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statement of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred. As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under ASC 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with ASC 842. Lessee Disclosures The Company leases certain property and equipment under operating and finance leases. The Company's leases have remaining lease terms of less than 1 year to 41 years, some of which include options to extend the lease for up to 5 years, and some of which include options to terminate the lease within 1 year. Finance leases are not material to the Company. The components of lease expense were as follows: December 29, (In thousands) Lease cost: Operating lease cost 61,205 Supplemental cash flow information related to leases was as follows: December 29, (In thousands) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 50,155 Supplemental balance sheet information related to leases was as follows: December 29, (In thousands, except lease term and discount rate) Operating Leases: Operating lease right-of-use assets $ 167,276 Accrued expenses and other current liabilities $ 36,573 Operating lease liabilities 146,399 Total operating liabilities $ 182,972 Weighted Average Remaining Lease Term in Years Operating leases 7.5 Weighted Average Remaining Discount Rate Operating leases 3.3% Maturities of lease liabilities as of December 29, 2019 were as follows: Operating Leases (In thousands) 2020 $ 44,512 2021 36,958 2022 25,419 2023 19,594 2024 17,721 2025 and thereafter 66,808 Total lease payments 211,012 Less imputed interest (28,040 ) Total $ 182,972 Under ASC 840, minimum rental commitments under noncancelable operating leases as of December 30, 2018 were as follows: $56.4 million in fiscal year 2019 , $46.6 million in fiscal year 2020 , $33.5 million in fiscal year 2021 , $22.1 million in fiscal year 2022 , $15.6 million in fiscal year 2023 and $67.6 million in fiscal year 2024 and thereafter . Lessor Disclosures
Leases of Lessor Disclosure [Text Block]	Lessor Disclosures

Industry Segment and Geographic

Industry Segment and Geographic Area Information	12 Months Ended
	Dec. 29, 2019
Segment Reporting [Abstract]
Industry Segment Information	Industry Segment and Geographic Area Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1. The principal products and services of the Company's two operating segments are: • Discovery & Analytical Solutions . Provides products and services targeted towards the life sciences and applied markets. • Diagnostics . Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, emerging market diagnostics and applied genomics markets. The Diagnostics segment serves the diagnostics market. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended: December 29, December 30, December 31, (In thousands) Discovery & Analytical Solutions Product revenue $ 1,054,862 $ 1,010,899 $ 941,328 Service revenue 691,299 682,312 637,131 Total revenue 1,746,161 1,693,211 1,578,459 Operating income from continuing operations (1) 238,331 230,481 205,259 Diagnostics Product revenue 962,180 924,594 536,086 Service revenue 175,332 160,191 142,437 Total revenue 1,137,512 1,084,785 678,523 Operating income from continuing operations 189,330 153,196 146,862 Corporate Operating loss from continuing operations (2) (65,688 ) (59,793 ) (56,506 ) Continuing Operations Product revenue 2,017,042 1,935,493 1,477,414 Service revenue 866,631 842,503 779,568 Total revenue 2,883,673 2,777,996 2,256,982 Operating income from continuing operations 361,973 323,884 295,615 Interest and other expense, net (see Note 6) 124,831 66,201 (1,103 ) Income from continuing operations before income taxes $ 237,142 $ 257,683 $ 296,718 ____________________________ (1) Legal costs for significant litigation matters in the Company's Discovery & Analytical Solutions segment were $2.2 million , $5.3 million and $2.7 million for fiscal years 2019, 2018 and 2017 , respectively. Legal costs for significant litigation matters in the Company's Diagnostics segment were $0.1 million and $0.2 million for fiscal years 2019 and 2018 , respectively. (2) Stock compensation expense from acceleration of executive compensation was $7.7 million for fiscal year 2019 . Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended December 29, 2019 : Depreciation and Amortization Expense Capital Expenditures December 29, December 30, December 31, December 29, December 30, December 31, (In thousands) (In thousands) Discovery & Analytical Solutions $ 74,445 $ 70,362 $ 72,590 $ 27,778 $ 34,852 $ 26,200 Diagnostics 136,476 107,434 31,204 46,863 54,737 11,262 Corporate 3,104 2,792 1,206 1,690 3,664 1,627 Continuing operations $ 214,025 $ 180,588 $ 105,000 $ 76,331 $ 93,253 $ 39,089 Discontinued operations $ — $ — $ 929 $ — $ — $ 182 Total Assets December 29, December 30, December 31, (In thousands) Discovery & Analytical Solutions $ 3,082,917 $ 2,567,054 $ 2,611,737 Diagnostics 3,368,598 3,358,964 3,447,437 Corporate 87,049 49,504 32,289 Total assets $ 6,538,564 $ 5,975,522 $ 6,091,463 The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 29, 2019 and net long-lived assets based on physical location as of December 29, 2019 and December 30, 2018 : Revenue December 29, December 30, December 31, (In thousands) U.S. $ 974,187 $ 906,398 $ 837,018 International: China 581,688 559,865 374,931 Germany 146,577 142,411 91,669 Italy 101,461 95,908 77,477 India 97,423 92,327 84,812 France 96,994 97,990 80,153 Japan 82,478 79,238 76,322 United Kingdom 70,703 72,124 65,164 Other international 732,162 731,735 569,436 Total international 1,909,486 1,871,598 1,419,964 Total sales $ 2,883,673 $ 2,777,996 $ 2,256,982 Net Long-Lived Assets* December 29, December 30, December 31, (In thousands) U.S. $ 269,183 $ 201,649 $ 210,116 International: Germany 119,612 99,181 88,249 China 71,216 61,261 64,815 United Kingdom 51,659 33,429 28,028 Finland 29,052 16,211 14,764 Singapore 23,063 14,942 9,240 India 19,691 14,636 14,820 Italy 14,152 11,324 10,334 Brazil 9,126 8,237 7,963 Poland 7,216 3,212 2,269 Canada 6,485 5,454 5,201 Other international 39,150 20,775 20,245 Total international 390,422 288,662 265,928 Total net long-lived assets $ 659,605 $ 490,311 $ 476,044 * Long-lived assets consist of property and equipment, net, operating lease right-of-use assets, rental equipment, software and other long-term assets.

Quarterly Financial Information

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 29, 2019
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	Quarterly Financial Information (Unaudited) Selected quarterly financial information is as follows for the fiscal years ended: First Quarter Second Quarter Third Quarter Fourth Quarter (1) Year (In thousands, except per share data) December 29, 2019 Revenue $ 648,737 $ 722,517 $ 706,923 $ 805,496 $ 2,883,673 Gross profit 307,806 347,793 342,275 398,181 1,396,055 Restructuring and other costs, net 7,639 6,161 14,068 1,560 29,428 Operating income from continuing operations 53,330 91,735 78,660 138,248 361,973 Income from continuing operations before income taxes 36,765 71,827 63,254 65,296 237,142 Income from continuing operations 35,453 69,141 58,610 64,549 227,753 Loss from discontinued operations and dispositions (41 ) (54 ) (52 ) (48 ) (195 ) Net income 35,412 69,087 58,558 64,501 227,558 Basic earnings per share: Income from continuing operations $ 0.32 $ 0.62 $ 0.53 $ 0.58 $ 2.06 Loss from discontinued operations and dispositions (0.00 ) (0.00 ) (0.00 ) (0.00 ) (0.00 ) Net income 0.32 0.62 0.53 0.58 2.06 Diluted earnings per share: Income from continuing operations $ 0.32 $ 0.62 $ 0.53 $ 0.58 $ 2.04 Loss from discontinued operations and dispositions (0.00 ) (0.00 ) (0.00 ) (0.00 ) (0.00 ) Net income 0.32 0.62 0.52 0.58 2.04 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 December 30, 2018 Revenue $ 643,972 $ 703,362 $ 674,313 $ 756,349 $ 2,777,996 Gross profit 292,222 340,140 332,327 376,250 1,340,939 Restructuring and other costs, net 6,578 — 6,508 (1,942 ) 11,144 Operating income from continuing operations 39,935 88,064 80,202 115,683 323,884 Income from continuing operations before income taxes 28,505 71,708 78,041 79,429 257,683 Income from continuing operations 26,035 64,673 75,445 71,322 237,475 (Loss) gain from discontinued operations and dispositions (11 ) (610 ) 1,103 (30 ) 452 Net income 26,024 64,063 76,548 71,292 237,927 Basic earnings per share: Income from continuing operations $ 0.24 $ 0.59 $ 0.68 $ 0.64 $ 2.15 (Loss) gain from discontinued operations and dispositions (0.00 ) (0.01 ) 0.01 (0.00 ) 0.00 Net income 0.24 0.58 0.69 0.64 2.15 Diluted earnings per share: Income continuing operations $ 0.23 $ 0.58 $ 0.68 $ 0.64 $ 2.13 (Loss) gain from discontinued operations and dispositions (0.00 ) (0.01 ) 0.01 (0.00 ) 0.00 Net income 0.23 0.57 0.69 0.64 2.13 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 ____________________________ (1) The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.

Nature of Operations and Acco_2

Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Policies)	12 Months Ended
	Dec. 29, 2019
Accounting Policies [Abstract]
Consolidation [Policy Text Block]	The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation.
Segment Reporting [Policy Text Block]
Fiscal Periods [Policy Text Block]	The Company's fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. Each of the fiscal years ended December 29, 2019 (" fiscal year 2019 "), December 30, 2018 (" fiscal year 2018 ") and December 31, 2017 (" fiscal year 2017 ") included 52
Accounting Policies and Estimates [Policy Text Block]	Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
Revenue Recognition [Policy Text Block]
Warranty Costs [Policy Text Block]	Warranty Costs: The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period.
Shipping and Handling Costs [Policy Text Block]	Shipping and Handling Costs: The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue.
Inventories [Policy Text Block]	Inventories : Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements.
Income Taxes [Policy Text Block]	Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. When the Company determines during the period that previously undistributed earnings of certain international subsidiaries no longer meet the requirements of indefinite reinvestment, the Company recognizes the income tax expense in that period. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 7 below for additional details.
Property, Plant and Equipment [Policy Text Block]	Property, Plant and Equipment: The Company depreciates property, plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 8 years. Certain tooling costs are capitalized and amortized over a 3 -year life, while repairs and maintenance costs are expensed.
Asset Retirement Obligations [Policy Text Block]	Asset Retirement Obligations : The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as interest expense. The amounts recorded in the consolidated financial statements are not material to any year presented.
Change in Accounting for Pension and Other Postretirement Benefits [Policy Text Block]	Pension and Other Postretirement Benefits:
Translation of Foreign Currencies [Policy Text Block]	Translation of Foreign Currencies:
Business Combinations [Policy Text Block]	Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. Measurement period adjustments are made in the period in which the amounts are determined and the current period income effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition date. All changes that do not qualify as measurement period adjustments are also included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.
Goodwill and Other Intangible Assets [Policy Text Block]	Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of a trade name that is not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships and purchased technologies, which are being amortized over their estimated useful lives. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset . In addition, the Company evaluates the remaining useful life of its non-amortizing intangible asset at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful life of non-amortizing intangible asset is no longer indefinite, the asset will be tested for impairment. The intangible asset will then be amortized prospectively over its estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Amortizing intangible assets are reviewed for impairment when indicators of impairment are present. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 13 below for additional details.
Stock-Based Compensation [Policy Text Block]	Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected term and the expected price volatility of the underlying stock. The Company estimates the expected term assumption based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 19 below.
Marketable Securities and Investments [Policy Text Block]	Marketable Securities and Investments: Investments in debt securities that are classified as available for sale are recorded at their fair values with unrealized gains and losses included in accumulated other comprehensive (loss) income until realized. Investments in equity securities are recorded at their fair values with unrealized holding gains and losses included in earnings. Investments in equity securities without a readily available fair value are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, with changes included in earnings.
Cash Flows [Policy Text Block]	Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.
Environmental Matters [Policy Text Block]	Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.
Research and Development Expense, Policy [Policy Text Block]	Research and Development: Research and development costs are expensed as incurred. The fair value of acquired IPR&D costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned.
Restructuring Charges [Policy Text Block]	Restructuring and Other Costs: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of its operations with its growth strategy, the integration of its business units and its productivity initiatives. In connection with these initiatives, the Company has recorded restructuring and other charges, as more fully described in Note 5 below, which include employee severance, other exit costs as well as costs of terminating certain lease agreements or contracts and other costs associated with relocating facilities. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Prior to recording restructuring charges for employee separation agreements, the Company notifies all employees of termination. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Prior to adoption of Accounting Standards Codification ("ASC") 842, Leases , costs related to lease terminations were recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceased use.
New Accounting Pronouncement or Change in Accounting Principle, Description	Comprehensive Income: Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.
Derivative Instruments and Hedging [Policy Text Block]	Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive (loss) income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. The Company also has entered into other foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into interest and other expense, net on the consolidated financial statements. The Company also uses foreign currency denominated debt to hedge its investments in certain foreign subsidiaries. Realized and unrealized translation adjustments from these hedges are included in the foreign currency translation component of AOCI, as well as the offset translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 eliminates certain exceptions and adds guidance to reduce complexity in accounting for income taxes. Specifically, this guidance: (1) removes the intraperiod tax allocation exception to the incremental approach; (2) removes the ownership changes in investments exception in determining when a deferred tax liability is recognized after an investor in a foreign entity transitions to or from the equity method of accounting and applies this provision on a modified retrospective basis through a cumulative-effect adjustment to retained earnings at the beginning of the period of adoption; and (3) removes the exception to using the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. ASU 2019-12 also simplifies accounting principles by making other changes, including requiring an entity to: (1) evaluate whether a step-up in tax basis of goodwill relates to a business combination or a separate transaction; (2) make a policy election to not allocate consolidated income taxes when a member of a consolidated tax return is not subject to income tax and to apply this provision retrospectively to all periods presented; and (3) recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and apply this provision either retrospectively for all periods presented or on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The provisions of this guidance (except as specifically mentioned above) are to be applied prospectively upon their effective date. ASU 2019-12 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those years. Early adoption is permitted but requires simultaneous adoption of all provisions of this guidance. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In April 2019, the FASB issued Accounting Standards Update No. 2019-04, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ("ASU 2019-04"). ASU 2019-04 clarifies certain aspects of previously issued accounting standards related to: (1) ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements ("ASU 2016-13"), in areas of accrued interest receivable, transfers of loans and debt securities between classifications, recoveries and prepayments, (2) ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities ("ASU 2017-12"), in areas of partial-term fair value hedges, fair value hedge basis adjustments, certain disclosures and transition requirements and (3) ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"), in areas of remeasurement of equity securities under ASC 820, Fair Value Measurement , when using the measurement alternative and remeasurement of equity securities at historical exchange rates. The amendments related to ASU 2016-13 are required to be adopted in conjunction with that accounting standards update, as further described below. Since the Company has already adopted ASU 2017-12 and ASU 2016-01, the related amendments in ASU 2019-04 are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted in any interim period. The amendments to ASU 2017-12 can either be adopted retrospectively as of the date of adoption of ASU 2017-12 or they can be adopted prospectively. The amendments to ASU 2016-01 are required to be applied using a modified-retrospective adoption approach with a cumulative-effect adjustment to retained earnings as of the date of adoption of ASU 2016-01, except for those related to equity securities without readily determinable fair values that are measured using the measurement alternative, which are required to be applied prospectively. The standard was effective for the Company beginning on December 30, 2019, the first day of the Company's fiscal year 2020. The Company will apply the provisions of this guidance prospectively. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract ("ASU 2018-15"). ASU 2018-15 aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the guidance on capitalizing costs associated with developing or obtaining internal-use software (and hosting arrangements that include an internal-use software license). The provisions of this guidance are to be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The standard was effective for the Company beginning on December 30, 2019, the first day of the Company's fiscal year 2020. The Company will apply the provisions of this guidance prospectively. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans ("ASU 2018-14"). ASU 2018-14 adds, removes, and clarifies disclosure requirements related to defined benefit pension and other postretirement plans. ASU 2018-14 adds requirements for an entity to disclose the weighted-average interest crediting rates used in the entity’s cash balance pension plans and other similar plans; and an explanation of the reasons for significant gains and losses related to changes in the benefit obligation for the period . Further, ASU 2018-14 removes guidance that currently requires the following disclosures: the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year; the amount and timing of plan assets expected to be returned to the employer; information about (1) benefits covered by related-party insurance and annuity contracts and (2) significant transactions between the plan and related parties; and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. ASU 2018-14 also clarifies the guidance in Compensation-Retirement Benefits (Topic 715-20-50-3) on defined benefit plans to require disclosure of (1) the projected benefit obligation ("PBO") and fair value of plan assets for pension plans with PBOs in excess of plan assets (the same disclosure with reference to the accumulated postretirement benefit obligation rather than the PBO is required for other postretirement benefit plans) and (2) the accumulated benefit obligation ("ABO") and fair value of plan assets for pension plans with ABOs in excess of plan assets. The provisions of this guidance are to be applied retrospectively to all periods presented upon their effective date. ASU 2018-14 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within those years with early adoption permitted. The Company is currently evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company's consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued Accounting Standards Update No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). ASU 2018-13 adds, removes, and modifies certain disclosures related to fair value measurements. ASU 2018-13 adds requirements for an entity to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Further, ASU 2018-13 removes the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. ASU 2018-13 also modifies existing disclosure requirements related to measurement uncertainty. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are to be applied retrospectively to all periods presented upon their effective date. The standard was effective for the Company beginning on December 30, 2019, the first day of the Company's fiscal year 2020. The adoption is not expected to have a material impact on the Company's disclosures related to fair value measurements. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments . ASU 2016-13 changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The standard requires entities to use the expected loss impairment model and will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance sheet credit exposures. Entities are required to estimate the lifetime “expected credit loss” for each applicable financial asset and record an allowance that, when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The standard also amends the impairment model for available-for-sale (“AFS”) debt securities and requires entities to determine whether all or a portion of the unrealized loss on an AFS debt security is a credit loss. An entity will recognize an allowance for credit losses on an AFS debt security as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment. The provisions of this guidance are to be applied using a modified-retrospective approach. A prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. Subsequent to the issuance of ASU 2016-13, in November 2018, the FASB issued Accounting Standards Update No. 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses ("ASU 2018-19"), in April 2019, the FASB issued ASU 2019-04, and in May 2019, the FASB issued Accounting Standards Update No. 2019-05, Financial Instruments - Credit Losses (Topic 326), Targeted Transition Relief ("ASU 2019-05") . The amendments in ASU 2018-19 clarify that receivables arising from operating leases are not within the scope of Subtopic 326-20, Financial Instruments - Credit Losses - Measured at Amortized Cost . Instead, impairment of receivables arising from operating leases should be accounted for in accordance with Topic 842, Leases . The amendments in ASU 2019-04 clarify the measurement of allowance for credit losses on accrued interest receivable; the inclusion of expected recoveries in the allowance for credit losses; the permission of a prepayment-adjusted effective interest rate when determining the allowance for credit losses; and the steps entities should take when recording the transfer of loans or debt securities between measurement classifications. The amendments in ASU 2019-05 provide an option to irrevocably elect the fair value option in Subtopic 825-10, Financial Instruments-Overall , on an instrument-by-instrument basis, for eligible financial assets measured at amortized cost basis upon adoption of ASU 2016-13, but this fair value option election does not apply to held-to-maturity debt securities. The effective date and transition requirements for the amendments in ASU 2018-19, ASU 2019-04 and ASU 2019-05 are the same as the effective date and transition requirements of ASU 2016-13, which is effective for annual reporting periods beginning after December 15, 2019, and interim periods within those years. The standards were effective for the Company beginning on December 30, 2019, the first day of the Company's fiscal year 2020. The Company adopted these standards using the modified-retrospective approach. The adoption of the standard resulted in a decrease in retained earnings at December 30, 2019 of approximately $1.3 million from the cumulative effect of initially applying the standards as of that date. In addition, the adoption of the standard resulted in an increase in reserve for doubtful accounts of $1.7 million and an increase in deferred tax assets of $0.5 million from the tax impact of the cumulative adjustments. The adoption did not have an impact on cash from or used in operating, investing or financing activities in the Company's consolidated statement of cash flows at December 30, 2019. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease of assets will primarily depend on its classification as a finance or operating lease. ASU 2016-02 also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The provisions of this guidance are effective for annual periods beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. ASU 2016-02 is to be applied using a modified retrospective approach. Subsequent to the issuance of ASU 2016-02, in July 2018, the FASB issued Accounting Standards Update No. 2018-10, Codification Improvements to Topic 842, Leases ("ASU 2018-10") and Accounting Standards Update No. 2018-11, Leases (Topic 842): Targeted Improvements ("ASU 2018-11"), and in March 2019, the FASB issued Accounting Standards Update No. 2019-01, Leases (Topic 842): Codification Improvements ("ASU 2019-01"). The amendments in ASU 2018-10 clarify, correct or remove inconsistencies in the guidance provided under ASU 2016-02 related to sixteen specific issues identified. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard. Under the new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity's reporting for the comparative periods presented in the financial statements in the period of adoption will continue to be in accordance with Accounting Standards Codification (“ASC”) 840, Leases ("ASC 840"). An entity that elects this additional (and optional) transition method must provide the required disclosures under ASC 840 for all periods that continue to be in accordance with ASC 840. ASU 2018-11 also provides lessors with a practical expedient, by class of underlying asset, to not separate nonlease components from the associated lease component and, instead, to account for those components as a single component if certain criteria are met. ASU 2019-01 provides clarification on implementation issues associated with adopting ASU 2016-02. ASU 2019-01 provides guidance on transition disclosures related to Topic 250, Accounting Changes and Error Corrections , specifically paragraph 205-10-50-3, which requires entities to provide in the fiscal year in which a new accounting principle is adopted the identical disclosures for interim periods after the date of adoption. The guidance in ASU 2019-01 explicitly provides an exception to the paragraph 250-10-50-3 interim disclosure requirements in the Topic 842 transition disclosure requirements. The effective date and transition requirements for these standards are the same as the effective date and transition requirements of ASU 2016-02. The standards were effective for the Company beginning on December 31, 2018, the first day of the Company's fiscal year 2019. The Company did not early adopt these standards and adopted these standards using the optional transition method. The Company applied the modified retrospective approach, and applied the new leases standards at December 31, 2018, with a cumulative effect adjustment recognized in the opening balance of retained earnings in fiscal year 2019. As a lessee, the most significant impact of the standards relates to the recognition of the right-of-use assets and lease liabilities for the operating leases in the balance sheet. In addition, the Company had deferred gains from sale-leaseback transactions that are being amortized in operating expenses over the lease terms and the leases are accounted for as operating leases under ASC 840. Under the new standards, the Company recognized the deferred gains from the sales as a cumulative effect adjustment in retained earnings at December 31, 2018. The Company also derecognized the impact of its build-to-suit arrangements in which the Company was the deemed owner during the construction period, for which the construction is complete and the lease commenced before the initial date of adoption. The adoption of the standards resulted in an increase in retained earnings at December 31, 2018 of approximately $13.3 million for the cumulative effect of initially applying the standards as of that date. In addition, the adoption of the standards resulted in the recognition of right-of-use assets of approximately $199.5 million and lease liabilities of approximately $147.1 million , primarily related to the facilities operating leases, a decrease in property and equipment of approximately $34.6 million and an increase in deferred tax liabilities of $4.6 million for the tax impact of the cumulative adjustments. The adoption did not have an impact on cash from or used in operating, investing or financing activities in the Company's consolidated statement of cash flows at December 31, 2018.

Leases (Policies)

Leases (Policies)	12 Months Ended
	Dec. 29, 2019
Leases [Abstract]
Leases [Policy Text Block]	Changes in significant accounting policies Except for the changes below, the Company consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. The Company adopted ASC 842 with a date of initial application of December 31, 2018 ("transition date"). As a result, the Company has changed its accounting policy for leases as detailed below. The Company applied ASC 842 using the modified retrospective method and applied the new leases standard at transition date, with a cumulative effect adjustment recognized in the opening balance of retained earnings in fiscal year 2019. Therefore, the comparative information has not been adjusted and continues to be reported under ASC 840. As a lessee, the Company recognized operating leases in the consolidated balance sheet under ASC 842. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized at the transition date based on the present value of the remaining lease payments over the lease term. As most of the Company's leases as of the transition date did not provide an implicit rate, the Company used its incremental borrowing rate based on the information available at transition date in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities. The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statement of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred. As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under ASC 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with ASC 842.
Lessee, Leases [Policy Text Block]	As a lessee, the Company recognized operating leases in the consolidated balance sheet under ASC 842. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the Company's consolidated balance sheet. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized at the transition date based on the present value of the remaining lease payments over the lease term. As most of the Company's leases as of the transition date did not provide an implicit rate, the Company used its incremental borrowing rate based on the information available at transition date in determining the present value of lease payments. The Company used the implicit rate when readily determinable. The operating lease ROU asset excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as cars, the Company accounts for the lease and non-lease components as a single lease component. Additionally, for certain equipment leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities. The Company has made an accounting policy election not to recognize ROU assets and lease liabilities that arise from short-term leases for facilities and equipment. Instead, the Company recognizes the lease payments in the consolidated statement of operations on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred.
Lessor, Leases [Policy Text Block]	As a lessor, the Company applies the practical expedient to not separate non-lease components from the associated lease component and instead accounts for those components as a single component if the non-lease components otherwise would be accounted for under ASC 606, Revenue From Contracts With Customers (“ASC 606”), and both of the following criteria are met: 1) the timing and pattern of transfer of the non-lease component or components and associated lease component are the same; and 2) the lease component, if accounted for separately, would be classified as an operating lease. If the non-lease component or components associated with the lease component are the predominant component of the combined component, the Company accounts for the combined component in accordance with ASC 606. Otherwise, the Company accounts for the combined component as an operating lease in accordance with ASC 842.

Business Combinations and Ass_2

Business Combinations and Asset Purchases (Tables)	12 Months Ended
	Dec. 29, 2019
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma information presents the combined financial results for the Company and EUROIMMUN as if the acquisition of EUROIMMUN had been completed at the beginning of fiscal year 2016: December 31, (In thousands, except per share data) Pro Forma Statement of Operations Information (Unaudited): Revenue $ 2,562,580 Income from continuing operations 143,459 Basic earnings per share: Income from continuing operations $ 1.31 Diluted earnings per share: Income from continuing operations $ 1.29
Fair Values of the Business Combinations and Allocations for the Acquisitions Completed	The total purchase price for the acquisitions in fiscal year 2017 have been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: EUROIMMUN Other (In thousands) Fair value of business combination: Cash payments $ 1,413,113 $ 140,861 Other liability — 1,273 Working capital and other adjustments — (93 ) Less: cash acquired (25,018 ) (2,439 ) Total $ 1,388,095 $ 139,602 Identifiable assets acquired and liabilities assumed: Current assets $ 121,174 $ 16,268 Property, plant and equipment 109,859 11,356 Other assets 71,621 1,691 Identifiable intangible assets: Core technology 160,000 12,400 Trade names 36,000 3,000 Customer relationships 710,000 43,700 In-process research and development ("IPR&D") 1,400 — Goodwill 591,304 75,250 Deferred taxes (251,886 ) (15,735 ) Liabilities assumed (100,020 ) (8,328 ) Debt assumed (61,357 ) — Total $ 1,388,095 $ 139,602 The total purchase price for the acquisitions in fiscal year 2019 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Cisbio Meizheng Other (In thousands) Fair value of business combination: Cash payments $ 219,795 $ 145,000 $ 45,042 Other liability — 6,446 638 Contingent consideration — 12,100 634 Working capital and other adjustments 138 2,961 302 Less: cash acquired (12,542 ) (2,108 ) (1,334 ) Total $ 207,391 $ 164,399 $ 45,282 Identifiable assets acquired and liabilities assumed: Current assets $ 43,554 $ 15,160 $ 4,042 Property, plant and equipment 4,835 6,278 727 Other assets 100 32 481 Identifiable intangible assets: Core technology 90,000 36,500 27,667 Trade names 5,000 4,900 1,310 Customer relationships 39,000 53,000 6,700 Goodwill 72,341 81,457 17,006 Deferred taxes (34,886 ) (21,231 ) (6,658 ) Debt assumed — (706 ) (2,698 ) Liabilities assumed (12,553 ) (10,991 ) (3,295 ) Total $ 207,391 $ 164,399 $ 45,282 The total purchase price for the acquisitions in fiscal year 2018 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: (In thousands) Fair value of business combination: Cash payments $ 95,950 Other liability 3,354 Contingent consideration 6,200 Working capital and other adjustments 261 Less: cash acquired (1,132 ) Total $ 104,633 Identifiable assets acquired and liabilities assumed: Current assets $ 4,905 Property, plant and equipment 1,166 Other assets 776 Identifiable intangible assets: Core technology 31,956 Trade names 1,070 GC Libraries 2,065 Customer relationships 10,200 Goodwill 65,886 Deferred taxes (9,049 ) Debt assumed (461 ) Liabilities assumed (3,881 ) Total $ 104,633

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 29, 2019
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue [Table Text Block]	In the following tables, revenue is disaggregated by primary geographical market, end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments revenue. Reportable Segments For the fiscal year ended December 29, 2019 December 30, 2018 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 717,205 $ 401,591 $ 1,118,796 $ 680,117 $ 385,005 $ 1,065,122 Europe 495,768 291,610 787,378 494,707 283,385 778,092 Asia 533,188 444,311 977,499 518,387 416,395 934,782 $ 1,746,161 $ 1,137,512 $ 2,883,673 $ 1,693,211 $ 1,084,785 $ 2,777,996 Primary end-markets Diagnostics $ — $ 1,137,512 $ 1,137,512 $ — $ 1,084,785 $ 1,084,785 Life sciences 977,200 — 977,200 934,690 — 934,690 Applied markets 768,961 — 768,961 758,521 — 758,521 $ 1,746,161 $ 1,137,512 $ 2,883,673 $ 1,693,211 $ 1,084,785 $ 2,777,996 Timing of revenue recognition Products and services transferred at a point in time $ 1,276,499 $ 1,053,974 $ 2,330,473 $ 1,210,745 $ 1,002,213 $ 2,212,958 Services transferred over time 469,662 83,538 553,200 482,466 82,572 565,038 $ 1,746,161 $ 1,137,512 $ 2,883,673 $ 1,693,211 $ 1,084,785 $ 2,777,996

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 29, 2019
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	The summary pre-tax operating results of the discontinued operations were as follows during the three fiscal years ended: December 29, December 30, December 31, (In thousands) Revenue $ — $ — $ 44,343 Cost of revenue — — 32,933 Selling, general and administrative expenses — — 5,869 Research and development expenses — — 4,891 Restructuring and other costs, net — — — Income from discontinued operations before income taxes $ — $ — $ 650
Schedule of Gains and Losses on Disposition of Discontinued Operations [Table Text Block]	The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years ended: December 29, December 30, December 31, (In thousands) (Loss) gain on disposition of the Medical Imaging business $ — $ (793 ) $ 179,615 Loss on disposition of Fluid Sciences business — (66 ) — (Loss) gain on disposition of discontinued operations before income taxes $ — $ (859 ) $ 179,615

Restructuring and Contract Te_2

Restructuring and Contract Terminaiton Charges, Net (Tables)	12 Months Ended
	Dec. 29, 2019
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions implemented during fiscal years 2019, 2018 and 2017 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Diagnostics Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Severance Excess Facility (In thousands, except headcount data) Q4 2019 Plan 22 $ 2,404 $ 177 $ — $ — $ 2,581 Q3 FY2020 — Q3 2019 Plan 259 2,641 11,156 — — 13,797 Q2 FY2020 — Q2 2019 Plan 44 1,129 4,461 — — 5,590 Q1 FY2020 — Q1 2019 Plan 105 1,459 6,001 — — 7,460 Q4 FY2019 — Q4 2018 Plan 1 — 348 — — 348 Q1 FY2019 — Q3 2018 Plan 61 618 1,146 — — 1,764 Q4 FY2019 — Q1 2018 Plan 47 902 5,096 — — 5,998 Q4 FY2019 — Q4 2017 Plan 29 255 1,680 — — 1,935 Q1 FY2019 — Q3 2017 Plan 27 1,021 1,321 — — 2,342 Q4 FY2018 — Q1 2017 Plan 90 1,631 5,000 33 33 6,697 Q2 FY2018 Q2 FY2018
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the Company's restructuring accrual balances and related activity by restructuring plan, as well as other accrual balances and related activity, during fiscal years 2019, 2018 and 2017 in continuing operations: Balance at January 1, 2017 2017 Charges and Changes in Estimates, Net 2017 Amounts Paid Balance at December 31, 2017 2018 Charges and Changes in Estimates, Net 2018 Amounts Paid Balance at December 30, 2018 2019 Charges and Changes in Estimates, Net 2019 Amounts Paid Balance at December 29, 2019 Severance: Q4 2019 Plan $ — $ — $ — $ — $ — $ — $ — $ 2,581 $ (1,692 ) $ 889 Q3 2019 Plan — — — — — — — 13,797 (7,486 ) 6,311 Q2 2019 Plan — — — — — — — 5,590 (3,701 ) 1,889 Q1 2019 Plan — — — — — — — 7,483 (5,354 ) 2,129 Q4 2018 Plan — — — — 348 — 348 3 (351 ) — Q3 2018 Plan (1) — — — — 2,054 (639 ) 1,415 (77 ) (1,314 ) 24 Q1 2018 Plan (2) — — — — 5,998 (4,389 ) 1,609 (1,069 ) (282 ) 258 Q4 2017 Plan — 1,935 (16 ) 1,919 (381 ) (1,538 ) — — — — Q3 2017 Plan — 2,342 (270 ) 2,072 (1,204 ) (868 ) — — — — Q1 2017 Plan (3) — 6,631 (4,133 ) 2,498 (983 ) (1,232 ) 283 (276 ) (7 ) — Facility: Q1 2017 Plan — 66 (33 ) 33 — (33 ) — — — — Previous Plans (4) 10,424 (1,568 ) (4,457 ) 4,399 570 (2,581 ) 2,388 117 (1,140 ) 1,365 Restructuring 10,424 9,406 (8,909 ) 10,921 6,402 (11,280 ) 6,043 28,149 (21,327 ) 12,865 Contract Termination 117 3,251 (320 ) 3,048 4,742 (7,653 ) 137 452 (401 ) 188 Other Costs — — — — — — — 827 — 827 Total Restructuring and Other Liabilities $ 10,541 $ 12,657 $ (9,229 ) $ 13,969 $ 11,144 $ (18,933 ) $ 6,180 $ 29,428 $ (21,728 ) $ 13,880 ____________________________ (1) During fiscal year 2019 , the Company recognized pre-tax restructuring reversals of $0.4 million in the Diagnostics segment related to lower than expected costs associated with workforce reductions and an additional expense of $0.3 million in the Discovery & Analytical Solutions segment for the Q3 2018 Plan. (2) During fiscal year 2019 , the Company recognized pre-tax restructuring reversals of $1.1 million in the Discovery & Analytical Solutions segment related to lower than expected costs associated with workforce reductions for the Q1 2018 Plan. (3) During fiscal year 2019 , the Company recognized pre-tax restructuring reversals of $0.3 million in the Discovery & Analytical Solutions segment related to lower than expected costs associated with workforce reductions for the Q1 2017 Plan. (4) During fiscal year 2019 , the Company recognized pre-tax restructuring expense of $0.1 million in the Discovery & Analytical Solutions segment related to higher than expected costs associated with workforce reductions for the Previous Plans.

Interest and Other Expense (I_2

Interest and Other Expense (Income), Net (Tables)	12 Months Ended
	Dec. 29, 2019
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and other expense, net, consisted of the following for the fiscal years ended: December 29, December 30, January 1, Interest income $ (1,495 ) $ (1,141 ) $ (2,571 ) Interest expense 63,627 66,976 43,940 Loss (gain) on disposition of businesses and assets, net (see Note 4) 2,469 (12,844 ) 309 Debt extinguishment costs (see Note 14) 32,541 — — Other expense (income), net 27,689 13,210 (42,781 ) Total interest and other expense, net $ 124,831 $ 66,201 $ (1,103 )

Income Taxes (Tables)

Income Taxes (Tables) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018
Income Tax Disclosure [Abstract]
Summary of Income Tax Contingencies [Table Text Block]	The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: December 29, December 30, December 31, (In thousands) Unrecognized tax benefits, beginning of year $ 33,009 $ 30,308 $ 29,607 Gross increases—tax positions in prior periods 4,433 6,931 749 Gross decreases—tax positions in prior periods (2,183 ) (1,622 ) (828 ) Gross increases—current-period tax positions 152 — 2,346 Settlements (45 ) (2,253 ) (324 ) Lapse of statute of limitations — (181 ) (1,371 ) Foreign currency translation adjustments 181 (174 ) 129 Unrecognized tax benefits, end of year $ 35,547 $ 33,009 $ 30,308
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The components of income from continuing operations before income taxes were as follows for the fiscal years ended: December 29, December 30, December 31, (In thousands) U.S. $ 29,252 $ 32,627 $ 3,743 Non-U.S. 207,890 225,056 292,975 Total $ 237,142 $ 257,683 $ 296,718
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the provision for income taxes on continuing operations were as follows: Current Expense Deferred Expense (Benefit) Total (In thousands) Fiscal year ended December 29, 2019 Federal $ 3,735 $ (267 ) $ 3,468 State 4,425 (1,574 ) 2,851 Non-U.S. 62,582 (59,512 ) 3,070 Total $ 70,742 $ (61,353 ) $ 9,389 Fiscal year ended December 30, 2018 Federal $ 7,938 $ (5,250 ) $ 2,688 State 2,345 2,572 4,917 Non-U.S. 61,028 (48,425 ) 12,603 Total $ 71,311 $ (51,103 ) $ 20,208 Fiscal year ended December 31, 2017 Federal $ 62,003 $ 35,435 $ 97,438 State 3,332 (792 ) 2,540 Non-U.S. 45,639 (5,789 ) 39,850 Total $ 110,974 $ 28,854 $ 139,828
Schedule of Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations [Table Text Block]	The total provision for (benefit from) income taxes included in the consolidated financial statements is as follows for the fiscal years ended: December 29, December 30, December 31, (In thousands) Continuing operations $ 9,389 $ 20,208 $ 139,828 Discontinued operations 195 (1,311 ) 44,522 Total $ 9,584 $ 18,897 $ 184,350
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision is as follows for the fiscal years ended: December 29, December 30, December 31, (In thousands) Tax at statutory rate $ 49,799 $ 54,114 $ 103,851 Non-U.S. rate differential, net (32,124 ) (27,281 ) (65,836 ) U.S. taxation of multinational operations 4,251 7,047 5,408 State income taxes, net 1,941 2,028 1,810 Prior year tax matters (5,103 ) 1,124 (2,888 ) Effect of stock compensation (2,053 ) (6,331 ) (5,067 ) General business tax credits (4,325 ) (3,738 ) (8,249 ) Change in valuation allowance (1,117 ) (759 ) 1,951 Tax elections (3,700 ) — — Impact of U.S. Tax Act 2,718 (2,025 ) 106,538 Others, net (898 ) (3,971 ) 2,310 Total $ 9,389 $ 20,208 $ 139,828
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of December 29, 2019 and December 30, 2018 were as follows: December 29, December 30, (In thousands) Deferred tax assets: Inventory $ 4,662 $ — Reserves and accruals 46,817 39,487 Accrued compensation 18,953 21,709 Net operating loss and credit carryforwards 116,751 144,421 Accrued pension 35,890 31,146 Restructuring reserve 2,983 1,780 Deferred revenue 30,412 31,045 Operating lease liabilities 46,477 — Total deferred tax assets 302,945 269,588 Deferred tax liabilities: Inventory — (278 ) Postretirement health benefits (4,106 ) (3,406 ) Depreciation and amortization (330,768 ) (309,958 ) Operating lease right-of-use assets (42,774 ) — All other, net (1,780 ) (1,879 ) Total deferred tax liabilities (379,428 ) (315,521 ) Valuation allowance (88,449 ) (102,087 ) Net deferred tax liabilities $ (164,932 ) $ (148,020 )
Schedule of Deferred Income Taxes, Domestic and Foreign [Table Text Block]	The components of net deferred tax (liabilities) assets as of December 29, 2019 and December 30, 2018 were as follows: December 29, December 30, (In thousands) U.S. $ 43,683 $ 52,469 Non-U.S. (208,615 ) (200,489 ) Total $ (164,932 ) $ (148,020 )
Components of net deferred tax asset recognized [Table Text Block]	The components of net deferred tax liabilities as of December 29, 2019 and December 30, 2018 were recognized in the consolidated balance sheets as follows: December 29, December 30, (In thousands) Other assets, net $ 60,004 $ 79,312 Long-term liabilities (224,936 ) (227,332 ) Total $ (164,932 ) $ (148,020 )
Deferred tax assets, other assets, net	$ 60,004	$ 79,312
Deferred tax liabilities, Long-term liabilities	(224,936)	(227,332)
Deferred Tax Liabilities, Net	$ (164,932)	$ (148,020)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 29, 2019
Earnings Per Share [Abstract]
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: December 29, December 30, December 31, (In thousands) Number of common shares—basic 110,827 110,561 109,857 Effect of dilutive securities: Stock options 541 761 708 Restricted stock awards 133 212 294 Number of common shares—diluted 111,501 111,534 110,859 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 364 349 287

Accounts Receivable, Net Accoun

Accounts Receivable, Net Accounts Receivable, Net (Tables)	12 Months Ended
	Dec. 29, 2019
Accounts, Notes, Loans and Financing Receivable [Line Items]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	Accounts receivable, net as of December 29, 2019 and December 30, 2018 consisted of the following: December 29, December 30, (In thousands) Accounts receivable, net, current $ 725,184 $ 632,669 Long-term accounts receivable, net, included in Other assets 19,677 — Total accounts receivable, net $ 744,861 $ 632,669

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Dec. 29, 2019
Inventory Disclosure [Abstract]
Schedule of Net Inventories	Inventories as of December 29, 2019 and December 30, 2018 consisted of the following: December 29, December 30, (In thousands) Raw materials $ 130,673 $ 119,115 Work in progress 26,409 18,110 Finished goods 199,855 201,122 Total inventories $ 356,937 $ 338,347

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 29, 2019
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment [Table Text Block]	Property, plant and equipment as of December 29, 2019 and December 30, 2018 , consisted of the following: December 29, December 30, (In thousands) At cost: Land $ 5,272 $ 5,482 Building and leasehold improvements 250,639 272,277 Machinery and equipment 445,669 402,424 Total property, plant and equipment 701,580 680,183 Accumulated depreciation (383,357 ) (361,593 ) Total property, plant and equipment, net $ 318,223 $ 318,590

Marketable Securities and Inv_2

Marketable Securities and Investments (Tables)	12 Months Ended
	Dec. 29, 2019
Marketable Securities [Abstract]
Schedule of Investments, Noncurrent [Table Text Block]	Investments as of December 29, 2019 and December 30, 2018 consisted of the following: December 29, December 30, (In thousands) Marketable securities $ 2,906 $ 2,447 Equity investments 29,228 16,783 $ 32,134 $ 19,230
Available-for-sale Securities [Table Text Block]	Marketable securities classified as available for sale as of December 29, 2019 and December 30, 2018 consisted of the following: Market Value Gross Unrealized Holding Cost Gains (Losses) (In thousands) December 29, 2019 Equity securities $ 752 $ 1,109 $ — $ (357 ) Fixed-income securities 7 7 — — Other 2,147 2,210 — (63 ) $ 2,906 $ 3,326 $ — $ (420 ) December 30, 2018 Equity securities $ 671 $ 1,037 $ — $ (366 ) Fixed-income securities 22 22 — — Other 1,754 1,817 — (63 ) $ 2,447 $ 2,876 $ — $ (429 )

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for fiscal years 2019 and 2018 are as follows: Discovery & Analytical Solutions Diagnostics Consolidated Balance at December 31, 2017 $ 1,344,235 $ 1,657,963 $ 3,002,198 Foreign currency translation (32,189 ) (35,289 ) (67,478 ) Acquisitions, earnouts and other 22,946 (5,058 ) 17,888 Balance at December 30, 2018 1,334,992 1,617,616 2,952,608 Foreign currency translation (8,559 ) (9,725 ) (18,284 ) Acquisitions, earnouts and other 172,387 4,516 176,903 Balance at December 29, 2019 $ 1,498,820 $ 1,612,407 $ 3,111,227
Identifiable Intangible Asset Balances	Identifiable intangible asset balances at December 29, 2019 by category and by business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,122 $ 2,709 $ 30,831 Less: Accumulated amortization (27,142 ) (281 ) (27,423 ) Net patents 980 2,428 3,408 Trade names and trademarks 39,859 48,138 87,997 Less: Accumulated amortization (23,632 ) (16,663 ) (40,295 ) Net trade names and trademarks 16,227 31,475 47,702 Licenses 50,393 8,103 58,496 Less: Accumulated amortization (47,607 ) (2,126 ) (49,733 ) Net licenses 2,786 5,977 8,763 Core technology 390,116 298,973 689,089 Less: Accumulated amortization (205,263 ) (115,663 ) (320,926 ) Net core technology 184,853 183,310 368,163 Customer relationships 313,898 847,628 1,161,526 Less: Accumulated amortization (156,967 ) (221,221 ) (378,188 ) Net customer relationships 156,931 626,407 783,338 IPR&D — 1,328 1,328 Net amortizable intangible assets 361,777 850,925 1,212,702 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 432,361 $ 850,925 $ 1,283,286 Identifiable intangible asset balances at December 30, 2018 by category and business segment were as follows: Discovery & Analytical Solutions Diagnostics Consolidated Patents $ 28,030 $ 14,616 $ 42,646 Less: Accumulated amortization (25,978 ) (11,775 ) (37,753 ) Net patents 2,052 2,841 4,893 Trade names and trademarks 29,811 48,335 78,146 Less: Accumulated amortization (21,728 ) (12,073 ) (33,801 ) Net trade names and trademarks 8,083 36,262 44,345 Licenses 50,178 3,127 53,305 Less: Accumulated amortization (44,376 ) (1,174 ) (45,550 ) Net licenses 5,802 1,953 7,755 Core technology 240,734 300,177 540,911 Less: Accumulated amortization (189,033 ) (76,711 ) (265,744 ) Net core technology 51,701 223,466 275,167 Customer relationships 222,892 866,635 1,089,527 Less: Accumulated amortization (128,142 ) (165,822 ) (293,964 ) Net customer relationships 94,750 700,813 795,563 IPR&D — 1,360 1,360 Net amortizable intangible assets 162,388 966,695 1,129,083 Non-amortizing intangible asset: Trade name 70,584 — 70,584 Total $ 232,972 $ 966,695 $ 1,199,667

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 29, 2019
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt [Table Text Block]	The following table summarizes the maturities of the Company’s indebtedness as of December 29, 2019 : Sr. Unsecured Revolving Credit Facility Maturing 2024 April 2021 Notes 2026 Notes 2029 Notes Other Debt Facilities Total (In thousands) 2020 $ — $ — $ — $ — $ 9,974 $ 9,974 2021 — 335,370 — — 7,910 343,280 2022 — — — — 3,759 3,759 2023 — — — — 2,278 2,278 2024 325,377 — — — 1,287 326,664 2025 and thereafter — — 558,950 850,000 536 1,409,486 Total before unamortized discount and debt issuance costs 325,377 335,370 558,950 850,000 25,744 2,095,441 Unamortized discount and debt issuance costs (3,356 ) (1,194 ) (6,756 ) (10,120 ) — (21,426 ) Total $ 322,021 $ 334,176 $ 552,194 $ 839,880 $ 25,744 $ 2,074,015

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 29, 2019
Accounts Payable and Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses and other current liabilities as of December 29, 2019 and December 30, 2018 consisted of the following: December 29, December 30, (In thousands) Payroll and incentives $ 77,892 $ 86,549 Employee benefits 42,405 44,060 Deferred revenue 164,261 155,064 Federal, non-U.S. and state income taxes 29,876 30,687 Other accrued operating expenses 188,898 212,467 Total accrued expenses and other current liabilities $ 503,332 $ 528,827

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018
Pension Plans, Defined Benefit
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Components of Net Periodic Benefit Cost (Credit)	Net periodic pension cost (credit) for U.S. and non-U.S. plans included the following components for fiscal years ended: December 29, December 30, December 31, (In thousands) Service and administrative costs $ 6,598 $ 6,853 $ 4,951 Interest cost 16,546 16,146 16,707 Expected return on plan assets (24,561 ) (28,939 ) (26,401 ) Actuarial loss (gain) 27,134 17,146 (7,085 ) Curtailment gain (1,547 ) — — Amortization of prior service (credit) cost (152 ) 375 (195 ) Net periodic pension cost (credit) $ 24,018 $ 11,581 $ (12,023 )
Schedule of Net Funded Status		The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 29, 2019 and December 30, 2018 . December 29, 2019 December 30, 2018 Non-U.S. U.S. Non-U.S. U.S. (In thousands) Actuarial present value of benefit obligations: Accumulated benefit obligations $ 338,722 $ 304,710 $ 304,065 $ 283,310 Change in benefit obligations: Projected benefit obligations at beginning of year $ 311,168 $ 283,310 $ 343,410 $ 308,713 Service and administrative costs 4,248 2,350 4,528 2,325 Interest cost 5,448 11,098 5,484 10,662 Benefits paid and plan expenses (12,778 ) (21,162 ) (13,081 ) (19,709 ) Participants’ contributions 162 — 176 — Business acquisitions — — 537 — Plan amendments — — 533 — Plan curtailments (1,420 ) — — — Actuarial loss (gain) 34,602 29,114 (13,141 ) (18,681 ) Effect of exchange rate changes 25 — (17,278 ) — Projected benefit obligations at end of year $ 341,455 $ 304,710 $ 311,168 $ 283,310 Change in plan assets: Fair value of plan assets at beginning of year $ 159,163 $ 234,342 $ 179,736 $ 253,427 Actual return on plan assets 19,873 41,270 (5,653 ) (14,376 ) Benefits paid and plan expenses (12,778 ) (21,162 ) (13,081 ) (19,709 ) Employer’s contributions 8,200 — 8,480 15,000 Participants’ contributions 162 — 176 — Effect of exchange rate changes 5,240 — (10,495 ) — Fair value of plan assets at end of year $ 179,860 $ 254,450 $ 159,163 $ 234,342 Net liabilities recognized in the consolidated balance sheets $ (161,595 ) $ (50,260 ) $ (152,005 ) $ (48,968 ) Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 36,699 $ — $ 31,419 $ — Current liabilities (6,764 ) — (6,752 ) — Long-term liabilities (191,530 ) (50,260 ) (176,672 ) (48,968 ) Net liabilities recognized in the consolidated balance sheets $ (161,595 ) $ (50,260 ) $ (152,005 ) $ (48,968 ) Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — $ (278 ) $ — Actuarial assumptions as of the year-end measurement date: Discount rate 1.34 % 3.01 % 2.07 % 4.05 % Rate of compensation increase 3.36 % None 3.48 % None Actuarial assumptions used to determine net periodic pension cost during the year were as follows: December 29, 2019 December 30, 2018 December 31, 2017 Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Discount rate 2.07 % 4.05 % 1.99 % 3.56 % 2.06 % 4.06 % Rate of compensation increase 3.48 % None 3.50 % None 3.64 % None Expected rate of return on assets 5.30 % 7.25 % 5.90 % 7.25 % 6.00 % 7.25 %
Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]		The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: December 29, December 30, (In thousands) Pension Plans with Projected Benefit Obligations in Excess of Plan Assets Projected benefit obligations $ 198,294 $ 183,424 Fair value of plan assets — — Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets Accumulated benefit obligations $ 195,657 $ 180,560 Fair value of plan assets — —
Schedule of Allocation of Plan Assets		Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 29, 2019 and December 30, 2018 , and target asset allocations for fiscal year 2020 are as follows: Target Allocation Percentage of Plan Assets at January 3, 2021 December 29, 2019 December 30, 2018 Asset Category Non-U.S. U.S. Non-U.S. U.S. Non-U.S. U.S. Equity securities 0-5% 40-60% — % 41 % 48 % 39 % Debt securities 85-90% 40-60% 87 % 59 % 51 % 61 % Other 10-15% 0-10% 13 % — % 1 % — % Total 100 % 100 % 100 % 100 % 100 % 100 %
Schedule of Changes in Fair Value of Plan Assets	The fair values of the Company’s pension plan assets as of December 29, 2019 and December 30, 2018 by asset category, classified in the three levels of inputs described in Note 22 to the consolidated financial statements are as follows: Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 6,177 $ 6,177 $ — $ — Equity securities: U.S. large-cap 57,797 57,797 — — International large-cap value 26,914 26,914 — — U.S. small mid-cap 2,700 2,700 — — Emerging markets growth 12,853 12,853 — — Domestic real estate funds 2,010 2,010 — — Foreign real estate funds 22,688 — — 22,688 Fixed income securities: Non-U.S. treasury securities 93,473 — 93,473 — Corporate and U.S. debt instruments 139,300 47,104 92,196 — Corporate bonds 29,846 — 29,846 — High yield bond funds 5,734 5,734 — — Other types of investments: Multi-strategy hedge funds 1,721 — — 1,721 Non-U.S. government index linked bonds 33,097 — 33,097 — Total assets measured at fair value $ 434,310 $ 161,289 $ 248,612 $ 24,409 Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 6,326 $ 6,326 $ — $ — Equity Securities: U.S. large-cap 35,072 35,072 — — International large-cap value 24,175 24,175 — — U.S. small-cap 1,928 1,928 — — Emerging markets growth 11,993 11,993 — — Equity index funds 54,342 — 54,342 — Domestic real estate funds 1,353 1,353 — — Foreign real estate funds 22,196 — — 22,196 Commodity funds 886 886 — — Fixed income securities: Non-U.S. Treasury Securities 23,352 — 23,352 — Corporate and U.S. debt instruments 131,211 48,133 83,078 — Corporate bonds 24,848 — 24,848 — High yield bond funds 5,186 5,186 — — Other types of investments: Multi-strategy hedge funds 16,934 — — 16,934 Non-U.S. government index linked bonds 33,703 — 33,703 — Total assets measured at fair value $ 393,505 $ 135,052 $ 219,323 $ 39,130
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets		A reconciliation of the beginning and ending Level 3 assets for fiscal years 2019, 2018 and 2017 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Foreign Real Estate Funds Multi-strategy Hedge Funds Total (In thousands) Balance at January 1, 2017 $ — $ 23,790 $ 23,790 Sales — (8,189 ) (8,189 ) Realized gains — 1,542 1,542 Unrealized losses — (354 ) (354 ) Balance at December 31, 2017 — 16,789 16,789 Purchases 22,196 — 22,196 Unrealized gains — 145 145 Balance at December 30, 2018 22,196 16,934 39,130 Sales — (15,586 ) (15,586 ) Realized gains — 4,175 4,175 Unrealized gains (losses) 492 (3,802 ) (3,310 ) Balance at December 29, 2019 $ 22,688 $ 1,721 $ 24,409
Schedule of Expected Benefit Payments		The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Non-U.S. U.S. (In thousands) 2020 $ 11,540 $ 19,200 2021 12,006 19,346 2022 12,083 19,449 2023 12,362 19,561 2024 13,119 19,539 2025-2029 66,950 94,159
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Components of Net Periodic Benefit Cost (Credit)		Net periodic postretirement medical benefit (credit) cost included the following components for the fiscal years ended: December 29, December 30, December 31, (In thousands) Service cost $ 87 $ 106 $ 92 Interest cost 116 120 125 Expected return on plan assets (1,175 ) (1,254 ) (1,114 ) Actuarial (gain) loss (1,776 ) 1,621 (741 ) Net periodic postretirement medical benefit (credit) cost $ (2,748 ) $ 593 $ (1,638 )
Schedule of Net Funded Status		The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of December 29, 2019 and December 30, 2018 . December 29, December 30, (In thousands) Actuarial present value of benefit obligations: Retirees $ 583 $ 688 Active employees eligible to retire 362 408 Other active employees 1,966 2,317 Accumulated benefit obligations at beginning of year 2,911 3,413 Service cost 87 106 Interest cost 116 120 Benefits paid (122 ) (117 ) Actuarial loss (gain) 108 (611 ) Change in accumulated benefit obligations during the year 189 (502 ) Retirees 611 583 Active employees eligible to retire 420 362 Other active employees 2,069 1,966 Accumulated benefit obligations at end of year $ 3,100 $ 2,911 Change in plan assets: Fair value of plan assets at beginning of year $ 16,279 $ 17,374 Actual return on plan assets 2,937 (993 ) Benefits reimbursements paid — (102 ) Fair value of plan assets at end of year $ 19,216 $ 16,279 Net assets recognized in the consolidated balance sheets $ 16,116 $ 13,368 Net amounts recognized in the consolidated balance sheets consist of: Other assets $ 16,116 $ 13,368 Net amounts recognized in accumulated other comprehensive income consist of: Prior service cost $ — $ — Actuarial assumptions as of the year-end measurement date: Discount rate 3.09 % 4.09 % Actuarial assumptions used to determine net cost during the year are as follows: December 29, December 30, December 31, Discount rate 4.09 % 3.60 % 4.11 % Expected rate of return on assets 7.25 % 7.25 % 7.25 %
Schedule of Changes in Fair Value of Plan Assets		The fair values of the Company’s plan assets at December 29, 2019 and December 30, 2018 by asset category, classified in the three levels of inputs described in Note 22, are as follows: Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 408 $ 408 $ — $ — Equity securities: U.S. large-cap 4,365 4,365 — — International large-cap value 2,033 2,033 — — U.S. small mid-cap 204 204 — — Emerging markets growth 971 971 — — Domestic real estate funds 152 152 — — Fixed income securities: Corporate debt instruments 10,520 3,557 6,963 — High yield bond funds 433 433 — — Other types of investments: Multi-strategy hedge funds 130 — — 130 Total assets measured at fair value $ 19,216 $ 12,123 $ 6,963 $ 130 Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Cash $ 390 $ 390 $ — $ — Equity securities: U.S. large-cap 2,436 2,436 — — International large-cap value 1,679 1,679 — — U.S. small mid-cap 134 134 — — Emerging markets growth 833 833 — — Domestic real estate funds 94 94 — — Commodity funds 62 62 — — Fixed income securities: Corporate debt instruments 9,115 3,344 5,771 — High yield bond funds 360 360 — — Other types of investments: Multi-strategy hedge funds 1,176 — — 1,176 Total assets measured at fair value $ 16,279 $ 9,332 $ 5,771 $ 1,176
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets		A reconciliation of the beginning and ending Level 3 assets for fiscal years 2019, 2018 and 2017 is as follows: Fair Value Measurements Using Significant Unobservable Inputs (Level 3): Multi-strategy Hedge Funds (In thousands) Balance at January 1, 2017 $ 1,508 Sales (562 ) Realized gains 229 Unrealized losses (24 ) Balance at December 31, 2017 1,151 Unrealized gains 25 Balance at December 30, 2018 1,176 Sales (1,074 ) Realized gains 315 Unrealized losses (287 ) Balance at December 29, 2019 $ 130
Schedule of Expected Benefit Payments		The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: Postretirement Medical Plan (In thousands) 2020 $ 130 2021 146 2022 165 2023 177 2024 187 2025-2029 995

Warranty Reserves (Tables)

Warranty Reserves (Tables)	12 Months Ended
	Dec. 29, 2019
Product Warranties Disclosures [Abstract]
Warranty Reserve Activity	A summary of warranty reserve activity for the fiscal years ended December 29, 2019 , December 30, 2018 and December 31, 2017 is as follows: (In thousands) Balance at January 1, 2017 $ 9,012 Provision charged to income 13,700 Payments (14,245 ) Adjustments to previously provided warranties, net (815 ) Foreign currency translation and acquisitions 1,398 Balance at December 31, 2017 9,050 Provision charged to income 13,545 Payments (13,775 ) Adjustments to previously provided warranties, net (157 ) Foreign currency translation and acquisitions (270 ) Balance at December 30, 2018 8,393 Provision charged to income 12,199 Payments (14,613 ) Adjustments to previously provided warranties, net 2,889 Foreign currency translation and acquisitions (56 ) Balance at December 29, 2019 $ 8,812

Stock Plans (Tables)

Stock Plans (Tables)	12 Months Ended
	Dec. 29, 2019
Share-based Payment Arrangement [Abstract]
Summary of Total Compensation Recognized Related to Outstanding Equity Awards	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2019, 2018 and 2017 : December 29, December 30, December 31, (In thousands) Cost of product and service revenue $ 1,620 $ 1,466 $ 1,254 Research and development expenses 1,061 1,359 1,389 Selling, general and administrative expenses 28,833 25,942 22,778 Total stock-based compensation expense $ 31,514 $ 28,767 $ 25,421
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model	The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: December 29, December 30, December 31, Risk-free interest rate 2.5 % 3.0 % 2.0 % Expected dividend yield 0.3 % 0.4 % 0.4 % Expected lives 5 years 5 years 5 years Expected stock volatility 22.8 % 20.7 % 22.4 %
Summary of Stock Option Activity	The following table summarizes stock option activity for the fiscal year ended December 29, 2019 : Number of Shares Weighted- Average Exercise Price (Shares in thousands) Outstanding at beginning of year 1,765 $ 52.91 Granted 304 93.66 Exercised (415 ) 47.60 Canceled (3 ) 75.52 Forfeited (116 ) 78.71 Outstanding at end of year 1,535 $ 60.42 Exercisable at end of year 954 $ 48.65
Summary of Restricted Stock Award Activity	The following table summarizes restricted stock award activity for the fiscal year ended December 29, 2019 : Number of Shares Weighted- Average Grant- Date Fair Value (Shares in thousands) Nonvested at beginning of year 465 $ 61.72 Granted 163 94.80 Vested (218 ) 55.20 Forfeited (65 ) 76.72 Nonvested at end of year 345 $ 78.69

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 29, 2019
Stockholders' Equity Note [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Currency Translation Adjustment, net of tax Unrecognized Prior Service Costs, net of tax Unrealized (Losses) Gains on Securities, net of tax Accumulated Other Comprehensive Income (Loss) (In thousands) Balance, January 1, 2017 $ (100,923 ) $ 399 $ (337 ) $ (100,861 ) Current year change 54,341 (77 ) 79 54,343 Balance, December 31, 2017 (46,582 ) 322 (258 ) (46,518 ) Current year change (123,388 ) (77 ) (9 ) (123,474 ) Reclassification to retained earnings upon adoption of ASU 2018-02 (6,489 ) — — (6,489 ) Balance, December 30, 2018 (176,459 ) 245 (267 ) (176,481 ) Current year change (23,978 ) 807 6 (23,165 ) Balance, December 29, 2019 $ (200,437 ) $ 1,052 $ (261 ) $ (199,646 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 29, 2019
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 29, 2019 and December 30, 2018 classified in one of the three classifications described above: Fair Value Measurements at December 29, 2019 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,906 $ 2,906 $ — $ — Foreign exchange derivative assets 451 — 451 — Foreign exchange derivative liabilities (1,538 ) — (1,538 ) — Contingent consideration (35,481 ) — — (35,481 ) Fair Value Measurements at December 30, 2018 Using: Total Carrying Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (In thousands) Marketable securities $ 2,447 $ 2,447 $ — $ — Foreign exchange derivative assets 750 — 750 — Foreign exchange derivative liabilities, net (594 ) — (594 ) — Contingent consideration (69,661 ) — — (69,661 )
Reconciliation of Beginning and Ending Level 3 Net Liabilities	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: (In thousands) Balance at January 1, 2017 $ (63,201 ) Amounts paid and foreign currency translation 35 Change in fair value (included within selling, general and administrative expenses) (2,162 ) Balance at December 31, 2017 (65,328 ) Additions (6,200 ) Amounts paid and foreign currency translation 16,506 Change in fair value (included within selling, general and administrative expenses) (14,639 ) Balance at December 30, 2018 (69,661 ) Additions (12,734 ) Amounts paid and foreign currency translation 50,795 Change in fair value (included within selling, general and administrative expenses) (3,881 ) Balance at December 29, 2019 $ (35,481 )

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 29, 2019
Leases [Abstract]
Lease, Cost [Table Text Block]	The components of lease expense were as follows: December 29, (In thousands) Lease cost: Operating lease cost 61,205
Supplemental Cash Flow Information Related To Leases [Table Text Block]	Supplemental cash flow information related to leases was as follows: December 29, (In thousands) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 50,155
Supplemental Balance Sheet Information Related To Leases [Table Text Block]	Supplemental balance sheet information related to leases was as follows: December 29, (In thousands, except lease term and discount rate) Operating Leases: Operating lease right-of-use assets $ 167,276 Accrued expenses and other current liabilities $ 36,573 Operating lease liabilities 146,399 Total operating liabilities $ 182,972 Weighted Average Remaining Lease Term in Years Operating leases 7.5 Weighted Average Remaining Discount Rate Operating leases 3.3%
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturities of lease liabilities as of December 29, 2019 were as follows: Operating Leases (In thousands) 2020 $ 44,512 2021 36,958 2022 25,419 2023 19,594 2024 17,721 2025 and thereafter 66,808 Total lease payments 211,012 Less imputed interest (28,040 ) Total $ 182,972

Industry Segment and Geograph_2

Industry Segment and Geographic Area Information (Tables)	12 Months Ended
	Dec. 29, 2019
Segment Reporting [Abstract]
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below for the fiscal years ended: December 29, December 30, December 31, (In thousands) Discovery & Analytical Solutions Product revenue $ 1,054,862 $ 1,010,899 $ 941,328 Service revenue 691,299 682,312 637,131 Total revenue 1,746,161 1,693,211 1,578,459 Operating income from continuing operations (1) 238,331 230,481 205,259 Diagnostics Product revenue 962,180 924,594 536,086 Service revenue 175,332 160,191 142,437 Total revenue 1,137,512 1,084,785 678,523 Operating income from continuing operations 189,330 153,196 146,862 Corporate Operating loss from continuing operations (2) (65,688 ) (59,793 ) (56,506 ) Continuing Operations Product revenue 2,017,042 1,935,493 1,477,414 Service revenue 866,631 842,503 779,568 Total revenue 2,883,673 2,777,996 2,256,982 Operating income from continuing operations 361,973 323,884 295,615 Interest and other expense, net (see Note 6) 124,831 66,201 (1,103 ) Income from continuing operations before income taxes $ 237,142 $ 257,683 $ 296,718 ____________________________ (1) Legal costs for significant litigation matters in the Company's Discovery & Analytical Solutions segment were $2.2 million , $5.3 million and $2.7 million for fiscal years 2019, 2018 and 2017 , respectively. Legal costs for significant litigation matters in the Company's Diagnostics segment were $0.1 million and $0.2 million for fiscal years 2019 and 2018 , respectively. (2) Stock compensation expense from acceleration of executive compensation was $7.7 million for fiscal year 2019 .
Schedule of Depreciation, Amortization and Capital Expenditures	Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended December 29, 2019 : Depreciation and Amortization Expense Capital Expenditures December 29, December 30, December 31, December 29, December 30, December 31, (In thousands) (In thousands) Discovery & Analytical Solutions $ 74,445 $ 70,362 $ 72,590 $ 27,778 $ 34,852 $ 26,200 Diagnostics 136,476 107,434 31,204 46,863 54,737 11,262 Corporate 3,104 2,792 1,206 1,690 3,664 1,627 Continuing operations $ 214,025 $ 180,588 $ 105,000 $ 76,331 $ 93,253 $ 39,089 Discontinued operations $ — $ — $ 929 $ — $ — $ 182
Schedule of Total Assets by Segment	Total Assets December 29, December 30, December 31, (In thousands) Discovery & Analytical Solutions $ 3,082,917 $ 2,567,054 $ 2,611,737 Diagnostics 3,368,598 3,358,964 3,447,437 Corporate 87,049 49,504 32,289 Total assets $ 6,538,564 $ 5,975,522 $ 6,091,463
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	The following geographic area information for continuing operations includes revenue based on location of external customers for the three fiscal years ended December 29, 2019 and net long-lived assets based on physical location as of December 29, 2019 and December 30, 2018 : Revenue December 29, December 30, December 31, (In thousands) U.S. $ 974,187 $ 906,398 $ 837,018 International: China 581,688 559,865 374,931 Germany 146,577 142,411 91,669 Italy 101,461 95,908 77,477 India 97,423 92,327 84,812 France 96,994 97,990 80,153 Japan 82,478 79,238 76,322 United Kingdom 70,703 72,124 65,164 Other international 732,162 731,735 569,436 Total international 1,909,486 1,871,598 1,419,964 Total sales $ 2,883,673 $ 2,777,996 $ 2,256,982 Net Long-Lived Assets* December 29, December 30, December 31, (In thousands) U.S. $ 269,183 $ 201,649 $ 210,116 International: Germany 119,612 99,181 88,249 China 71,216 61,261 64,815 United Kingdom 51,659 33,429 28,028 Finland 29,052 16,211 14,764 Singapore 23,063 14,942 9,240 India 19,691 14,636 14,820 Italy 14,152 11,324 10,334 Brazil 9,126 8,237 7,963 Poland 7,216 3,212 2,269 Canada 6,485 5,454 5,201 Other international 39,150 20,775 20,245 Total international 390,422 288,662 265,928 Total net long-lived assets $ 659,605 $ 490,311 $ 476,044

Quarterly Financial Informati_2

Quarterly Financial Information (Unaudited) Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 29, 2019
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	Selected quarterly financial information is as follows for the fiscal years ended: First Quarter Second Quarter Third Quarter Fourth Quarter (1) Year (In thousands, except per share data) December 29, 2019 Revenue $ 648,737 $ 722,517 $ 706,923 $ 805,496 $ 2,883,673 Gross profit 307,806 347,793 342,275 398,181 1,396,055 Restructuring and other costs, net 7,639 6,161 14,068 1,560 29,428 Operating income from continuing operations 53,330 91,735 78,660 138,248 361,973 Income from continuing operations before income taxes 36,765 71,827 63,254 65,296 237,142 Income from continuing operations 35,453 69,141 58,610 64,549 227,753 Loss from discontinued operations and dispositions (41 ) (54 ) (52 ) (48 ) (195 ) Net income 35,412 69,087 58,558 64,501 227,558 Basic earnings per share: Income from continuing operations $ 0.32 $ 0.62 $ 0.53 $ 0.58 $ 2.06 Loss from discontinued operations and dispositions (0.00 ) (0.00 ) (0.00 ) (0.00 ) (0.00 ) Net income 0.32 0.62 0.53 0.58 2.06 Diluted earnings per share: Income from continuing operations $ 0.32 $ 0.62 $ 0.53 $ 0.58 $ 2.04 Loss from discontinued operations and dispositions (0.00 ) (0.00 ) (0.00 ) (0.00 ) (0.00 ) Net income 0.32 0.62 0.52 0.58 2.04 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 December 30, 2018 Revenue $ 643,972 $ 703,362 $ 674,313 $ 756,349 $ 2,777,996 Gross profit 292,222 340,140 332,327 376,250 1,340,939 Restructuring and other costs, net 6,578 — 6,508 (1,942 ) 11,144 Operating income from continuing operations 39,935 88,064 80,202 115,683 323,884 Income from continuing operations before income taxes 28,505 71,708 78,041 79,429 257,683 Income from continuing operations 26,035 64,673 75,445 71,322 237,475 (Loss) gain from discontinued operations and dispositions (11 ) (610 ) 1,103 (30 ) 452 Net income 26,024 64,063 76,548 71,292 237,927 Basic earnings per share: Income from continuing operations $ 0.24 $ 0.59 $ 0.68 $ 0.64 $ 2.15 (Loss) gain from discontinued operations and dispositions (0.00 ) (0.01 ) 0.01 (0.00 ) 0.00 Net income 0.24 0.58 0.69 0.64 2.15 Diluted earnings per share: Income continuing operations $ 0.23 $ 0.58 $ 0.68 $ 0.64 $ 2.13 (Loss) gain from discontinued operations and dispositions (0.00 ) (0.01 ) 0.01 (0.00 ) 0.00 Net income 0.23 0.57 0.69 0.64 2.13 Cash dividends declared per common share $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.28 ____________________________ (1) The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy.

Business Combinations and Ass_3

Business Combinations and Asset Purchases (Narrative) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 03, 2016
Business Acquisition [Line Items]
Revenue	$ 805,496,000	$ 706,923,000	$ 722,517,000	$ 648,737,000	$ 756,349,000	$ 674,313,000	$ 703,362,000	$ 643,972,000	$ 2,883,673,000	$ 2,777,996,000
Business Combination, Contingent Consideration, Liability, Current	(20,800,000)				(67,000,000)				(20,800,000)	(67,000,000)
Business Combination, Contingent Consideration, Liability, Noncurrent	14,700,000				2,700,000				14,700,000	2,700,000
Business Combination, Contingent Consideration, Liability, Total	(35,500,000)				(69,700,000)				$ (35,500,000)	(69,700,000)
Business Combination, Contingent Consideration Arrangements, Maximum Period									3 years
Business Combination, Contingent Consideration Arrangements, Description									Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). The expected maximum earnout period for an acquisition with open contingency period do not exceed 1.75 years from the acquisition date, and the remaining weighted average expected earnout period at December 29, 2019 was 11 months.
Goodwill	3,111,227,000				2,952,608,000				$ 3,111,227,000	2,952,608,000	$ 3,002,198,000
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions									1 year
Business Combination, Contingent Consideration Arrangements, Weighted Average Period									1 year 2 months 12 days
Business Combination, Acquisition Related Costs									$ 6,600,000	15,800,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	57,100,000								57,100,000
Foreign Currency Transaction Gain (Loss), before Tax									(6,500,000)	9,400,000	29,200,000
Interest Expense									63,627,000	66,976,000	$ 43,940,000
Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Operating Income (Loss) From Immaterial Acquisitions									$ 0
Weighted average amortization period (in years)									11 years
Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	4,042,000								$ 4,042,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(2,698,000)								(2,698,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	727,000								727,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	481,000								481,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	45,282,000								45,282,000
Business Acquisition, Cost of Acquired Entity, Cash Paid									45,042,000
Business Combination, Consideration Transferred, Liabilities Incurred									638,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value									(634,000)
Goodwill	17,006,000								17,006,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(6,658,000)								(6,658,000)
Working capital and other adjustments									302,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(3,295,000)								(3,295,000)
Cash Acquired									(1,334,000)
Business Combination, Consideration Transferred									45,282,000
Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	15,160,000								15,160,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(706,000)								(706,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	6,278,000								6,278,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	32,000								32,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	164,399,000								164,399,000
Business Acquisition, Cost of Acquired Entity, Cash Paid									145,000,000
Business Combination, Consideration Transferred, Liabilities Incurred									6,446,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value									(12,100,000)
Goodwill	81,457,000								81,457,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(21,231,000)								(21,231,000)
Working capital and other adjustments									2,961,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(10,991,000)								(10,991,000)
Cash Acquired									(2,108,000)
Business Combination, Consideration Transferred									164,399,000
Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	43,554,000								43,554,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	0								0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	4,835,000								4,835,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	100,000								100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	207,391,000								207,391,000
Business Acquisition, Cost of Acquired Entity, Cash Paid									219,795,000
Business Combination, Consideration Transferred, Liabilities Incurred									0
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value									0
Goodwill	72,341,000								72,341,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(34,886,000)								(34,886,000)
Working capital and other adjustments									138,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(12,553,000)								(12,553,000)
Cash Acquired									(12,542,000)
Business Combination, Consideration Transferred									207,391,000
Foreign Currency Transaction Gain (Loss), before Tax									2,600,000
Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Operating Income (Loss) From Immaterial Acquisitions										0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	4,905,000								4,905,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					(461,000)					(461,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					1,166,000					1,166,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	776,000								776,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					104,633,000					104,633,000
Business Acquisition, Cost of Acquired Entity, Cash Paid										95,950,000
Business Combination, Consideration Transferred, Liabilities Incurred										$ 3,354,000
Weighted average amortization period (in years)										11 years 2 months 12 days
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value										$ (6,200,000)
Goodwill	65,886,000								65,886,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(9,049,000)								(9,049,000)
Working capital and other adjustments									261,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(3,881,000)								(3,881,000)
Cash Acquired										(1,132,000)
Business Combination, Consideration Transferred										104,633,000
Interest Expense										700,000
Business Combination, Increase (Decrease) in Liabilities Assumed									(400,000)
Business Combination, Increase (Decrease) in Deferred Tax Liabilities									5,100,000
Goodwill, Purchase Accounting Adjustments									6,100,000
Business Combination, Increase (Decrease) in Other Assets									(100,000)
Business Combination, Increase (Decrease) in Current Assets									(1,600,000)
Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Weighted average amortization period (in years)											11 years 9 months 18 days
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											$ 127,300,000
Compensation Expense, Excluding Cost of Good and Service Sold									500,000	6,900,000
Foreign Currency Transaction Gain (Loss), before Tax										(700,000)
EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired											99.98%
Business Acquisition, Pro Forma Revenue											$ 2,562,580,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets											121,174,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities											(61,357,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment											109,859,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets											71,621,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net											1,388,095,000
Intangible Assets, Gross (Excluding Goodwill)											907,400,000
Business Acquisition, Cost of Acquired Entity, Cash Paid											1,413,113,000
Business Combination, Consideration Transferred, Liabilities Incurred											$ 0
Weighted average amortization period (in years)											16 years 1 month 6 days
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual											$ 13,500,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual											(1,000,000)
Business Acquisition, Transaction Costs											9,800,000
Goodwill											591,304,000
Goodwill, Acquired During Period											591,300,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total											(251,886,000)
Working capital and other adjustments											0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt											(100,020,000)
Cash Acquired											(25,018,000)
Business Combination, Consideration Transferred											1,388,095,000
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax											$ 143,459,000
Business Acquisition, Pro Forma Earnings Per Share, Basic											$ 1.31
Business Acquisition, Pro Forma Earnings Per Share, Diluted											$ 1.29
Fiscal Year 2017 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											$ 142,000,000
Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Aggregate Revenue from Immaterial Acquisitions											38,500,000
Operating Income (Loss) From Immaterial Acquisitions											0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets											16,268,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities											0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment											11,356,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets											1,691,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net											139,602,000
Business Acquisition, Cost of Acquired Entity, Cash Paid											140,861,000
Business Combination, Consideration Transferred, Liabilities Incurred											1,273,000
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											14,700,000
Goodwill											75,250,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total											(15,735,000)
Working capital and other adjustments											(93,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt											(8,328,000)
Cash Acquired											(2,439,000)
Business Combination, Consideration Transferred											139,602,000
Vanadis Diagnostics AB [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value									(19,000,000)			$ 56,900,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High												$ 93,000,000
Core Technology [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	27,667,000								27,667,000
Core Technology [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	36,500,000								36,500,000
Core Technology [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	90,000,000								90,000,000
Core Technology [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	31,956,000								31,956,000
Core Technology [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											160,000,000
Core Technology [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											12,400,000
Trade Names [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	1,310,000								1,310,000
Trade Names [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	4,900,000								4,900,000
Trade Names [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	5,000,000								5,000,000
Trade Names [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					1,070,000					1,070,000
Trade Names [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											36,000,000
Trade Names [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											3,000,000
Customer Relationships [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	6,700,000								6,700,000
Customer Relationships [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	53,000,000								53,000,000
Customer Relationships [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	39,000,000								39,000,000
Customer Relationships [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	10,200,000								10,200,000
Customer Relationships [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											710,000,000
Customer Relationships [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											43,700,000
In Process Research and Development [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											1,400,000
In Process Research and Development [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles											0
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,612,407,000				1,617,616,000				1,612,407,000	1,617,616,000	1,657,963,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	1,498,820,000				$ 1,334,992,000				1,498,820,000	$ 1,334,992,000	1,344,235,000
Euro Member Countries, Euro | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											1,200,000,000
United States of America, Dollars | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									433,100,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 31,800,000								31,800,000
United States of America, Dollars | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value									(12,700,000)
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									46,600,000
United States of America, Dollars | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									166,500,000
United States of America, Dollars | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									219,900,000
United States of America, Dollars | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments									$ 105,800,000
United States of America, Dollars | Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High											25,200,000
United States of America, Dollars | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											1,400,000,000
United States of America, Dollars | EUROIMMUM [Member] | Term Loan Credit Facility, 12 Months Maturity [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											200,000,000
United States of America, Dollars | EUROIMMUM [Member] | Line of Credit, Maturing August 11, 2021 [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											710,000,000
United States of America, Dollars | EUROIMMUM [Member] | Cash and Cash Equivalents [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments											503,100,000
India, Rupees | Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High											$ 1,600,000,000

Business Combinations and Ass_4

Business Combinations and Asset Purchases (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($)	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	$ 3,111,227,000	$ 2,952,608,000	$ 3,002,198,000
Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	45,042,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	634,000
Working capital and other adjustments	302,000
Less: cash acquired	1,334,000
Business Combination, Consideration Transferred	45,282,000
Current assets	4,042,000
Property, plant and equipment	727,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	481,000
Goodwill	17,006,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(6,658,000)
Liabilities assumed	(2,698,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(3,295,000)
Total	45,282,000
Business Combination, Consideration Transferred, Liabilities Incurred	638,000
Fiscal Year 2019 Other Acquisitions [Member] | United States of America, Dollars
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	12,700,000
Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	145,000,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	12,100,000
Working capital and other adjustments	2,961,000
Less: cash acquired	2,108,000
Business Combination, Consideration Transferred	164,399,000
Current assets	15,160,000
Property, plant and equipment	6,278,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	32,000
Goodwill	81,457,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(21,231,000)
Liabilities assumed	(706,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(10,991,000)
Total	164,399,000
Business Combination, Consideration Transferred, Liabilities Incurred	6,446,000
Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	219,795,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	0
Working capital and other adjustments	138,000
Less: cash acquired	12,542,000
Business Combination, Consideration Transferred	207,391,000
Current assets	43,554,000
Property, plant and equipment	4,835,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	100,000
Goodwill	72,341,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(34,886,000)
Liabilities assumed	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(12,553,000)
Total	207,391,000
Business Combination, Consideration Transferred, Liabilities Incurred	0
Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		95,950,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value		6,200,000
Working capital and other adjustments	261,000
Less: cash acquired		1,132,000
Business Combination, Consideration Transferred		104,633,000
Current assets	4,905,000
Property, plant and equipment		1,166,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	776,000
Goodwill	65,886,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(9,049,000)
Liabilities assumed		(461,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(3,881,000)
Total		104,633,000
Business Combination, Consideration Transferred, Liabilities Incurred		3,354,000
Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid			140,861,000
Working capital and other adjustments			(93,000)
Less: cash acquired			2,439,000
Business Combination, Consideration Transferred			139,602,000
Current assets			16,268,000
Property, plant and equipment			11,356,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			1,691,000
Goodwill			75,250,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total			(15,735,000)
Liabilities assumed			0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			(8,328,000)
Total			139,602,000
Business Combination, Consideration Transferred, Liabilities Incurred			1,273,000
EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid			1,413,113,000
Working capital and other adjustments			0
Less: cash acquired			25,018,000
Business Combination, Consideration Transferred			1,388,095,000
Current assets			121,174,000
Property, plant and equipment			109,859,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			71,621,000
Goodwill			591,304,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total			(251,886,000)
Liabilities assumed			(61,357,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			(100,020,000)
Total			1,388,095,000
Business Combination, Consideration Transferred, Liabilities Incurred			0
Core Technology [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	27,667,000
Core Technology [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	36,500,000
Core Technology [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	90,000,000
Core Technology [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	31,956,000
Core Technology [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			12,400,000
Core Technology [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			160,000,000
Trade Names [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	1,310,000
Trade Names [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	4,900,000
Trade Names [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	5,000,000
Trade Names [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		1,070,000
Trade Names [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			3,000,000
Trade Names [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			36,000,000
Customer Relationships [Member] | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	6,700,000
Customer Relationships [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	53,000,000
Customer Relationships [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	39,000,000
Customer Relationships [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	10,200,000
Customer Relationships [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			43,700,000
Customer Relationships [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			710,000,000
In Process Research and Development [Member] | Fiscal Year 2017 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			0
In Process Research and Development [Member] | EUROIMMUM [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			1,400,000
GC Libraries [Member] | Fiscal Year 2018 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	2,065,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,612,407,000	1,617,616,000	1,657,963,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	$ 1,498,820,000	$ 1,334,992,000	$ 1,344,235,000

Nature of Operations and Acco_3

Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Narrative) (Details) (Details) $ in Thousands	12 Months Ended
	Dec. 29, 2019USD ($)plansegments	Dec. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 30, 2019USD ($)	Dec. 31, 2018USD ($)	Jan. 01, 2018USD ($)
Number of Stock-based Compensation Plans | plan	1
Number of Operating Segments | segments	2
Operating Cycle	52
Defined Benefit Plan, Other Cost (Credit)	$ 25,300	$ 11,500	$ (9,200)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(447)	(8,004)	21,703
Restricted Cash	$ 17	$ 3,204	$ 236
Accounting Standards Update 2016-13 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				$ 1,300	$ 13,289
Impact of New Accounting Principles, Deferred Tax Assets				500
Impact of New Accounting Principles, Reserve for Doubtful Accounts				$ (1,700)
Accounting Standards Update 2018-02 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption						$ 0
Accounting Standards Update 2016-16 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption						(2,062)
Accounting Standards Update 2016-02 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption					(13,300)
Impact of New Accounting Principle, Right-of-use Asset					199,500
Impact of New Accounting Principle, Lease Liabilities					(147,100)
Impact of New Accounting Principle, Property and Equipment					(34,600)
Tax Impact of Cumulative Adjustments, Deferred Tax Liabilities					$ (4,600)
Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption						$ 10,209
Minimum [Member] | Building [Member]
Property, Plant and Equipment, Useful Life, Maximum	10 years
Minimum [Member] | Tools, Dies and Molds [Member]
Property, Plant and Equipment, Useful Life, Maximum	3 years
Maximum [Member] | Building [Member]
Property, Plant and Equipment, Useful Life, Maximum	40 years
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment, Useful Life, Maximum	8 years

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 2,883,673	$ 2,777,996	$ 2,256,982
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Asset, Net, Current	37,000	31,900
Contract with Customer, Liability, Current	29,900	30,800
Contract with Customer, Liability, Revenue Recognized	(21,200)	(21,800)
Increase (Decrease) in Unbilled Receivables	22,400	31,100
Unbilled Receivables Transferred To Accounts Receivables	(17,300)	(21,900)
Contract with Customer, Liability, Increase (Decrease)	20,400	23,600
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	2,330,473	2,212,958
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	553,200	565,038
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,118,796	1,065,122
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	787,378	778,092
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	977,499	934,782
Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,746,161	1,693,211	1,578,459
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,276,499	1,210,745
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	469,662	482,466
Discovery & Analytical Solutions [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	717,205	680,117
Discovery & Analytical Solutions [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	495,768	494,707
Discovery & Analytical Solutions [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	533,188	518,387
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,137,512	1,084,785	$ 678,523
Diagnostics [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,053,974	1,002,213
Diagnostics [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	83,538	82,572
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	401,591	385,005
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	291,610	283,385
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	444,311	416,395
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,137,512	1,084,785
Diagnostics [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,137,512	1,084,785
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	977,200	934,690
Life Sciences [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	977,200	934,690
Life Sciences [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	768,961	758,521
Applied Markets [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	768,961	758,521
Applied Markets [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0

Discontinued Operations Narrati

Discontinued Operations Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	$ 0	$ (859)	$ 179,615
(Benefit from) provision for income taxes on discontinued operations and dispositions	195	(1,311)	44,522
Disposal Group, Including Discontinued Operation, Liabilities, Current	2,112	2,165
Fluid Sciences Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes	0	(66)	$ 0
Medical Imaging Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Period of Continuing Involvement after Disposal			12 years
(Loss) gain on disposition of discontinued operations before income taxes	$ 0	(793)	$ 179,615
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation			43,100
Disposal Group, Including Discontinued Operation, Consideration			277,400
Disposal Group, Including Discontinued Operation, Working Capital Adjustment			4,200
Pre-tax gain on disposition of discontinued operations			179,600
Suzhou PerkinElmer Medical Laboratory Co. Ltd [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes			(1,100)
Disposal Group, Including Discontinued Operation, Consideration			$ 2,300
Multispectral Imaging Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) gain on disposition of discontinued operations before income taxes		13,000
Disposal Group, Including Discontinued Operation, Consideration		$ 37,300

Changes in Accounting Policies

Changes in Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended									12 Months Ended
	Dec. 29, 2019		Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax										$ (2,883,673)	$ (2,777,996)	$ (2,256,982)
Selling, general and administrative expenses										815,318	811,913	626,018
Research and development expenses										189,336	193,998	139,464
Restructuring and other costs, net	$ 1,560		$ 14,068	$ 6,161	$ 7,639	$ (1,942)	$ 6,508	$ 0	$ 6,578	29,428	11,144	12,657
Interest and other expense, net										124,831	66,201	(1,103)
Restructuring and contract termination charges, net										(29,428)	(11,144)	(12,657)
Operating income from continuing operations	138,248	[1]	78,660	91,735	53,330	115,683	80,202	88,064	39,935	361,973	323,884	295,615
Nonoperating Income (Expense)										124,831	66,201	(1,103)
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	65,296	[1]	63,254	71,827	36,765	79,429	78,041	71,708	28,505	237,142	257,683	296,718
Provision for income taxes										9,389	20,208	139,828
Income from discontinued operations before income taxes										0	0	650
Operating income from continuing operations	64,549	[1]	58,610	69,141	35,453	71,322	75,445	64,673	26,035	227,753	237,475	156,890
(Loss) gain on disposition of discontinued operations before income taxes										0	(859)	179,615
Cash and cash equivalents	191,877					163,111				191,877	163,111	202,134
Accounts receivable, net	(725,184)					(632,669)				(725,184)	(632,669)
Inventories	356,937					338,347				356,937	338,347
Other current assets	(100,381)					(100,507)				(100,381)	(100,507)
Property, plant and equipment, net	318,223					318,590				318,223	318,590
Intangible assets, net	1,283,286					1,199,667				1,283,286	1,199,667
Goodwill	3,111,227					2,952,608				3,111,227	2,952,608	3,002,198
Other assets, net	284,173					270,023				284,173	270,023
Current portion of long-term debt	9,974					14,856				9,974	14,856
Assets	(6,538,564)					(5,975,522)				(6,538,564)	(5,975,522)
Accounts payable	235,855					220,949				235,855	220,949
Accrued restructuring and contract termination costs	11,559					4,834				11,559	4,834
Accrued expenses and other current liabilities	503,332					528,827				503,332	528,827
Current liabilities of discontinued operations	2,112					2,165				2,112	2,165
Long-term debt	2,064,041					1,876,624				2,064,041	1,876,624
Long-term liabilities	751,468					742,312				751,468	742,312
Liabilities	3,724,740					3,390,567				3,724,740	3,390,567
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0					0				0	0
Common Stock, Value, Issued	111,140					110,597				111,140	110,597
Capital in excess of par value	90,357					48,772				90,357	48,772
Retained earnings	2,811,973					2,602,067				2,811,973	2,602,067
Accumulated other comprehensive loss	(199,646)					(176,481)				(199,646)	(176,481)	(46,518)	$ (100,861)
Stockholders' Equity Attributable to Parent	2,813,824					2,584,955				2,813,824	2,584,955	2,503,188	$ 2,153,570
Liabilities and Equity	(6,538,564)					(5,975,522)				(6,538,564)	(5,975,522)
Net income	64,501	[1]	58,558	69,087	35,412	71,292	76,548	64,063	26,024	227,558	237,927	292,633
Provision For Income Taxes On Discontinued Operations And Dispositions										195	1,311	(44,522)
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	$ (48)		$ (52)	$ (54)	$ (41)	$ (30)	$ 1,103	$ (610)	$ (11)	(195)	452	135,743
Product [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax										(2,017,042)	(1,935,493)	(1,477,414)
Cost of Goods and Services Sold										(956,398)	(908,228)	(707,962)
Service [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax										(866,631)	(842,503)	(779,568)
Cost of Goods and Services Sold										$ (531,220)	$ (528,829)	$ (475,266)
[1]	The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million

Summary Operating Results of Di

Summary Operating Results of Discontinued Operations for the Periods Prior to Disposition (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue	$ 0	$ 0	$ 44,343
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	0	0	32,933
Disposal Group, Including Discontinued Operation, General and Administrative Expense	0	0	5,869
Disposal Group, Including Discontinued Operations, Research and development expenses	0	0	4,891
Disposal Group, Including Discontinued Operations, Restructuring and contract termination charges, net	0	0	0
Loss from discontinued operations before income taxes	$ 0	$ 0	$ 650

Restructuring and Contract Te_3

Restructuring and Contract Termination Charges, Net (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net	$ 1,560	$ 14,068	$ 6,161	$ 7,639	$ (1,942)	$ 6,508	$ 0	$ 6,578	$ 29,428	$ 11,144	$ 12,657
Accrued restructuring and contract termination costs	11,559				4,834				11,559	4,834
Restructuring Reserve1	13,900				6,200				13,900	6,200
Accrued restructuring and contract termination costs	13,880				6,180				13,880	6,180	13,969	$ 10,541
Short-term accrued restructuring and other costs [Member]
Restructuring Cost and Reserve [Line Items]
Accrued restructuring and contract termination costs	11,600				4,800				11,600	4,800
Accrued expenses and other current liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Accrued restructuring and contract termination costs	400								400
Long-term liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Noncurrent	800				1,400				800	1,400
Operating lease liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Noncurrent	1,100								1,100
Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Accrued restructuring and contract termination costs	188				137				188	137	3,048	117
Facility Relocation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net									800
Accrued restructuring and contract termination costs	$ 827				$ 0				827	0	0	$ 0
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2019 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net									200
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2018 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net										5,000
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | 2017 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net										$ 3,600
Diagnostics [Member] | Contract Termination [Member] | 2019 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net									$ 200
Diagnostics [Member] | Contract Termination [Member] | 2017 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs, net											$ 500

Restructuring and Contract Te_4

Restructuring and Contract Termination Charges, Net Restructuring and Contract Termination Charges, Net (Schedule of Initial Charges) (Details) $ in Thousands

3 Months Ended

12 Months Ended

Dec. 29, 2019USD ($)employees

Sep. 29, 2019USD ($)

Jun. 30, 2019USD ($)employees

Mar. 31, 2019USD ($)employees

Dec. 30, 2018USD ($)employees

Sep. 30, 2018USD ($)employees

Jul. 01, 2018USD ($)

Apr. 01, 2018USD ($)employees

Dec. 31, 2017USD ($)employees

Oct. 01, 2017USD ($)employees

Apr. 02, 2017USD ($)employees

Dec. 29, 2019USD ($)

Dec. 30, 2018USD ($)

Dec. 31, 2017USD ($)

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 1,560

$ 14,068

$ 6,161

$ 7,639

$ (1,942)

$ 6,508

$ 0

$ 6,578

$ 29,428

$ 11,144

$ 12,657

Q4 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

22

Restructuring and other costs, net

$ 2,581

Q3 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

259

Restructuring and other costs, net

13,797

Q2 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

44

Restructuring and other costs, net

$ 5,590

Q1 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

105

Restructuring and other costs, net

$ 7,460

Q4 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

1

Restructuring and other costs, net

$ 348

Q3 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

61

Restructuring and other costs, net

$ 1,764

Q1 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

47

Restructuring and other costs, net

$ 5,998

Q4 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

29

Restructuring and other costs, net

$ 1,935

Q3 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

27

Restructuring and other costs, net

$ 2,342

Q1 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Cost, Number of Positions Eliminated | employees

90

Restructuring and other costs, net

$ 6,697

Diagnostics [Member] | Severance [Member] | Q4 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 2,404

Diagnostics [Member] | Severance [Member] | Q3 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

2,641

Diagnostics [Member] | Severance [Member] | Q2 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

1,129

Diagnostics [Member] | Severance [Member] | Q1 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

1,459

Diagnostics [Member] | Severance [Member] | Q4 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Severance [Member] | Q3 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

618

Diagnostics [Member] | Severance [Member] | Q1 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

902

Diagnostics [Member] | Severance [Member] | Q4 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

255

Diagnostics [Member] | Severance [Member] | Q3 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

1,021

Diagnostics [Member] | Severance [Member] | Q1 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

1,631

Diagnostics [Member] | Facility Closing [Member] | Q4 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q3 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q2 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q1 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q4 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q3 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q1 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q4 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q3 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

0

Diagnostics [Member] | Facility Closing [Member] | Q1 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

33

Discovery & Analytical Solutions [Member] | Severance [Member] | Q4 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

177

Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

11,156

Discovery & Analytical Solutions [Member] | Severance [Member] | Q2 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

4,461

Discovery & Analytical Solutions [Member] | Severance [Member] | Q1 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

6,001

Discovery & Analytical Solutions [Member] | Severance [Member] | Q4 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

348

Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

1,146

Discovery & Analytical Solutions [Member] | Severance [Member] | Q1 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

5,096

Discovery & Analytical Solutions [Member] | Severance [Member] | Q4 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

1,680

Discovery & Analytical Solutions [Member] | Severance [Member] | Q3 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

1,321

Discovery & Analytical Solutions [Member] | Severance [Member] | Q1 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

5,000

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q4 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q2 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2019 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q4 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2018 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q4 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 0

Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2017 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and other costs, net

$ 33

Restructuring and Contract Te_5

Restructuring and Contract Termination Charges, Net (Schedule of Restructuring Plan Activity) (Details) - USD ($)	3 Months Ended											12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 31, 2017	Oct. 01, 2017	Apr. 02, 2017	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Restructuring Reserve [Roll Forward]
Beginning balance				$ 6,180,000				$ 13,969,000			$ 10,541,000	$ 6,180,000	$ 13,969,000	$ 10,541,000
Restructuring Charges and Changes in Estimates												29,428,000	11,144,000	12,657,000
Amounts paid and foreign currency translation												(21,728,000)	(18,933,000)	(9,229,000)
Ending balance	$ 13,880,000				$ 6,180,000				$ 13,969,000			13,880,000	6,180,000	13,969,000
Restructuring and other costs, net	1,560,000	$ 14,068,000	$ 6,161,000	7,639,000	(1,942,000)	$ 6,508,000	$ 0	6,578,000				29,428,000	11,144,000	12,657,000
Employee Severance and Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				6,043,000				10,921,000			10,424,000	6,043,000	10,921,000	10,424,000
Restructuring Charges and Changes in Estimates												28,149,000	6,402,000	9,406,000
Amounts paid and foreign currency translation												(21,327,000)	(11,280,000)	(8,909,000)
Ending balance	12,865,000				6,043,000				10,921,000			12,865,000	6,043,000	10,921,000
Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				137,000				3,048,000			117,000	137,000	3,048,000	117,000
Restructuring Charges and Changes in Estimates												452,000	4,742,000	3,251,000
Amounts paid and foreign currency translation												(401,000)	(7,653,000)	(320,000)
Ending balance	188,000				137,000				3,048,000			188,000	137,000	3,048,000
Facility Relocation [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0			0	0	0	0
Restructuring Charges and Changes in Estimates												827,000	0	0
Amounts paid and foreign currency translation												0	0	0
Ending balance	827,000				0				0			827,000	0	0
Restructuring and other costs, net												800,000
Q4 2019 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Beginning balance											0			0
Restructuring and other costs, net	2,581,000
Q4 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0				0	0
Restructuring Charges and Changes in Estimates												2,581,000	0	0
Amounts paid and foreign currency translation												(1,692,000)	0	0
Ending balance	889,000				0				0			889,000	0	0
Q3 2019 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Beginning balance											0			0
Restructuring and other costs, net		13,797,000
Q3 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0				0	0
Restructuring Charges and Changes in Estimates												13,797,000	0	0
Amounts paid and foreign currency translation												(7,486,000)	0	0
Ending balance	6,311,000				0				0			6,311,000	0	0
Q2 2019 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Beginning balance											0			0
Restructuring and other costs, net			5,590,000
Q2 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0				0	0
Restructuring Charges and Changes in Estimates												5,590,000	0	0
Amounts paid and foreign currency translation												(3,701,000)	0	0
Ending balance	1,889,000				0				0			1,889,000	0	0
Q1 2019 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Beginning balance											0			0
Restructuring and other costs, net				7,460,000
Q1 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				0				0	0
Restructuring Charges and Changes in Estimates												7,483,000	0	0
Amounts paid and foreign currency translation												(5,354,000)	0	0
Ending balance	2,129,000				0				0			2,129,000	0	0
Q4 2018 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Beginning balance											0			0
Restructuring and other costs, net					348,000
Q4 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				348,000				0				348,000	0
Restructuring Charges and Changes in Estimates												3,000	348,000	0
Amounts paid and foreign currency translation												(351,000)	0	0
Ending balance	0				348,000				0			0	348,000	0
Previous restructuring and integration plans [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				2,388,000				4,399,000			10,424,000	2,388,000	4,399,000	10,424,000
Restructuring Charges and Changes in Estimates												117,000	570,000	(1,568,000)
Amounts paid and foreign currency translation												(1,140,000)	(2,581,000)	(4,457,000)
Ending balance	1,365,000				2,388,000				4,399,000			1,365,000	2,388,000	4,399,000
Q3 2018 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Beginning balance											0			0
Restructuring and other costs, net						1,764,000
Q3 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				1,415,000				0				1,415,000	0
Restructuring Charges and Changes in Estimates												(77,000)	2,054,000	0
Amounts paid and foreign currency translation												(1,314,000)	(639,000)	0
Ending balance	24,000				1,415,000				0			24,000	1,415,000	0
Q1 2018 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Beginning balance											0			0
Restructuring and other costs, net								5,998,000
Q1 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				1,609,000				0				1,609,000	0
Restructuring Charges and Changes in Estimates												(1,069,000)	5,998,000	0
Amounts paid and foreign currency translation												(282,000)	(4,389,000)	0
Ending balance	258,000				1,609,000				0			258,000	1,609,000	0
Q4 2017 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Beginning balance											0			0
Restructuring and other costs, net									1,935,000
Q4 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				1,919,000				0	1,919,000
Restructuring Charges and Changes in Estimates												0	(381,000)	1,935,000
Amounts paid and foreign currency translation												0	(1,538,000)	(16,000)
Ending balance	0				0				1,919,000			0	0	1,919,000
Q3 2017 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Beginning balance											0			0
Restructuring and other costs, net										$ 2,342,000
Q3 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				2,072,000				0	2,072,000
Restructuring Charges and Changes in Estimates												0	(1,204,000)	2,342,000
Amounts paid and foreign currency translation												0	(868,000)	(270,000)
Ending balance	0				0				2,072,000			0	0	2,072,000
Q1 2017 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Beginning balance											0			0
Restructuring and other costs, net											6,697,000
Q1 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				283,000				2,498,000				283,000	2,498,000
Restructuring Charges and Changes in Estimates												(276,000)	(983,000)	6,631,000
Amounts paid and foreign currency translation												(7,000)	(1,232,000)	(4,133,000)
Ending balance	0				283,000				2,498,000			0	283,000	2,498,000
Q1 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Beginning balance				0				33,000			0	0	33,000	0
Restructuring Charges and Changes in Estimates												0	0	66,000
Amounts paid and foreign currency translation												0	(33,000)	(33,000)
Ending balance	0				0				33,000			0	0	33,000
Diagnostics [Member] | Q4 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net	2,404,000
Diagnostics [Member] | Q4 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net	0
Diagnostics [Member] | Q3 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net		2,641,000
Diagnostics [Member] | Q3 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net		0
Diagnostics [Member] | Q2 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net			1,129,000
Diagnostics [Member] | Q2 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net			0
Diagnostics [Member] | Q1 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net				1,459,000
Diagnostics [Member] | Q1 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net				0
Diagnostics [Member] | Q4 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net					0
Diagnostics [Member] | Q4 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net					0
Diagnostics [Member] | Q3 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(400,000)
Restructuring and other costs, net						618,000
Diagnostics [Member] | Q3 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net						0
Diagnostics [Member] | Q1 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net								902,000
Diagnostics [Member] | Q1 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net								0
Diagnostics [Member] | Q4 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net									255,000
Diagnostics [Member] | Q4 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net									0
Diagnostics [Member] | 2017 Contract Termination Charges [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net														$ 500,000
Diagnostics [Member] | Q3 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net										1,021,000
Diagnostics [Member] | Q3 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net										0
Diagnostics [Member] | Q1 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net											1,631,000
Diagnostics [Member] | Q1 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net											33,000
Discovery & Analytical Solutions [Member] | Q4 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net	177,000
Discovery & Analytical Solutions [Member] | Q4 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net	$ 0
Discovery & Analytical Solutions [Member] | Q3 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net		11,156,000
Discovery & Analytical Solutions [Member] | Q3 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net		$ 0
Discovery & Analytical Solutions [Member] | Q2 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net			4,461,000
Discovery & Analytical Solutions [Member] | Q2 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net			$ 0
Discovery & Analytical Solutions [Member] | Q1 2019 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net				6,001,000
Discovery & Analytical Solutions [Member] | Q1 2019 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net				$ 0
Discovery & Analytical Solutions [Member] | Q4 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net					348,000
Discovery & Analytical Solutions [Member] | Q4 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net					$ 0
Discovery & Analytical Solutions [Member] | Previous restructuring and integration plans [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												100,000
Discovery & Analytical Solutions [Member] | Q3 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												300,000
Restructuring and other costs, net						1,146,000
Discovery & Analytical Solutions [Member] | Q3 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net						$ 0
Discovery & Analytical Solutions [Member] | Q1 2018 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												(1,100,000)
Restructuring and other costs, net								5,096,000
Discovery & Analytical Solutions [Member] | Q1 2018 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net								$ 0
Discovery & Analytical Solutions [Member] | Q4 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net									1,680,000
Discovery & Analytical Solutions [Member] | Q4 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net									$ 0
Discovery & Analytical Solutions [Member] | 2017 Contract Termination Charges [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net													$ 3,600,000
Discovery & Analytical Solutions [Member] | Q3 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net										1,321,000
Discovery & Analytical Solutions [Member] | Q3 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net										$ 0
Discovery & Analytical Solutions [Member] | Q1 2017 Restructuring Plan [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Change in estimates												$ (300,000)
Restructuring and other costs, net											5,000,000
Discovery & Analytical Solutions [Member] | Q1 2017 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member]
Restructuring Reserve [Roll Forward]
Restructuring and other costs, net											$ 33,000

Interest and Other Expense (I_3

Interest and Other Expense (Income), Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Foreign Currency Transaction Gain (Loss), before Tax	$ 6,500	$ (9,400)	$ (29,200)
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	(3,500)	11,700	(4,500)
Gain on disposition of businesses and assets, net	2,469	(12,844)	309
Defined Benefit Plan, Other Cost (Credit)	25,300	11,500	(9,200)
Interest income	(1,495)	(1,141)	(2,571)
Interest expense	63,627	66,976	43,940
Gain (Loss) on Extinguishment of Debt	32,541	0	0
Other expense, net	27,689	13,210	(42,781)
Total interest and other expense, net	$ 124,831	$ 66,201	$ (1,103)

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Income Tax Contingency [Line Items]
Income Tax Holiday, Aggregate Dollar Amount	$ (10,400)	$ (10,300)	$ (10,100)
Impact of benefits derived from tax holidays on earnings per share, basic	$ 0.09	$ (0.09)	$ (0.09)
Impact of benefits derived from tax holidays on earnings per share, diluted	$ (0.09)	$ (0.09)	$ (0.09)
Valuation Allowance, Amount	$ 88,449	$ 102,087
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning of period	33,009	30,308	$ 29,607
Gross increases - tax positions in prior period	4,433	6,931	749
Gross decreases - tax positions in prior period	(2,183)	(1,622)	(828)
Gross increases - current-period tax positions	152	0	2,346
Settlements	(45)	(2,253)	(324)
Lapse of statute of limitations	0	(181)	(1,371)
Foreign currency translation adjustments	181	(174)	129
Unrecognized tax benefits, end of period	35,547	33,009	30,308
Income Tax Penalties and Interest Accrued	4,100	2,500
Income Tax Penalties and Interest Expense	1,600	400	(300)
Unrecognized Tax Benefits, Ending Balance	35,500
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate	33,800
Unrecognized Tax Benefits Expected To Be Resolved With In A Year	2,400
Undistributed Earnings of Foreign Subsidiaries Not Meeting Requirements to be Reinvested		1,400,000
Income Tax Expense (Benefits) on Undistributed Foreign Earnings		2,900
Foreign earnings invested outside U.S.	$ 449,200
Open Tax Years by Major Tax Jurisdiction, Begin Date	2010
Tax Adjustments, Settlements, and Unusual Provisions	$ 23,400	8,100	98,600
Excess tax benefit from exercise of common stock options	0	0
2017 Tax Cuts and Jobs Act [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense	86,000
Tax Adjustments, Settlements, and Unusual Provisions	(2,700)	(2,000)
Discrete Income Tax Expense (Benefit), Tax Reform Trueup			106,500
Other Tax Matters [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	(1,400)	1,100	(2,800)
Excess tax benefits on stock compensation [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	4,900	7,200	$ (5,100)
2017 Tax Cuts and Jobs Act, Refinement [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Income Tax Expense on Repatriated Earnings		$ (4,600)
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense	2,700
Valuation allowance adjustments [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	12,300
Tax elections adjustments [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	3,700
True-up of Return-to-Provision [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Adjustments, Settlements, and Unusual Provisions	6,700
General Business [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount	5,700
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	213,800
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount	6,700
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	408,700
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Tax Credit Carryforward, Amount	100
Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	$ 33,600
China [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Income Tax Holiday, Termination Date	12/31/2019
Singapore [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Income Tax Holiday, Termination Date	12/31/2023

Income Taxes Income Before Inco

Income Taxes Income Before Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended									12 Months Ended
	Dec. 29, 2019	[1]	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Income Tax Contingency [Line Items]
U.S.										$ 29,252	$ 32,627	$ 3,743
Non-U.S.										207,890	225,056	292,975
Income from continuing operations before income taxes	$ 65,296		$ 63,254	$ 71,827	$ 36,765	$ 79,429	$ 78,041	$ 71,708	$ 28,505	$ 237,142	$ 257,683	$ 296,718
[1]	The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million

Income Taxes Components of the

Income Taxes Components of the Provision (Benefits from) Income Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Income Tax Contingency [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount	$ (32,124)	$ (27,281)	$ (65,836)
Federal current	3,735	7,938	62,003
Federal deferred expense (benefit)	(267)	(5,250)	35,435
Federal total	3,468	2,688	97,438
State current	4,425	2,345	3,332
State deferred expense (benefit)	(1,574)	2,572	(792)
State total	2,851	4,917	2,540
Non-U.S. current	62,582	61,028	45,639
Non-U.S.deferred expense benefit	(59,512)	(48,425)	(5,789)
Non-U.S. total	3,070	12,603	39,850
Total current	70,742	71,311	110,974
Total deferred expense (benefit)	(61,353)	(51,103)	28,854
Total	9,389	20,208	139,828
Discontinued operations	195	(1,311)	44,522
Total provision for income taxes	9,584	18,897	184,350
Singapore, Finland, Netherlands and China [Member]
Income Tax Contingency [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount		$ 18,700	$ 55,900
Singapore, Finland, and The Netherlands [Member]
Income Tax Contingency [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount	$ 16,700

Income Taxes Reconciliation of

Income Taxes Reconciliation of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Income Tax Contingency [Line Items]
Tax at statutory rate	$ 49,799	$ 54,114	$ 103,851
Non-U.S. rate differential, net	(32,124)	(27,281)	(65,836)
U.S. taxation of multinational operations	4,251	7,047	5,408
State income taxes, net	1,941	2,028	1,810
Prior year tax matters	(5,103)	1,124	(2,888)
Effect of Stock Compensation	(2,053)	(6,331)	(5,067)
Federal tax credits	(4,325)	(3,738)	(8,249)
Change in valuation allowance	(1,117)	(759)	1,951
Tax Elections	(3,700)	0	0
Tax Adjustments, Settlements, and Unusual Provisions	23,400	8,100	98,600
Other, net	(898)	(3,971)	2,310
Total	9,389	20,208	139,828
Singapore, Finland, Netherlands and China [Member]
Income Tax Contingency [Line Items]
Non-U.S. rate differential, net		18,700	55,900
Singapore, Finland, and The Netherlands [Member]
Income Tax Contingency [Line Items]
Non-U.S. rate differential, net	16,700
2017 Tax Cuts and Jobs Act [Member]
Income Tax Contingency [Line Items]
Tax Adjustments, Settlements, and Unusual Provisions	(2,700)	(2,000)
Impact of U.S. Tax Act	$ 2,718	$ (2,025)	$ 106,538

Income Taxes Components of Defe

Income Taxes Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018
Income Tax Contingency [Line Items]
Inventory	$ 4,662	$ 0
Reserves and accruals	46,817	39,487
Accrued compensation	18,953	21,709
Net operating loss and credit carryforwards	116,751	144,421
Accrued pension	35,890	31,146
Restructuring reserve	2,983	1,780
Deferred revenue	30,412	31,045
Deferred tax assets, operating lease liabilities	46,477	0
Deferred Tax Assets, Gross	302,945	269,588
Deferred Tax Liabilities, Inventory	0	(278)
Postretirement health benefits	(4,106)	(3,406)
Depreciation and amortization	(330,768)	(309,958)
Deferred Tax Liabilities, Other	(1,780)	(1,879)
Deferred tax liabilities, operating lease right-of-use assets	(42,774)	0
Total deferred tax liabilities	(379,428)	(315,521)
Valuation allowance	(88,449)	(102,087)
Deferred Tax Liabilities, Net	(164,932)	(148,020)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	13,600
Domestic Country [Member]
Income Tax Contingency [Line Items]
Net deferred tax liabilities	(43,683)	(52,469)
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Deferred Tax Liabilities, Net	$ (208,615)	$ (200,489)

Income Taxes Summary of Loss an

Income Taxes Summary of Loss and Tax Credit Carryforwards (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018
Income Tax Contingency [Line Items]
Valuation Allowance, Amount	$ 88,449	$ 102,087
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	213,800
Tax Credit Carryforward, Amount	6,700
Foreign Tax Authority [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	408,700
Tax Credit Carryforward, Amount	100
Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	33,600
General Business [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Amount	$ 5,700
Minimum [Member] | Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Expiration Date	Jan. 1, 2020
Maximum [Member] | Internal Revenue Service (IRS) [Member]
Income Tax Contingency [Line Items]
Tax Credit Carryforward, Expiration Date	Dec. 31, 2038

Earnings Per Share (Schedule of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Number of common shares-basic	110,827	110,561	109,857
Effect of dilutive securities, Stock options	541	761	708
Effect of dilutive securities, Restricted stock	133	212	294
Number of common shares-diluted	111,501	111,534	110,859
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	364	349	287

Accounts Receivable, Net (Detai

Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Dec. 29, 2019	Dec. 30, 2018
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	$ 725,184	$ 632,669
Accounts Receivable, after Allowance for Credit Loss, Noncurrent	19,677	0
Accounts Receivable, after Allowance for Credit Loss	744,861	632,669
Reserves for doubtful accounts	$ 35,200	$ 30,600

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 29, 2019	Dec. 30, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 130,673	$ 119,115
Work in progress	26,409	18,110
Finished goods	199,855	201,122
Total inventories	$ 356,937	$ 338,347

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 701,580	$ 680,183
Accumulated depreciation	(383,357)	(361,593)
Total property, plant and equipment, net	318,223	318,590
Depreciation expense	49,700	44,700	$ 31,300
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	5,272	5,482
Building and leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	250,639	272,277
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 445,669	$ 402,424

Marketable Securities and Inv_3

Marketable Securities and Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]
Unrealized gains (losses) on securities, net of tax	$ 6	$ (9)	$ 79
Marketable securities	2,906	2,447
Marketable Securities and Investments	32,134	19,230
Equity Securities without Readily Determinable Fair Value, Amount	29,228	16,783
Equity Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost	1,109	1,037
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	752	671
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(357)	(366)
Fixed Income Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost	7	22
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	7	22
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0	0
Available-for-sale Securities, Other [Member]
Debt Securities, Available-for-sale [Line Items]
Cost	2,210	1,817
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	2,147	1,754
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(63)	(63)
Available-for-sale Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Cost	3,326	2,876
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Market value	2,906	2,447
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	$ (420)	$ (429)

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Net [Line Items]
Total amortization expense related to finite-lived intangible assets	$ 164,300	$ 135,900	$ 73,700
Future Amortization Expense, Year One	188,800
Future Amortization Expense, Year Two	173,000
Future Amortization Expense, Year Three	156,600
Future Amortization Expense, Year Four	132,600
Future Amortization Expense, Year Five	111,300
Finite-Lived Intangible Assets, Net	1,212,702	1,129,083
Goodwill	$ 3,111,227	2,952,608	3,002,198
Impairment Testing Date	Jan. 1, 2019
Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	$ 47,702	44,345
Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	8,763	7,755
Discovery & Analytical Solutions [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	361,777	162,388
Goodwill	1,498,820	1,334,992	1,344,235
Discovery & Analytical Solutions [Member] | Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	16,227	8,083
Discovery & Analytical Solutions [Member] | Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	2,786	5,802
Diagnostics [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	850,925	966,695
Goodwill	1,612,407	1,617,616	$ 1,657,963
Diagnostics [Member] | Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	31,475	36,262
Diagnostics [Member] | Licenses [Member]
Goodwill and Intangible Assets Net [Line Items]
Finite-Lived Intangible Assets, Net	$ 5,977	$ 1,953

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018
Changes in the carrying amount of goodwill
Foreign currency translation	$ (18,284)	$ (67,478)
Acquisitions, earn outs and other	176,903	17,888
Ending balance	3,111,227	2,952,608
Diagnostics [Member]
Changes in the carrying amount of goodwill
Foreign currency translation	(9,725)	(35,289)
Acquisitions, earn outs and other	4,516	(5,058)
Ending balance	1,612,407	1,617,616
Discovery & Analytical Solutions [Member]
Changes in the carrying amount of goodwill
Foreign currency translation	(8,559)	(32,189)
Acquisitions, earn outs and other	172,387	22,946
Ending balance	$ 1,498,820	$ 1,334,992

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($) $ in Thousands	Dec. 29, 2019	Dec. 30, 2018
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	$ 1,212,702	$ 1,129,083
Totals	1,283,286	1,199,667
Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	30,831	42,646
Less: Accumulated amortization	(27,423)	(37,753)
Net amortizable intangible assets	3,408	4,893
Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	87,997	78,146
Less: Accumulated amortization	(40,295)	(33,801)
Net amortizable intangible assets	47,702	44,345
Non-amortizing intangible assets	70,584	70,584
Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	58,496	53,305
Less: Accumulated amortization	(49,733)	(45,550)
Net amortizable intangible assets	8,763	7,755
Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	689,089	540,911
Less: Accumulated amortization	(320,926)	(265,744)
Net amortizable intangible assets	368,163	275,167
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	1,161,526	1,089,527
Less: Accumulated amortization	(378,188)	(293,964)
Net amortizable intangible assets	783,338	795,563
In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	1,328	1,360
Diagnostics [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	850,925	966,695
Totals	850,925	966,695
Diagnostics [Member] | Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	2,709	14,616
Less: Accumulated amortization	(281)	(11,775)
Net amortizable intangible assets	2,428	2,841
Diagnostics [Member] | Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	48,138	48,335
Less: Accumulated amortization	(16,663)	(12,073)
Net amortizable intangible assets	31,475	36,262
Non-amortizing intangible assets	0	0
Diagnostics [Member] | Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	8,103	3,127
Less: Accumulated amortization	(2,126)	(1,174)
Net amortizable intangible assets	5,977	1,953
Diagnostics [Member] | Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	298,973	300,177
Less: Accumulated amortization	(115,663)	(76,711)
Net amortizable intangible assets	183,310	223,466
Diagnostics [Member] | Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	847,628	866,635
Less: Accumulated amortization	(221,221)	(165,822)
Net amortizable intangible assets	626,407	700,813
Diagnostics [Member] | In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	1,328	1,360
Discovery & Analytical Solutions [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	361,777	162,388
Totals	432,361	232,972
Discovery & Analytical Solutions [Member] | Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	28,122	28,030
Less: Accumulated amortization	(27,142)	(25,978)
Net amortizable intangible assets	980	2,052
Discovery & Analytical Solutions [Member] | Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	39,859	29,811
Less: Accumulated amortization	(23,632)	(21,728)
Net amortizable intangible assets	16,227	8,083
Non-amortizing intangible assets	70,584	70,584
Discovery & Analytical Solutions [Member] | Licenses [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	50,393	50,178
Less: Accumulated amortization	(47,607)	(44,376)
Net amortizable intangible assets	2,786	5,802
Discovery & Analytical Solutions [Member] | Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	390,116	240,734
Less: Accumulated amortization	(205,263)	(189,033)
Net amortizable intangible assets	184,853	51,701
Discovery & Analytical Solutions [Member] | Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	313,898	222,892
Less: Accumulated amortization	(156,967)	(128,142)
Net amortizable intangible assets	156,931	94,750
Discovery & Analytical Solutions [Member] | In Process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	$ 0	$ 0

Debt (Details)

Debt (Details) € in Millions	Oct. 13, 2019USD ($)	Sep. 12, 2019USD ($)	Apr. 11, 2018USD ($)	Jul. 19, 2016USD ($)	Oct. 25, 2011USD ($)	Dec. 29, 2019USD ($)	Dec. 30, 2012USD ($)	Dec. 29, 2019EUR (€)	Sep. 17, 2019USD ($)	Dec. 30, 2018USD ($)	Dec. 30, 2018EUR (€)	Jul. 19, 2016EUR (€)	Sep. 30, 2012USD ($)
Unamortized discount and debt issuance costs						$ (21,426,000)
Maturities of Long-term Debt [Abstract]
2017						9,974,000
2018						343,280,000
2019						3,759,000
2020						2,278,000
2021						326,664,000
Thereafter						1,409,486,000
Long-term Debt Before Unamortized Discount						2,095,441,000
Total						2,074,015,000
Other Long-term Debt, Current						9,974,000				$ 14,856,000
Line of Credit, Maturing August 11, 2021 [Member]
Aggregate borrowings under the amended facility										418,000,000
Unamortized Debt Issuance Expense										2,400,000
Maturities of Long-term Debt [Abstract]
Total										415,600,000
Line of Credit, Maturing September 17, 2024 [Member]
Unsecured revolving credit facility, amount									$ 1,000,000,000
Line of Credit Facility, Remaining Borrowing Capacity						663,200,000
Letters of credit issued and outstanding						$ 11,400,000
Interest rate terms under amended senior unsecured revolving credit facility						The interest rates on the Eurocurrency Rate loans are based on the Eurocurrency Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The interest rates on the US Dollar Base Rate loans are based on the US Dollar Base Rate at the time of borrowing, plus a percentage spread based on the credit rating of the Company's debt. The base rate is the higher of (i) the Federal Funds Rate (as defined in the new credit agreement) plus 50 basis points, (ii) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its "prime rate," or (iii) the Eurocurrency Rate plus 1.00%. The Eurocurrency margin as of December 29, 2019 was 102.0 basis points.
Weighted average interest rates under amended senior unsecured revolving credit facility						The weighted average Eurocurrency interest rate as of December 29, 2019 was 1.67%, resulting in a weighted average effective Eurocurrency Rate, including the margin, of 2.68%, which was the interest applicable to the borrowings outstanding as of December 29, 2019.
Aggregate borrowings under the amended facility						$ 325,400,000
Unamortized discount and debt issuance costs						(3,356,000)
Unamortized Debt Issuance Expense						3,400,000
Maturities of Long-term Debt [Abstract]
2017						0
2018						0
2019						0
2020						0
2021						325,377,000
Thereafter						0
Long-term Debt Before Unamortized Discount						325,377,000
Total						$ 322,021,000
Line of Credit, Maturing September 17, 2024 [Member] | Base Rate Option Three [Member] | Line of Credit [Member]
Basis spread on variable rate						1.00%
Line of Credit, Maturing September 17, 2024 [Member] | Eurocurrency Rate [Member]
Basis spread on variable rate						1.02%
Line of Credit, Maturing September 17, 2024 [Member] | Base Rate Option Two [Member] | Line of Credit [Member]
Basis spread on variable rate						0.50%
Line of Credit, Maturing December 16, 2016 [Member] | Eurocurrency Rate [Member]
Description of variable rate basis						Eurocurrency margin
Line of Credit, Maturing December 16, 2016 [Member] | Base Rate Option Two [Member]
Description of variable rate basis						Federal Funds
2021 Notes [Member]
Unsecured senior notes, interest rate percent					5.00%
Unsecured senior notes, face value					$ 500,000,000
Gross proceeds from the issuance of debt instrument					$ 493,600,000
Senior unsecured notes issuance as percentage of principal amount					99.40%
Unamortized Debt Issuance Expense										1,600,000
Debt Redemption, Make-whole						$ 31,300,000
Debt Redemption, Pre-tax Non-operating Charges						32,300,000
Debt Redemption, Deferred costs and Original Issue Discount						2,000,000
Reverse Treasury Rate Lock Settlement	$ 1,000,000					(1,000,000)
Maturities of Long-term Debt [Abstract]
Total										497,400,000
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Debt Instrument, Maturity Date				Jul. 19, 2026
Unsecured senior notes, interest rate percent												1.875%
Gross proceeds from the issuance of debt instrument				$ 492,300,000
Senior unsecured notes issuance as percentage of principal amount												99.118%
Unamortized discount and debt issuance costs						(6,756,000)
Unamortized Debt Issuance Expense						3,300,000				3,800,000
Debt Instrument, Redemption Percentage Upon Change of Control and Downgrade of Debt Instrument				101.00%
Maturities of Long-term Debt [Abstract]
2017						0
2018						0
2019						0
2020						0
2021						0
Thereafter						558,950,000
Long-term Debt Before Unamortized Discount						558,950,000
Total						$ 552,194,000				564,500,000
Financing Lease Obligations [Member]
Additional Financing Lease Obligations							$ 11,500,000
Maturities of Long-term Debt [Abstract]
Other Long-term Debt													$ 29,300,000
Other Long-term Debt, Current										1,500,000
Other Long-term Debt, Noncurrent										33,000,000
Other Debt Facilities - EUROIMMUN [Member]
Maturities of Long-term Debt [Abstract]
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €								€ 25.6
Long-term Debt, Percentage Bearing Variable Interest, Amount | €								€ 0.1
Other Debt Facilities - EUROIMMUN [Member] | Minimum [Member]
Unsecured senior notes, interest rate percent						1.10%		1.10%
Other Debt Facilities - EUROIMMUN [Member] | Maximum [Member]
Unsecured senior notes, interest rate percent						21.50%		21.50%
Other Debt Facilities - EUROIMMUN [Member] | Euribor Rate [Member]
Basis spread on variable rate						1.50%
Other Debt Facilities [Member]
Unamortized discount and debt issuance costs						$ 0
Maturities of Long-term Debt [Abstract]
2017						9,974,000
2018						7,910,000
2019						3,759,000
2020						2,278,000
2021						1,287,000
Thereafter						536,000
Long-term Debt Before Unamortized Discount						25,744,000
Total						$ 25,744,000
Other Unsecured Revolving Debt Facilities [Member]
Other Unsecured Revolving Credit Facility										5,800,000
Other Unsecured Revolving Debt Facilities [Member] | Minimum [Member]
Unsecured senior notes, interest rate percent						2.30%		2.30%
Other Secured Bank Loan [Member]
Maturities of Long-term Debt [Abstract]
Secured Debt | €								€ 1.9			€ 0.3
Other Secured Bank Loan [Member] | Minimum [Member]
Unsecured senior notes, interest rate percent						1.95%		1.95%
Other Secured Bank Loan [Member] | Maximum [Member]
Unsecured senior notes, interest rate percent						21.50%		21.50%
0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Interest rate terms under amended senior unsecured revolving credit facility						Interest on the April 2021 Notes is payable annually on April 9th each year.
Unsecured senior notes, interest rate percent			0.60%
Gross proceeds from the issuance of debt instrument			$ 298,700,000
Senior unsecured notes issuance as percentage of principal amount			99.95%
Unamortized discount and debt issuance costs						$ (1,194,000)
Unamortized Debt Issuance Expense										$ 2,000,000
Debt Instrument, Redemption Percentage Upon Change of Control and Downgrade of Debt Instrument			101.00%
Maturities of Long-term Debt [Abstract]
2017						0
2018						335,370,000
2019						0
2020						0
2021						0
Thereafter						0
Long-term Debt Before Unamortized Discount						335,370,000
Total						$ 334,176,000
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Treasury Rate [Member]
Basis spread on variable rate						0.15%
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Interest rate terms under amended senior unsecured revolving credit facility						The 2029 Notes mature in September 2029 and bear interest at an annual rate of 3.3%. Interest on the 2029 Notes is payable semi-annually on March 15th and September 15th each year.
Unsecured senior notes, interest rate percent		3.30%
Unsecured senior notes, face value		$ 850,000,000
Gross proceeds from the issuance of debt instrument		$ 847,200,000
Senior unsecured notes issuance as percentage of principal amount		99.67%
Unamortized discount and debt issuance costs						$ (10,120,000)
Unamortized Debt Issuance Expense						7,400,000
Debt Instrument, Redemption Percentage Upon Change of Control and Downgrade of Debt Instrument		101.00%
Maturities of Long-term Debt [Abstract]
2017						0
2018						0
2019						0
2020						0
2021						0
Thereafter						850,000,000
Long-term Debt Before Unamortized Discount						850,000,000
Total						$ 839,880,000
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Treasury Rate [Member]
Basis spread on variable rate						0.25%
Euro Member Countries, Euro | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Unsecured senior notes, face value | €												€ 500
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member]
Maturities of Long-term Debt [Abstract]
Other Long-term Debt | €								€ 21.3			28
Euro Member Countries, Euro | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Unsecured senior notes, face value			$ 300,000,000
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]
Maturities of Long-term Debt [Abstract]
Other Long-term Debt | €								23.8			€ 32.1
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €								23.7
Secured Debt | €								6.3
Unsecured Debt | €								€ 17.5
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member] | Minimum [Member]
Unsecured senior notes, interest rate percent						1.10%		1.10%
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member] | Maximum [Member]
Unsecured senior notes, interest rate percent						4.30%		4.30%

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 29, 2019	Dec. 30, 2018
Accounts Payable and Accrued Liabilities, Current [Abstract]
Payroll and incentives	$ 77,892	$ 86,549
Employee benefits	42,405	44,060
Deferred revenue	164,261	155,064
Federal, non-U.S. and state income taxes	29,876	30,687
Other accrued operating expenses	188,898	212,467
Total accrued expenses and other current liabilities	$ 503,332	$ 528,827

Employee Benefit Plans (Schedul

Employee Benefit Plans (Schedule of Net Benefit Costs, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 6,598	$ 6,853	$ 4,951
Interest cost	16,546	16,146	16,707
Expected return on plan assets	(24,561)	(28,939)	(26,401)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment	1,547	0	0
Actuarial loss (gain)	27,134	17,146	(7,085)
Amortization of prior service cost	(152)	375	(195)
Net periodic benefit cost	$ 24,018	$ 11,581	$ (12,023)

Employee Benefit Plans (Sched_2

Employee Benefit Plans (Schedule of Net Funded Status, Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Change in benefit obligations:
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change	$ (4,400)	$ (1,000)	$ (2,600)
Actuarial assumptions as of the year-end measurement date:
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Projected Benefit Obligation	195,657	180,560
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets	0	0
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation	198,294	183,424
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets	0	0
Foreign Plan [Member]
Change in plan assets:
Employer's contributions	8,200	8,500	8,400
UNITED STATES
Change in plan assets:
Employer's contributions		$ 15,000
Other Pension Plan [Member]
Actuarial assumptions as of the year-end measurement date:
Rate of compensation increase		3.48%
Foreign Plan [Member]
Actuarial present value of benefit obligations: [Abstract]
Accumulated benefit obligations	338,722	$ 304,065
Change in benefit obligations:
Projected benefit obligations at beginning of year	311,168	343,410
Service cost	4,248	4,528
Interest cost	5,448	5,484
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	162	176
Defined Benefit Plan, Benefit Obligation, Business Combination	0	537
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	(1,420)	0
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change	0	533
Actuarial loss (gain)	34,602	(13,141)
Effect of exchange rate changes	25	(17,278)
Projected benefit obligations at end of year	341,455	311,168	343,410
Change in plan assets:
Fair value of plan assets at beginning of year	159,163	179,736
Actual return on plan assets	19,873	(5,653)
Benefits paid and plan expenses	(12,778)	(13,081)
Employer's contributions	8,200	8,480
Participant's contributions	162	176
Effect of exchange rate changes	5,240	(10,495)
Fair value of plan assets at end of year	179,860	159,163	$ 179,736
Net amounts recognized in the consolidated balance sheets consist of:
Net amounts recognized in the consolidated balance sheets	(161,595)	(152,005)
Assets for Plan Benefits, Defined Benefit Plan	36,699	31,419
Current liabilities	(6,764)	(6,752)
Noncurrent liabilities	(191,530)	(176,672)
Net amounts recognized in accumulated other comprehensive income consist of:
Prior service cost	$ 0	$ (278)
Actuarial assumptions as of the year-end measurement date:
Discount rate	1.34%	2.07%	1.99%	2.06%
Rate of compensation increase	3.36%	3.48%	3.50%	3.64%
Expected rate of return on assets		5.30%	5.90%	6.00%
Defined Benefit Plan, Benefit Obligation, Benefits Paid	$ 12,778	$ 13,081
UNITED STATES
Actuarial present value of benefit obligations: [Abstract]
Accumulated benefit obligations	304,710	283,310
Change in benefit obligations:
Projected benefit obligations at beginning of year	283,310	308,713
Service cost	2,350	2,325
Interest cost	11,098	10,662
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefit Obligation, Business Combination	0	0
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	0	0
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change	0	0
Actuarial loss (gain)	29,114	(18,681)
Effect of exchange rate changes	0	0
Projected benefit obligations at end of year	304,710	283,310	$ 308,713
Change in plan assets:
Fair value of plan assets at beginning of year	234,342	253,427
Actual return on plan assets	41,270	(14,376)
Benefits paid and plan expenses	(21,162)	(19,709)
Employer's contributions	0	15,000
Participant's contributions	0	0
Effect of exchange rate changes	0	0
Fair value of plan assets at end of year	254,450	234,342	$ 253,427
Net amounts recognized in the consolidated balance sheets consist of:
Net amounts recognized in the consolidated balance sheets	(50,260)	(48,968)
Assets for Plan Benefits, Defined Benefit Plan	0	0
Current liabilities	0	0
Noncurrent liabilities	(50,260)	(48,968)
Net amounts recognized in accumulated other comprehensive income consist of:
Prior service cost	$ 0	$ 0
Actuarial assumptions as of the year-end measurement date:
Discount rate	3.01%	4.05%	3.56%	4.06%
Rate of compensation increase	0.00%	0.00%	0.00%	0.00%
Expected rate of return on assets		7.25%	7.25%	7.25%
Defined Benefit Plan, Benefit Obligation, Benefits Paid	$ 21,162	$ 19,709

Employee Benefit Plans (Sched_3

Employee Benefit Plans (Schedule of Allocation of Plan Assets, Pension Plans) (Details)	12 Months Ended
	Jan. 03, 2021	Dec. 29, 2019	Dec. 30, 2018
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		100.00%	100.00%
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		100.00%	100.00%
Other Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		13.00%	1.00%
Other Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		0.00%	0.00%
Debt Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		87.00%	51.00%
Debt Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		59.00%	61.00%
Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		0.00%	48.00%
Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities		41.00%	39.00%
Forecast [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities	100.00%
Forecast [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Equity Securities	100.00%
Forecast [Member] | Minimum [Member] | Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	0.00%
Forecast [Member] | Minimum [Member] | Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	40.00%
Forecast [Member] | Minimum [Member] | Debt Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	85.00%
Forecast [Member] | Minimum [Member] | Debt Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	40.00%
Forecast [Member] | Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	10.00%
Forecast [Member] | Minimum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	0.00%
Forecast [Member] | Maximum [Member] | Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	5.00%
Forecast [Member] | Maximum [Member] | Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	60.00%
Forecast [Member] | Maximum [Member] | Debt Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	90.00%
Forecast [Member] | Maximum [Member] | Debt Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	60.00%
Forecast [Member] | Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	15.00%
Forecast [Member] | Maximum [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit, Target Asset Allocation Percentage	10.00%

Employee Benefit Plans (Sched_4

Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Pension Plans) (Details) - Pension Plans, Defined Benefit - USD ($) $ in Thousands	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 434,310	$ 393,505
Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,700	1,928
Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,177	6,326
Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	57,797	35,072
Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	26,914	24,175
Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	12,853	11,993
Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		54,342
Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,010	1,353
Equity Securities, Foreign Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	22,688	22,196
Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		886
Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	93,473	23,352
Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	139,300	131,211
Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	29,846	24,848
Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,734	5,186
Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,721	16,934
Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	33,097	33,703
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	161,289	135,052
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,700	1,928
Fair Value, Inputs, Level 1 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,177	6,326
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	57,797	35,072
Fair Value, Inputs, Level 1 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	26,914	24,175
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	12,853	11,993
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,010	1,353
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Foreign Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		886
Fair Value, Inputs, Level 1 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	47,104	48,133
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,734	5,186
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	248,612	219,323
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		54,342
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Foreign Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fair Value, Inputs, Level 2 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	93,473	23,352
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	92,196	83,078
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	29,846	24,848
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	33,097	33,703
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	24,409	39,130	$ 16,789	$ 23,790
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Small-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Cash [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Large-cap [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, International large-cap value[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Equity Index Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Domestic Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Foreign Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	22,688	22,196
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Commodity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fair Value, Inputs, Level 3 [Member] | Debt Security, Government, Non-US [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, High Yield Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,721	16,934	$ 16,789	$ 23,790
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0

Employee Benefit Plans (Sched_5

Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Other Postretirement Benefits Plan [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	$ 16,279	$ 17,374
Realized gains (losses)	1,776	(1,621)	$ 741
Fair value of plan assets at end of year	19,216	16,279	17,374
Other Postretirement Benefits Plan [Member] | Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,176
Fair value of plan assets at end of year	130	1,176
Pension Plans, Defined Benefit
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	393,505
Fair value of plan assets at end of year	434,310	393,505
Pension Plans, Defined Benefit | Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	16,934
Fair value of plan assets at end of year	1,721	16,934
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefits Plan [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,176
Fair value of plan assets at end of year	130	1,176
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefits Plan [Member] | Multi-strategy hedge funds [Member]
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,176	1,151	1,508
Realized gains (losses)	315		229
Unrealized gains (losses)	(287)	25	(24)
Fair value of plan assets at end of year	130	1,176	1,151
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale	(15,586)		(8,189)
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase		22,196
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	39,130	16,789	23,790
Realized gains (losses)	4,175		1,542
Unrealized gains (losses)	(3,310)	145	(354)
Fair value of plan assets at end of year	24,409	39,130	16,789
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | Foreign Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale	0		0
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase		22,196
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	22,196	0	0
Realized gains (losses)	0		0
Unrealized gains (losses)	492	0	0
Fair value of plan assets at end of year	22,688	22,196	0
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit | Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Decrease for Sale	(15,586)		(8,189)
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase for Purchase		0
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	16,934	16,789	23,790
Realized gains (losses)	4,175		1,542
Unrealized gains (losses)	(3,802)	145	(354)
Fair value of plan assets at end of year	$ 1,721	$ 16,934	$ 16,789

Employee Benefit Plans (Sched_6

Employee Benefit Plans (Schedule of Expected Benefit Payments, Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 03, 2021
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
2018	$ 11,540
2019	12,006
2020	12,083
2021	12,362
2022	13,119
2023-2026	66,950
Defined Benefit Plan, Plan Assets, Contributions by Employer	8,200	$ 8,500	$ 8,400
Foreign Plan [Member] | Forecast [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected contributions in next fiscal year				$ 6,600
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
2018	19,200
2019	19,346
2020	19,449
2021	19,561
2022	19,539
2023-2026	$ 94,159
Defined Benefit Plan, Plan Assets, Contributions by Employer		$ 15,000

Employee Benefit Plans (Sched_7

Employee Benefit Plans (Schedule of Net Benefit Costs, Other Postretirement Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 6,598	$ 6,853	$ 4,951
Interest cost	16,546	16,146	16,707
Expected return on plan assets	(24,561)	(28,939)	(26,401)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment	1,547	0	0
Actuarial loss (gain)	(27,134)	(17,146)	7,085
Amortization of prior service cost	(152)	375	(195)
Net periodic benefit cost	24,018	11,581	(12,023)
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	87	106	92
Interest cost	116	120	125
Expected return on plan assets	(1,175)	(1,254)	(1,114)
Defined Benefit Plan, Amortization of Gain (Loss)	(1,776)	1,621	(741)
Actuarial loss (gain)	108	(611)
Net periodic benefit cost	$ (2,748)	$ 593	$ (1,638)

Employee Benefit Plans (Sched_8

Employee Benefit Plans (Schedule of Net Funded Status, Other Postretirement Benefit Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	4.09%	3.60%	4.11%
Change in benefit obligations:
Projected benefit obligations at beginning of year	$ 2,911	$ 3,413
Service cost	87	106	$ 92
Interest cost	116	120	125
Defined Benefit Plan, Benefit Obligation, Benefits Paid	122	117
Actuarial loss (gain)	108	(611)
Change in accumulated benefit obligations during the year	189	(502)
Projected benefit obligations at end of year	3,100	2,911	3,413
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	16,279	17,374
Actual return on plan assets	2,937	(993)
Defined Benefit Plan, Plan Assets, Payment for Settlement	0	(102)
Fair value of plan assets at end of year	19,216	16,279	$ 17,374
Net amounts recognized in the consolidated balance sheets	16,116	13,368
Assets for Plan Benefits, Defined Benefit Plan	16,116	13,368
Prior service cost	$ 0	$ 0
Discount rate	3.09%	4.09%
Expected rate of return on assets	7.25%	7.25%	7.25%
Retirees [Member]
Change in benefit obligations:
Projected benefit obligations at beginning of year	$ 583	$ 688
Projected benefit obligations at end of year	611	583	$ 688
Active Employees Eligible to Retire [Member]
Change in benefit obligations:
Projected benefit obligations at beginning of year	362	408
Projected benefit obligations at end of year	420	362	408
Other Active Employees [Member]
Change in benefit obligations:
Projected benefit obligations at beginning of year	1,966	2,317
Projected benefit obligations at end of year	$ 2,069	$ 1,966	$ 2,317

Employee Benefit Plans (Sched_9

Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Other Postretirement Benefit Plans) (Details) - USD ($) $ in Thousands	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 434,310	$ 393,505
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	19,216	16,279	$ 17,374
Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	161,289	135,052
Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	12,123	9,332
Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	248,612	219,323
Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,963	5,771
Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	24,409	39,130	16,789	$ 23,790
Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	130	1,176
Cash [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,177	6,326
Cash [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	408	390
Cash [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,177	6,326
Cash [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	408	390
Cash [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	57,797	35,072
Equity Securities, U.S. Large-cap [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,365	2,436
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	57,797	35,072
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,365	2,436
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	26,914	24,175
Equity Securities, International large-cap value[Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,033	1,679
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	26,914	24,175
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,033	1,679
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Equity Index Funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		54,342
Equity Securities, Equity Index Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	971	833
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	971	833
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		54,342
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Domestic Real Estate Funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,010	1,353
Equity Securities, Domestic Real Estate Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	152	94
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,010	1,353
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	152	94
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Foreign Real Estate Funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	22,688	22,196
Equity Securities, Foreign Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Foreign Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, Foreign Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	22,688	22,196
Equity Securities, Commodity Funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		886
Equity Securities, Commodity Funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		62
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		886
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		62
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fixed Income Funds, Corporate Debt Instruments [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	139,300	131,211
Fixed Income Funds, Corporate Debt Instruments [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	10,520	9,115
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	47,104	48,133
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,557	3,344
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	92,196	83,078
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,963	5,771
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, Corporate Bonds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	29,846	24,848
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	29,846	24,848
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,734	5,186
Fixed Income Funds, High Yield Bonds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	433	360
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,734	5,186
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	433	360
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,721	16,934
Other Types of Investments, Multi-strategy hedge funds [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	130	1,176
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,721	16,934	16,789	23,790
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	130	1,176	$ 1,151	$ 1,508
Equity Securities, U.S. Small-cap [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,700	1,928
Equity Securities, U.S. Small-cap [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	204	134
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,700	1,928
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 1 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	204	134
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 2 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Pension Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 3 [Member] | Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0

Employee Benefit Plans (Sche_10

Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Other Postretirement Benefit Plans) (Details) - Other Postretirement Benefits Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	$ 16,279	$ 17,374
Realized gains (losses)	1,776	(1,621)	$ 741
Fair value of plan assets at end of year	19,216	16,279	17,374
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	1,176
Fair value of plan assets at end of year	130	1,176
Multi-strategy hedge funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets at beginning of year	1,176
Fair value of plan assets at end of year	130	1,176
Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement	1,074		562
Fair value of plan assets at beginning of year	1,176	1,151	1,508
Realized gains (losses)	315		229
Unrealized gains (losses)	(287)	25	(24)
Fair value of plan assets at end of year	$ 130	$ 1,176	$ 1,151

Employee Benefit Plans (Sche_11

Employee Benefit Plans (Schedule of Expected Benefit Payments, Other Postretirement Benefits) (Details) - USD ($) $ in Thousands	Jan. 03, 2021	Dec. 29, 2019
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
2018		$ 11,540
2019		12,006
2020		12,083
2021		12,362
2022		13,119
2023-2026		66,950
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
2018		19,200
2019		19,346
2020		19,449
2021		19,561
2022		19,539
2023-2026		94,159
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
2018		130
2019		146
2020		165
2021		177
2022		187
2023-2026		$ 995
Forecast [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	$ 6,600

Employee Benefit Plans (Savings

Employee Benefit Plans (Savings Plan) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation	100.00%
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match	5.00%
Defined Benefit, 401(k) Savings Plan Expense	$ 13.6	$ 13.2	$ 12.5

Employee Benefit Plans (Supplem

Employee Benefit Plans (Supplemental Executive Retirement Plan) (Details) - Supplemental Employee Retirement Plans, Defined Benefit [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$ 25.7	$ 22.1
Fair value of plan assets	2.1	1.8
Pension expense	$ 4.8	$ (0.3)	$ 3.2

Employee Benefit Plans (Nonqual

Employee Benefit Plans (Nonqualified Deferred Compensation Plans) (Details) $ in Millions	Dec. 29, 2019USD ($)
Management [Member]
Defined Benefit Plan Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Recorded Liability	$ 1.1

Contingencies (Details)

Contingencies (Details) $ in Millions	12 Months Ended
	Dec. 29, 2019USD ($)years	Dec. 30, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
Management's estimate of total cost of ultimate disposition of known environmental matters | $	$ 7.7	$ 7.9
Number of years over which estimated environmental cost will be paid | years	10

Warranty Reserves (Details)

Warranty Reserves (Details) $ in Thousands	12 Months Ended
	Dec. 29, 2019USD ($)years	Dec. 30, 2018USD ($)	Dec. 31, 2017USD ($)
Warranty reserve activity
Period of warranty protection beyond date of sale (in years) | years	1
Balance beginning of period	$ 8,393	$ 9,050	$ 9,012
Provision charged to income	12,199	13,545	13,700
Payments	(14,613)	(13,775)	(14,245)
Adjustments to previously provided warranties, net	2,889	(157)	(815)
Foreign currency and acquisitions	(56)	(270)	1,398
Balance end of period	$ 8,812	$ 8,393	$ 9,050

Stock Plans (Narrative) (Detail

Stock Plans (Narrative) (Details)	12 Months Ended
	Dec. 29, 2019USD ($)plan$ / sharesshares	Dec. 30, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock-based Compensation Plans | plan	1
Total income tax benefit recognized for stock-based compensation	$ 11,600,000	$ 13,600,000	$ 14,500,000
Stock-based compensation costs capitalized as part of inventory	300,000
Options related excess tax benefit, classified as a financing cash activity	0	0
Aggregate intrinsic value for stock options outstanding	$ 56,200,000
Weighted average remaining contractual term of options (in years)	3 years 9 months 18 days
Aggregate intrinsic value for stock options exercisable	$ 46,200,000
Weighted average remaining contractual term of options exercisable (in years)	2 years 10 months 24 days
Number of shares vested and expected to vest in the future | shares	1,500,000
Aggregate intrinsic value of vested and expected to vest stock options	$ 56,200,000
Weighted average remaining contractual term for options vested and expected to vest	3 years 9 months 18 days
Total pre-tax stock-based compensation expense	$ 31,514,000	$ 28,767,000	$ 25,421,000
Deferred compensation liability	10,400,000
Acceleration of executive compensation	$ 7,700,000
Performance Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares		$ 73.23	$ 52.69
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	10,116	0	15,139
Total pre-tax stock-based compensation expense	$ 5,600,000	$ 7,700,000	$ 8,700,000
Shares/units granted | shares	0	37,281	49,845
Awards/units outstanding | shares	71,213
Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 95.84	$ 72.17	$ 63.14
Total pre-tax stock-based compensation expense	$ 700,000	$ 800,000
Shares/units granted | shares	7,301	11,088	12,006
Stock award program for non-employees Directors, fair market value	$ 100,000	$ 100,000
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 94.80
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	65,000
Fair value of restricted stock awards vested	$ 12,000,000	10,400,000	$ 10,600,000
Total pre-tax stock-based compensation expense	12,700,000	$ 11,700,000	$ 10,300,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$ 14,800,000
Shares/units granted | shares	163,000
Awards/units outstanding | shares	345,000	465,000
Weighted-average period for recognition of unrecognized compensation cost, years	1 year 4 months 24 days
Option vesting period (in years)	3 years
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan | shares	5,000,000
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 82.25	$ 69.57	$ 67.09
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date	95.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate	10.00%
Shares/units granted | shares	33,843	21,321	36,769
Shares available for grant under employee stock purchase plan | shares	800,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of options | $ / shares	$ 22.63	$ 17.56	$ 11.83
Total intrinsic value of options exercised	$ 19,100,000	$ 35,000,000	$ 17,600,000
Cash received from option exercises	19,700,000	24,800,000	18,000,000
Total pre-tax stock-based compensation expense	6,700,000	$ 5,400,000	$ 4,700,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$ 6,300,000
Weighted-average period for recognition of unrecognized compensation cost, years	1 year 9 months 18 days
Option vesting period (in years)		3 years
Stock Options Expiration Period After Date of Grant		7 years
Performance Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	$ 92.95	$ 80.31
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	18,777
Total pre-tax stock-based compensation expense	$ 5,900,000	$ 3,200,000
Shares/units granted | shares	76,218	39,133
Awards/units outstanding | shares	145,114

Stock Plans (Summary of Total C

Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 31,514	$ 28,767	$ 25,421
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,620	1,466	1,254
Research and development expenses [Member ]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,061	1,359	1,389
Selling, general and administrative and other expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 28,833	$ 25,942	$ 22,778

Stock Plans (Weighted-Average A

Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	2.50%	3.00%	2.00%
Expected dividend yield	0.30%	0.40%	0.40%
Expected lives, years	5 years	5 years	5 years
Expected stock volatility	22.80%	20.70%	22.40%

Stock Plans (Summary of Stock O

Stock Plans (Summary of Stock Option Activity) (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018
Stock option activity
Shares outstanding at beginning of the year	1,765
Shares granted	304
Shares exercised	(415)
Shares canceled		(3)
Shares forfeited	(116)
Shares outstanding at end of year	1,535	1,765
Shares exercisable at end of year	954
Number of shares vested and expected to vest in the future	1,500
Weighted-average price, outstanding at beginning of year (per share)	$ 52.91
Weighted-average price, granted (per share)	93.66
Weighted-average price, exercised (per share)	47.60
Weighted-average price, canceled (per share)		$ 75.52
Weighted-average price, forfeited (per share)	78.71
Weighted-average price, outstanding at end of year (per share)	60.42	$ 52.91
Weighted-average price, exercisable at end of year (per share)	$ 48.65

Stock Plans (Summary of Restric

Stock Plans (Summary of Restricted Stock Award Activity) (Details) shares in Thousands	12 Months Ended
	Dec. 29, 2019$ / sharesshares
Restricted Stock Units (RSUs) [Member]
Restricted stock award activity
Performance factor percentage minimum	0.00%
Performance factor percentage maximum	200.00%
Restricted Stock Awards [Member]
Restricted stock award activity
Nonvested at beginning of year | shares	465
Shares, granted | shares	163
Shares, vested | shares	(218)
Shares, forfeited | shares	(65)
Nonvested at end of year | shares	345
Weighted-average grant-date fair value, nonvested at beginning of year (per share) | $ / shares	$ 61.72
Weighted-average grant-date fair value of stock granted (per share) | $ / shares	94.80
Weighted-average grant-date fair value, vested (per share) | $ / shares	55.20
Weighted-average grant-date fair value, forfeited (per share) | $ / shares	76.72
Weighted-average grant-date fair value, nonvested at end of year (per share) | $ / shares	$ 78.69

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended									12 Months Ended
	Mar. 29, 2020	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jul. 23, 2018
Schedule of Stockholders' Equity [Line Items]
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans										68,536	66,506	78,644
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans										$ 6,300	$ 5,200	$ 4,400
Cash dividends (per share)		$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.28	$ 0.28
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations										$ 6,313	$ 57,393	4,367
Dividends accrued		$ 7,800								7,800
Unrecognized prior service credit (cost), net of tax										807	(77)	(77)
Unrecognized prior service credit (cost), net of tax1										800	$ (100)	$ (100)
Dividends Payable, Date Declared		Oct. 24, 2019
Repurchase Program, 07/23/2018 [Member]
Schedule of Stockholders' Equity [Line Items]
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 197,800								$ 197,800
Stock Repurchase Program, Authorized Amount													$ 250,000
Subsequent Event [Member]
Schedule of Stockholders' Equity [Line Items]
Cash dividends (per share)	$ 0.07
Dividends Payable, Date Declared	Jan. 23, 2020

Stockholders' Equity (Component

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Cumulative Translation Adjustment Summary [Roll Forward]
Foreign currency translation adjustment, net of tax, beginning of year	$ (176,459)	$ (46,582)	$ (100,923)
Current year change	(23,978)	(123,388)	54,341
Foreign currency translation adjustment, net of tax, end of year	(200,437)	(176,459)	(46,582)
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax		0
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax		0
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		(6,489)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	(23,165)	(123,474)
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustments Reclassification From AOCI to Earnings Due to ASU 2018-02	0	6,489	0
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustments Reclassification From AOCI to Earnings, Net of Tax		(6,489)
Unrecognized prior service costs, net of tax	1,052	245	322	$ 399
Unrecognized prior service costs, net of tax, current year change	807	(77)	(77)
Unrealized (losses) gains on securities, net of tax	(261)	(267)	(258)	(337)
Unrealized (losses) gains on securities, net of tax, current year change	6	(9)	79
Other comprehensive (loss) income	(23,165)	(129,963)	54,343
Accumulated other comprehensive income (loss)	$ (199,646)	$ (176,481)	$ (46,518)	$ (100,861)

Derivatives And Hedging Activ_2

Derivatives And Hedging Activities (Details) $ in Thousands, € in Millions	9 Months Ended	12 Months Ended
	Sep. 29, 2019USD ($)	Dec. 29, 2019USD ($)	Dec. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 29, 2019EUR (€)	Dec. 30, 2018EUR (€)	Dec. 31, 2017EUR (€)
Derivative [Line Items]
Proceeds from Derivative Instrument, Investing Activities		$ 0	$ 0	$ 36,541
Company's business conducted outside United States		70.00%
Payments for (Proceeds from) Hedge, Financing Activities		$ 1,280	34,132	13,824
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months		0
Payments for Hedge, Financing Activities		$ 1,300	$ 34,100
European And Asian Currencies [Member]
Derivative [Line Items]
Maximum maturity period for foreign exchange contracts, in months		12 months
Duration of foreign currency derivative contract, days		30 days	30 days
Fair Value Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount		$ 277,600	$ 223,300	212,100
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure		(451)	(750)
Notional Amount of US Dollar Derivatives [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount		5,600	5,700	$ 1,300,000
Notional Amount of Euro Derivatives [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount | €					€ 105.8	€ 37.3	€ 57.2
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Net Investment Hedging [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments		203,300
Unrealized Gain (Loss) on Net Investment Hedge in AOCI		4,900	9,300
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Net Investment Hedging [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments		299,900
Unrealized Gain (Loss) on Net Investment Hedge in AOCI		8,000	$ 27,500
2021 Notes [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments		$ 500,000
Euro Member Countries, Euro | Cross-currency Swap [Member]
Derivative [Line Items]
Derivative, Fixed Interest Rate		2.47%			2.47%
Euro Member Countries, Euro | Cross-currency Swap [Member] | Net Investment Hedging [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments	$ 197,400
United States of America, Dollars | Cross-currency Swap [Member]
Derivative [Line Items]
Derivative, Fixed Interest Rate		5.00%			5.00%
United States of America, Dollars | Cross-currency Swap [Member] | Net Investment Hedging [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments		$ 220,000
Fair Value of Cross-currency Swap		$ 300

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) € in Millions	12 Months Ended
	Dec. 29, 2019USD ($)	Dec. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Jan. 03, 2016USD ($)	Dec. 29, 2019EUR (€)	Sep. 17, 2019USD ($)	Sep. 12, 2019USD ($)	Dec. 30, 2018EUR (€)	Apr. 11, 2018USD ($)	Jan. 01, 2017USD ($)	Jul. 19, 2016USD ($)	Jul. 19, 2016EUR (€)	Sep. 30, 2012USD ($)	Oct. 25, 2011USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 57,100,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	35,481,000	$ 69,661,000	$ 65,328,000							$ 63,201,000
Long-term Debt	$ 2,074,015,000
Business Combination, Contingent Consideration Arrangements, Maximum Period	3 years
Business Combination, Contingent Consideration Arrangements, Weighted Average Period	1 year 2 months 12 days
Payments for acquisition related contingent consideration	$ (29,942,000)	(12,800,000)	$ (8,940,000)
Line of Credit, Maturing September 17, 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured revolving credit facility, amount						$ 1,000,000,000
Long-term Debt	322,021,000
Revolving credit facility outstanding balance	325,400,000
Unamortized Debt Issuance Expense	3,400,000
Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €					€ 25.6
Long-term Debt, Percentage Bearing Variable Interest, Amount | €					€ 0.1
Line of Credit, Maturing August 11, 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt		415,600,000
Revolving credit facility outstanding balance		418,000,000
Unamortized Debt Issuance Expense		2,400,000
2021 Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, face value														$ 500,000,000
Long-term Debt		497,400,000
Debt Instrument, Interest Rate, Stated Percentage														5.00%
Discount on senior unsecured notes		(1,100,000)												$ (3,100,000)
Unamortized Debt Issuance Expense		1,600,000
Financing Lease Obligations [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt													$ 29,300,000
Finance Lease, Liability		34,500,000
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	552,194,000	564,500,000
Debt Instrument, Interest Rate, Stated Percentage											1.875%	1.875%
Discount on senior unsecured notes	(3,500,000)	(4,000,000)									$ (4,400,000)
Unamortized Debt Issuance Expense	3,300,000	3,800,000
0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	334,176,000
Debt Instrument, Interest Rate, Stated Percentage									0.60%
Discount on senior unsecured notes	(100,000)	(100,000)							$ (200,000)
Unamortized Debt Issuance Expense		2,000,000
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, face value							$ 850,000,000
Long-term Debt	839,880,000
Debt Instrument, Interest Rate, Stated Percentage							3.30%
Discount on senior unsecured notes	(2,700,000)						$ (2,800,000)
Unamortized Debt Issuance Expense	7,400,000
Unsecured senior notes, fair value	$ 872,300,000
Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.10%				1.10%
Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	21.50%				21.50%
Vanadis Diagnostics AB [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				$ 32,000,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				93,000,000
Payment for Contingent Consideration Liability, Financing Activities	$ 29,900,000	12,800,000
Payment for Contingent Consideration Liability, Operating Activities	20,900,000	3,700,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	19,000,000			$ (56,900,000)
Payments for acquisition related contingent consideration	$ 50,900,000	16,500,000
Vanadis Diagnostics AB [Member] | Minimum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Projected milestone date				2016
Conditional probability of success	95.00%			85.00%	95.00%
Cumulative probability of success				53.00%
Vanadis Diagnostics AB [Member] | Minimum [Member] | Measurement Input, Discount Rate [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Measurement Inputs, Discount Rate	3.50%			3.10%
Vanadis Diagnostics AB [Member] | Maximum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Projected milestone date	2020			2019
Conditional probability of success	98.00%			95.00%	98.00%
Cumulative probability of success				90.00%
Vanadis Diagnostics AB [Member] | Maximum [Member] | Measurement Input, Discount Rate [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Measurement Inputs, Discount Rate	4.40%			11.30%
Fiscal Year 2019 Other Acquisitions [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	$ 634,000
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €					€ 21.3			€ 28
Euro Member Countries, Euro | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, face value | €												€ 500
Unsecured senior notes, fair value	518,500,000	496,100,000
Euro Member Countries, Euro | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, face value									$ 300,000,000
Unsecured senior notes, fair value	$ 301,900,000	300,500,000
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €					23.8			32.1
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €					€ 23.7
United States of America, Dollars | Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.10%				1.10%
United States of America, Dollars | Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.30%				4.30%
United States of America, Dollars | Fiscal Year 2018 Other Acquisitions [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value		6,500,000
United States of America, Dollars | Fiscal Year 2019 Other Acquisitions [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	$ 12,700,000
Fair Value, Inputs, Level 2 [Member] | Other Debt Facilities - EUROIMMUN [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €					€ 25.7			€ 38.2
Fair Value, Inputs, Level 2 [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	334,200,000	$ 341,300,000
Fair Value, Inputs, Level 2 [Member] | 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	$ 839,900,000

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 35,481	$ 69,661	$ 65,328	$ 63,201
Fair Value, Recurring [Member] | Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	(2,906)	(2,447)
Foreign Currency Contract, Asset, Fair Value Disclosure	451	750
Foreign exchange derivative liabilities, net	(1,538)	(594)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	35,481	69,661
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	(2,906)	(2,447)
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0	0
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign Currency Contract, Asset, Fair Value Disclosure	451	750
Foreign exchange derivative liabilities, net	(1,538)	(594)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0	0
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 35,481	$ 69,661

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance beginning of period	$ (69,661)	$ (65,328)	$ (63,201)
Additions	(12,734)	(6,200)
Payments	(50,795)	(16,506)	(35)
Change in fair value (included within selling, general and administrative expenses)	(3,881)	(14,639)	(2,162)
Balance end of period	$ (35,481)	$ (69,661)	$ (65,328)

Leases (Details)

Leases (Details) $ in Thousands	12 Months Ended
	Dec. 29, 2019USD ($)
Leases [Abstract]
Operating Lease, Cost	$ 61,205
Schedule Of Supplemental Cash Flow Information Related To Leases [Line Items]
Operating Lease, Payments	$ 50,155

Leases Supplemental Balance She

Leases Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands	Dec. 29, 2019	Dec. 30, 2018
Schedule of Supplemental Balance Sheet Information Related To Leases [Line Items]
Operating Lease, Right-of-Use Asset	$ 167,276	$ 0
Operating Lease, Liability, Current	36,573
Operating Lease, Liability, Noncurrent	146,399	$ 0
Operating Lease, Liability	$ 182,972
Operating Lease, Weighted Average Remaining Lease Term	7 years 6 months
Operating Lease, Weighted Average Discount Rate, Percent	3.30%

Leases Lessee, Operating Lease,

Leases Lessee, Operating Lease, Liability, Maturity (Details) $ in Thousands	12 Months Ended
	Dec. 29, 2019USD ($)
Operating Lease Liabilities, Maturity [Line Items]
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months	$ 44,512
Lessee, Operating Lease, Liability, Payments, Due Year Two	36,958
Lessee, Operating Lease, Liability, Payments, Due Year Three	25,419
Lessee, Operating Lease, Liability, Payments, Due Year Four	19,594
Lessee, Operating Lease, Liability, Payments, Due Year Five	17,721
Lessee, Operating Lease, Liability, Payments, Due after Year Five	66,808
Operating Lease, Payments	50,155
Lessee, Operating Lease, Liability, Payments, Due	211,012
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(28,040)
Operating Lease, Liability	$ 182,972

Leases Minimum Rental Commitmen

Leases Minimum Rental Commitments Under Noncancelable Operating Leases, Under ASC 840 (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Operating Leases, Future Minimum Payments Due, Next Twelve Months		$ 56.4
Operating Leases, Future Minimum Payments, Due in Two Years		46.6
Operating Leases, Future Minimum Payments, Due in Three Years		$ 33.5
Operating Leases, Future Minimum Payments, Due in Four Years	$ 22.1
Operating Leases, Future Minimum Payments, Due in Five Years	15.6
Operating Leases, Future Minimum Payments, Due Thereafter	$ 67.6

Schedule of Sales and Operating

Schedule of Sales and Operating Income from Continuing Operations by Operating Segment (Details) $ in Thousands		3 Months Ended									12 Months Ended
		Dec. 29, 2019USD ($)	[1]	Sep. 29, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Jul. 01, 2018USD ($)	Apr. 01, 2018USD ($)	Dec. 29, 2019USD ($)segments	Dec. 30, 2018USD ($)	Dec. 31, 2017USD ($)
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations		$ 138,248		$ 78,660	$ 91,735	$ 53,330	$ 115,683	$ 80,202	$ 88,064	$ 39,935	$ 361,973	$ 323,884	$ 295,615
Number of Operating Segments | segments											2
Revenue from Contract with Customer, Excluding Assessed Tax											$ 2,883,673	2,777,996	2,256,982
Interest and other expense (income), net											124,831	66,201	(1,103)
Income from continuing operations before income taxes		$ 65,296		$ 63,254	$ 71,827	$ 36,765	$ 79,429	$ 78,041	$ 71,708	$ 28,505	237,142	257,683	296,718
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market											31,200	21,400
Acceleration of executive compensation											7,700
Diagnostics [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations											189,330	153,196	146,862
Revenue from Contract with Customer, Excluding Assessed Tax											1,137,512	1,084,785	678,523
Discovery & Analytical Solutions [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations	[2]										238,331	230,481	205,259
Revenue from Contract with Customer, Excluding Assessed Tax											1,746,161	1,693,211	1,578,459
Corporate [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Operating income from continuing operations	[3],[4]										(65,688)	(59,793)	(56,506)
Particular Diagnostics Case [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Legal Fees											100	200
Particular Discovery & Analytical Solutions Case [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Legal Fees											2,200	5,300	2,700
Product [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											2,017,042	1,935,493	1,477,414
Product [Member] | Diagnostics [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											962,180	924,594	536,086
Product [Member] | Discovery & Analytical Solutions [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											1,054,862	1,010,899	941,328
Service [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											866,631	842,503	779,568
Service [Member] | Diagnostics [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											175,332	160,191	142,437
Service [Member] | Discovery & Analytical Solutions [Member]
Schedule of Segment Reporting Information, by Segment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax											$ 691,299	$ 682,312	$ 637,131
[1]	The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million
[2]	Legal costs for significant litigation matters in the Company's Discovery & Analytical Solutions segment were $2.2 million , $5.3 million and $2.7 million for fiscal years 2019, 2018 and 2017 , respectively. Legal costs for significant litigation matters in the Company's Diagnostics segment were $0.1 million and $0.2 million for fiscal years 2019 and 2018 , respectively.
[3]	(2) Stock compensation expense from acceleration of executive compensation was $7.7 million for fiscal year 2019 .
[4]

Industry Segment and Geograph_3

Industry Segment and Geographic Area Information Schedule of Depreciation, Amortization and Capital Expenditures (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Depreciation and amortization expense	$ 214,025	$ 180,588	$ 105,000
Payments to Acquire Property, Plant, and Equipment	76,331	93,253	39,089
Diagnostics [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	136,476	107,434	31,204
Payments to Acquire Property, Plant, and Equipment	46,863	54,737	11,262
Discovery & Analytical Solutions [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	74,445	70,362	72,590
Payments to Acquire Property, Plant, and Equipment	27,778	34,852	26,200
Corporate [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	3,104	2,792	1,206
Payments to Acquire Property, Plant, and Equipment	1,690	3,664	1,627
Continuing Operations [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	214,025	180,588	105,000
Payments to Acquire Property, Plant, and Equipment	76,331	93,253	39,089
Discontinued Operations [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization expense	0	0	929
Payments to Acquire Property, Plant, and Equipment	$ 0	$ 0	$ 182

Industry Segment and Geograph_4

Industry Segment and Geographic Area Information Schedule of Total Assets by Segment (Details) - USD ($) $ in Thousands	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Schedule of Total Assets, by segment [Line Items]
Assets	$ 6,538,564	$ 5,975,522
Diagnostics [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	3,368,598	3,358,964	$ 3,447,437
Discovery & Analytical Solutions [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	3,082,917	2,567,054	2,611,737
Corporate [Member]
Schedule of Total Assets, by segment [Line Items]
Assets	$ 87,049	$ 49,504	32,289
Total assets [Member]
Schedule of Total Assets, by segment [Line Items]
Assets			$ 6,091,463

Industry Segment and Geograph_5

Industry Segment and Geographic Area Information Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 2,883,673	$ 2,777,996	$ 2,256,982
UNITED STATES
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	974,187	906,398	837,018
CHINA
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	581,688	559,865	374,931
UNITED KINGDOM
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	70,703	72,124	65,164
GERMANY
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	146,577	142,411	91,669
INDIA
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	97,423	92,327	84,812
ITALY
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	101,461	95,908	77,477
FRANCE
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	96,994	97,990	80,153
JAPAN
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	82,478	79,238	76,322
Other International [Member]
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	732,162	731,735	569,436
Total international [Member]
Sales by Geographic Area [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,909,486	$ 1,871,598	$ 1,419,964

Industry Segment and Geograph_6

Industry Segment and Geographic Area Information Schedule of Long-Lived Assets by Geographic Location (Details) - USD ($) $ in Thousands	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	$ 659,605	$ 490,311	$ 476,044
UNITED STATES
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	269,183	201,649	210,116
CHINA
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	71,216	61,261	64,815
UNITED KINGDOM
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	51,659	33,429	28,028
INDIA
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	19,691	14,636	14,820
FINLAND
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	29,052	16,211	14,764
SINGAPORE
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	23,063	14,942	9,240
BRAZIL
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	9,126	8,237	7,963
ITALY
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	14,152	11,324	10,334
GERMANY
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	119,612	99,181	88,249
CANADA
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	6,485	5,454	5,201
POLAND
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	7,216	3,212	2,269
Other International [Member]
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	39,150	20,775	20,245
Total international [Member]
Long-lived assets by Geographic Area [Line Items]
Total net long-lived assets	$ 390,422	$ 288,662	$ 265,928

Quarterly Financial Informati_3

Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended									12 Months Ended
	Dec. 29, 2019		Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Quarterly Financial Data [Abstract]
Revenue	$ 805,496		$ 706,923	$ 722,517	$ 648,737	$ 756,349	$ 674,313	$ 703,362	$ 643,972	$ 2,883,673	$ 2,777,996
Gross profit	398,181		342,275	347,793	307,806	376,250	332,327	340,140	292,222	1,396,055	1,340,939
Restructuring and other costs, net	1,560		14,068	6,161	7,639	(1,942)	6,508	0	6,578	29,428	11,144	$ 12,657
Operating income from continuing operations	138,248	[1]	78,660	91,735	53,330	115,683	80,202	88,064	39,935	361,973	323,884	295,615
Income from continuing operations before income taxes	65,296	[1]	63,254	71,827	36,765	79,429	78,041	71,708	28,505	237,142	257,683	296,718
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	(48)		(52)	(54)	(41)	(30)	1,103	(610)	(11)	(195)	452	135,743
Operating income from continuing operations	64,549	[1]	58,610	69,141	35,453	71,322	75,445	64,673	26,035	227,753	237,475	156,890
Net income	$ 64,501	[1]	$ 58,558	$ 69,087	$ 35,412	$ 71,292	$ 76,548	$ 64,063	$ 26,024	$ 227,558	$ 237,927	$ 292,633
Basic earnings per share:
Income from continuing operations	$ 0.58	[1]	$ 0.53	$ 0.62	$ 0.32	$ 0.64	$ 0.68	$ 0.59	$ 0.24	$ 2.06	$ 2.15	$ 1.43
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share	0		0	0	0	0	0.01	(0.01)	0	0	0	1.24
Net income	0.58	[1]	0.53	0.62	0.32	0.64	0.69	0.58	0.24	2.06	2.15	2.67
Diluted earnings per share:
Income from continuing operations	0.58	[1]	0.53	0.62	0.32	0.64	0.68	0.58	0.23	2.04	2.13	1.42
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share	0		0	0	0	0	0.01	(0.01)	0	0	0	1.22
Net income	0.58	[1]	0.52	0.62	0.32	0.64	0.69	0.57	0.23	2.04	2.13	$ 2.64
Cash dividends per common share	$ 0.07		$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.28	$ 0.28
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market										$ 31,200	$ 21,400
Tax Adjustments, Settlements, and Unusual Provisions										23,400	8,100	$ 98,600
Diagnostics [Member]
Quarterly Financial Data [Abstract]
Operating income from continuing operations										$ 189,330	$ 153,196	$ 146,862
[1]	The fourth quarter of fiscal year 2019 includes a pre-tax loss of $31.2 million as a result of the mark-to-market adjustment on postretirement benefit plans. The fourth quarter of fiscal year 2018 includes a pre-tax loss of $21.4 million

Uncategorized Items - pki122920

Label	Element	Value
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 376,568,000
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	10,209,000
Accounting Standards Update 2014-09 [Member] | Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Accounting Standards Update 2016-16 [Member] | Common Stock [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Accounting Standards Update 2016-16 [Member] | AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Accounting Standards Update 2016-16 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(2,062,000)
Accounting Standards Update 2016-16 [Member] | Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Accounting Standards Update 2016-13 [Member] | Common Stock [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Accounting Standards Update 2016-13 [Member] | AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Accounting Standards Update 2016-13 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	13,289,000
Accounting Standards Update 2016-13 [Member] | Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Accounting Standards Update 2018-02 [Member] | Common Stock [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Accounting Standards Update 2018-02 [Member] | AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(6,489,000)
Accounting Standards Update 2018-02 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	6,489,000
Accounting Standards Update 2018-02 [Member] | Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 0